Gum ARABIC (FDA # 71-15)

[redacted]

ARABIC

March 1972

Compound Report No. 5

STUDY OF MUTAGENIC EFFECTS OF GUM ARABIC (FDA No. 71-15)

Prepared for:

DHEW/PUBLIC HEALTH SERVICE
Food and Drug Administration
Rockville, Maryland

Contract No. FDA 71-267

SRI Project LSU-1348

Submitted by:

G. W. Newell and W. A. Maxwell

Approved by:

W. A. Skimmer, Executive Director
Life Sciences Division

00
01

INTRODUCTION

Under contract to the Food and Drug Administration, Stanford Research Institute is examining the mutagenicity of 14 selected chemical compounds (Contract No. FDA 71-267). This report describes the results of tests conducted on Gum Arabic (FDA No. 71-15).

Three methods are used for evaluating the genetic hazards of the test compounds. These are: (1) Host-Mediated Assay, (2) Cytogenetic Assay, and (3) Dominant Lethal Gene Test. Methodologies used to conduct these tests were described in detail in "Compound Report No. 1," January 1972. The same procedures were followed in obtaining the information presented in this report.

For the compound being considered here--and as will be the case for the remaining 11 compounds--single and repeated oral administrations were performed at three concentrations. These amounts were (1) a maximum tolerated dose or 5 g/kg, whichever was lower, (2) a low dose of 30 mg/kg or one near the use level, and (3) a level intermediate between the use level and the maximum tolerated dose.

02

SUMMARY

Host-Mediated Assay

Gum arabic (71-15) did not produce any measurable mutagenic response or alteration in the recombination frequency for *Saccharomyces cerevisiae* in either the host-mediated assay or the associated *in vitro* tests.

Cytogenetic Assay

A slight adverse effect on the metaphase chromosomes of rats fed gum-arabic at a concentration of 5.0 g/kg and 2.5 g/kg is produced at 5 hours. A similar effect is manifested in *in vitro* tissue culture tests on human embryonic lung cells at all concentrations, particularly the intermediate dose.

Dominant Lethal Gene Test

No consistent responses occurred to suggest that gum arabic is mutagenic to the rat as a result of this experimental procedure. The positive reference control compound, TEM, produced mutagenic responses from the second through the fifth weeks of the experiment, which is characteristic of this known mutagen at the dosage used.

RESULTS AND DISCUSSION

Host-Mediated Assay

Table 1 presents a summary of the host-mediated assay results for gum arabic (71-15). Table 2 contains the data obtained on each individual mouse. This table is a computer printout of the calculations made on the data obtained for each mouse. Because of the nature of the computer, it is necessary to exceed its maximum number of significant figures to obtain a value as an exponent. For this reason, 12 significant figures are printed. However, only three significant figures are used for calculations and reporting the results as summarized in Table 1. Table 3 summarizes the data obtained in the *in vitro* tests.

As can be seen from the results summarized in Table 1, no mutagenic response was observed for the two *Salmonella typhimurium* strains tested when mice were treated with the test compound. The mitotic recombination frequency of *Saccharomyces cerevisiae* was not affected. Similarly, no positive mutagenic response was detected in the *in vitro* tests.

Cytogenetic Assay

With one exception, Compound 71-15 generally exhibits no adverse effect on bone marrow metaphase chromosomes. Table 4 indicates that a moderate effect is produced by the intermediate (5.3%) and maximal (5.2%) doses at 6-hour sacrifice compared with the negative control (0.7%). At 24 and 48 hours and in the subacute study, the doses used exhibit effects in the same range or below that of the controls. The cause of the elevated negative control value at 24 hours is not known, but percentages for the other doses at this time are sufficiently lower, so that any adverse effect is probably not being masked.

Table 5 does not reveal any general trends for particular dose levels with respect to time. The negative control value rises sharply between 6 and 24 hours but declines after that. The low dose value fluctuates regularly. The intermediate and maximal dose values are elevated at 6 hours, with the intermediate dose value declining and leveling off and the maximal dose value becoming very low after that time.

The only effect, then, seems to be an early one elicited by the two highest dose levels. It is the result of an increased number of breaks and not of rearrangements.

The anaphase data given in Table 6 reveal elevated values for the three test dosage levels, although only the intermediate dose value is

markedly higher than the negative control. All three levels show the same increase over the negative control with respect to the numbers of bridges observed. Only the intermediate dose, however, greatly exceeds the negative control in the percentage of cells with acentric fragments, which, together with the increased percentage of cells with bridges, results in its overall greater effect compared with the negative control. One noteworthy feature of the anaphase data is the continuous increase in the percentage of cells containing more than one type of aberration as the maximal level is approached. This indicates a greater number of breaks occurring within any one cell with the increased dose level. In general, then, Compound 71-15 exerts a slight adverse effect on human embryonic lung cells (WI-38).

Dominant Lethal Gene Test

Single and multiple dose LD_{50} values are presented in Table 7. Ten g/kg of bodyweight of gum arabic given orally as a suspension in water caused neither deaths nor adverse effects; it did cause transient depression of the animals for a few hours following dosing. Multiple doses of 5 g/kg/day for five days, given orally as partial suspensions, caused no observable effects. Thus, the treatment levels for gum arabic in these mutagenic assays were 30 mg/kg (low dose) given orally as a solution in water, 2.5 g/kg (mid-dose) administered orally as a partial suspension in water, and 5 g/kg (high dose) given orally as a partial suspension in water.

In Table 8, summary data of the average implantations per pregnant female showed that gum arabic had no effect on this parameter for either single- or multiple-dosed groups. This parameter was only minimally affected for the TEM-treated group, showing a significant drop in implants at the fourth week.

Dead implants per pregnant female are summarized in Table 9. The TEM-treated group was markedly affected from the second through the fifth week. The high dose group (5 g/kg) at 5 weeks showed a significant increase in dead implants per pregnant female for males singly treated with gum arabic. This parameter showed no statistical difference from the controls throughout the remainder of the study.

Similar types of scattered responses were obtained in statistical treatment of: dead implants per total implants (see Table 10), corpora lutea per pregnant female (see Table 11), and pre-implantation loss per pregnant female (see Table 12).

Careful review and statistical treatment of the data do not show gum arabic to be a mutagen in the rat by the dominant lethal gene test.

W. A. Maxwell

W. A. Maxwell, Ph.D., Microbiologist
Life Sciences Division

G. W. Newell

G. W. Newell, Ph.D., Manager
Chemical and Environmental Toxicology

TABLE 1

HOST MEDIATED ASSAY
SUMMARY OF DATA

Compound No.: 71-15 (Gum Arabic)

A. Acute

Treatment	Organism					
	Salmonella				Saccharomyces	
	G46		TA 1530		D-3	
	MF	MFt/MFc	MF	MFt/MFc	RF	RFt/RFc
Maximum	1.45×10^{-6}	0.88	2.13×10^{-7}	1.01	1.22×10^{-4}	1.33
Intermediate	1.23×10^{-6}	0.75	1.66×10^{-7}	0.79	5.20×10^{-5}	0.57
Low Level	2.06×10^{-7}	0.12	1.47×10^{-7}	0.70	8.13×10^{-5}	0.89
Control (+)	1.86×10^{-5} ✓	11.27	1.68×10^{-6} ✓	7.96	1.13×10^{-3} ✓	12.36
Control (-)	1.65×10^{-6} ✓	1.00	2.11×10^{-7} ✓	1.00	9.14×10^{-5} ✓	1.00

B. Subacute

Treatment	Organism					
	Salmonella				Saccharomyces	
	G46		TA 1530		D-3	
	MF	MFt/MFc	MF	MFt/MFc	RF	RFt/RFc
Maximum	1.93×10^{-8}	1.74	6.85×10^{-8}	0.76	8.57×10^{-5}	1.30
Intermediate	1.67×10^{-8}	1.50	1.19×10^{-7}	1.33	1.17×10^{-4}	1.78
Low Level	9.15×10^{-9}	0.82	1.41×10^{-7}	1.57	9.17×10^{-5}	1.40
Control (-)	1.11×10^{-8} ✓	1.00	8.97×10^{-8} ✓	1.00	6.57×10^{-5} ✓	1.00

07

Table 2

HOST MEDIATED ASSAY
INDIVIDUAL MOUSE DATA

Compound No.: 71-15 (Gum Arabic)

Organism: G-46

Treatment: (+) CONTROL

A. Acute

Mouse No.	Ave. No. Mutant Colonies or Recombinants/ml	Ave. No. Colony Forming Units/ml	Mutation or Recombination Frequency
1	.175833333333ex 05	.785000000000ex 09	.223991507430ex-04
2	.103000000000ex 05	.678333333330ex 09	.151842751843ex-04
3	.870000000000ex 04	.890000000000ex 09	.977528089887ex-05
4	.132500000000ex 05	.496666666666ex 09	.266778523490ex-04
5	.187500000000ex 05	.640000000000ex 09	.292968750000ex-04
6	.753333333330ex 04	.926666666665ex 09	.812949640285ex-05
7	.143666666666ex 05	.485000000000ex 09	.296219931270ex-04
8	.102833333333ex 05	.881666666665ex 09	.116635160680ex-04
9	.163166666666ex 05	.110833333333ex 10	.147218045112ex-04
			.186078049203ex-04

B. Subacute

Mouse No.	Ave. No. Mutant Colonies or Recombinants/ml	Ave. No. Colony Forming Units/ml	Mutation or Recombination Frequency

03

Table 2 (continued)

HOST MEDIATED ASSAY
INDIVIDUAL MOUSE DATA

Compound No.: 71-15

Organism: G-46

Treatment: (-) CONTROL

A. Acute

Mouse No.	Ave. No. Mutant Colonies or Recombinants/ml	Ave. No. Colony Forming Units/ml	Mutation or Recombination Frequency
1	.496666666666ex 03	.356666666666ex 09	.139252336448ex-05
2	.147000000000ex 04	.681666666665ex 09	.215647921760ex-05
3	.296666666666ex 04	.963333333330ex 09	.307958477509ex-05
4	.122166666666ex 04	.910000000000ex 09	.134249084248ex-05
5	.565000000000ex 03	.126500000000ex 10	.446640316205ex-06
6	.173333333333ex 04	.201666666666ex 10	.859504132232ex-06
7	.165000000000ex 04	.728333333330ex 09	.226544622426ex-05
			.164895269604ex-05

B. Subacute

Mouse No.	Ave. No. Mutant Colonies or Recombinants/ml	Ave. No. Colony Forming Units/ml	Mutation or Recombination Frequency
1	.175000000000ex 02	.145500000000ex 10	.120274914089ex-07
2	.125000000000ex 02	.176666666666ex 10	.707547169813ex-08
3	.110000000000ex 02	.151666666666ex 10	.725274725277ex-08
4	.108333333333ex 02	.205000000000ex 10	.528455284551ex-08
5	.170000000000ex 02	.136000000000ex 10	.125000000000ex-07
6	.333333333333ex 02	.130166666666ex 10	.256081946223ex-07
7	.100000000000ex 02	.121000000000ex 10	.826446280991ex-08
			.111447029482ex-07

Table 2 (continued)

HOST MEDIATED ASSAY
INDIVIDUAL MOUSE DATA

Compound No.: 71-15

Organism: G-46

Treatment: MAXIMUM

A. Acute

Mouse No.	Ave. No. Mutant Colonies or Recombinants/ml	Ave. No. Colony Forming Units/ml	Mutation or Recombination Frequency
1	.255000000000ex 03	.473333333333ex 09	.538732394366ex-06
2	.833333333330ex 01	.566666666665ex 09	.147058823529ex-07
3	.833333333330ex 01	.591666666665ex 09	.140845070422ex-07
4	.211666666666ex 03	.316666666666ex 08	.668421052630ex-05
5	.114333333333ex 04	.290000000000ex 09	.394252873562ex-05
6	.583333333330ex 02	.641666666665ex 09	.909090909088ex-07
7	.133333333333ex 02	.781666666665ex 09	.170575692963ex-07
8	.321666666666ex 03	.986666666665ex 09	.326013513513ex-06
			.145353027740ex-05

B. Subacute

Mouse No.	Ave. No. Mutant Colonies or Recombinants/ml	Ave. No. Colony Forming Units/ml	Mutation or Recombination Frequency
1	.141666666666ex 02	.171000000000ex 10	.828460038982ex-08
2	.275000000000ex 02	.261666666666ex 10	.105095541401ex-07
3	.101666666666ex 03	.154000000000ex 10	.660173160168ex-07
4	.666666666665ex 01	.114666666666ex 10	.581395348839ex-08
5	.583333333330ex 01	.523333333330ex 09	.111464968152ex-07
6	.100000000000ex 02	.142833333333ex 10	.700116686115ex-08
7	.208333333333ex 02	.103166666666ex 10	.201938610663ex-07
8	.191666666666ex 02	.113333333333ex 10	.169117647058ex-07
9	.308333333333ex 02	.112166666666ex 10	.274888558693ex-07
			.192630632612ex-07

Table 2 (continued)

HOST MEDIATED ASSAY
INDIVIDUAL MOUSE DATA

Compound No.: 71-15

Organism: G-46

Treatment: INTERMEDIATE

A. Acute

Mouse No.	Ave. No. Mutant Colonies or Recombinants/ml	Ave. No. Colony Forming Units/ml	Mutation or Recombination Frequency
1	.403333333333ex 03	.658333333330ex 09	.612658227850ex-06
2	.154333333333ex 04	.228333333333ex 09	.675912408758ex-05
3	.160000000000ex 03	.525000000000ex 09	.304761904761ex-06
4	.333333333333ex 01	.385000000000ex 09	.865800865800ex-08
5	.393333333333ex 03	.830000000000ex 09	.473895582328ex-06
6	.650000000000ex 02	.890000000000ex 09	.730337078651ex-07
7	.290000000000ex 03	.843333333330ex 09	.343873517787ex-06
			.122514357668ex-05

B. Subacute

Mouse No.	Ave. No. Mutant Colonies or Recombinants/ml	Ave. No. Colony Forming Units/ml	Mutation or Recombination Frequency
1	.691666666665ex 02	.147666666666ex 10	.468397291197ex-07
2	.158333333333ex 02	.150000000000ex 10	.105555555555ex-07
3	.225000000000ex 02	.145500000000ex 10	.154639175257ex-07
4	.100000000000ex 02	.153333333333ex 10	.652173913044ex-08
5	.108333333333ex 02	.135500000000ex 10	.799507995077ex-08
6	.175000000000ex 02	.104833333333ex 10	.166931637520ex-07
7	.833333333330ex 01	.715000000000ex 09	.116550116549ex-07
8	.150000000000ex 02	.943333333330ex 09	.159010600707ex-07
9	.233333333333ex 02	.151500000000ex 10	.154015401539ex-07
10	.166666666666ex 02	.831666666665ex 09	.200400801602ex-07
			.167066877071ex-07

Table 2 (continued)

HOST MEDIATED ASSAY
INDIVIDUAL MOUSE DATA

Compound No.: 71-15

Organism: G-46

Treatment: LOW

A. Acute

Mouse No.	Ave. No. Mutant Colonies or Recombinants/ml	Ave. No. Colony Forming Units/ml	Mutation or Recombination Frequency
1	.333333333333ex 01	.573333333330ex 09	.581395348840ex-08
2	.466666666666ex 02	.966666666665ex 08	.482758620689ex-06
3	.500000000000ex 01	.736666666665ex 09	.678733031675ex-08
4	.433333333333ex 02	.775000000000ex 09	.559139784945ex-07
5	.100000000000ex 02	.104666666666ex 10	.955414012744ex-08
6	.418333333333ex 03	.110000000000ex 10	.380303030302ex-06
7	.535000000000ex 03	.107333333333ex 10	.498447204970ex-06
			.205654036911ex-06

B. Subacute

Mouse No.	Ave. No. Mutant Colonies or Recombinants/ml	Ave. No. Colony Forming Units/ml	Mutation or Recombination Frequency
1	.175000000000ex 02	.150500000000ex 10	.116279069767ex-07
2	.150000000000ex 02	.233333333333ex 10	.642857142858ex-08
3	.500000000000ex 01	.143500000000ex 10	.348432055749ex-08
4	.916666666665ex 01	.120666666666ex 10	.759668508290ex-08
5	.500000000000ex 01	.605000000000ex 09	.826446280991ex-08
6	.116666666666ex 02	.876666666665ex 09	.133079847908ex-07
7	.108333333333ex 02	.651666666665ex 09	.166240409207ex-07
8	.416666666666ex 01	.708333333330ex 09	.588235294119ex-08
			.915204068850ex-08

Table 2 (continued)

HOST MEDIATED ASSAY
INDIVIDUAL MOUSE DATA

Compound No.: 71-15

Organism: TA-1530

Treatment: (+) CONTROL

A. Acute

Mouse No.	Ave. No. Mutant Colonies or Recombinants/ml	Ave. No. Colony Forming Units/ml	Mutation or Recombination Frequency
1	.251666666666ex 03	.656666666665ex 09	.383248730964ex-06
2	.418333333333ex 03	.288333333333ex 09	.145086705202ex-05
3	.981666666665ex 03	.491666666666ex 09	.199661016949ex-05
4	.197500000000ex 03	.101666666666ex 09	.194262295083ex-05
5	.458333333333ex 03	.573333333330ex 09	.799418604655ex-06
6	.386666666666ex 03	.775000000000ex 09	.498924731181ex-06
7	.325000000000ex 03	.550000000000ex 08	.590909090909ex-05
8	.320000000000ex 03	.661666666665ex 09	.483627204031ex-06
			.168305129402ex-05

B. Subacute

Mouse No.	Ave. No. Mutant Colonies or Recombinants/ml	Ave. No. Colony Forming Units/ml	Mutation or Recombination Frequency

Table 2 (continued)

HOST MEDIATED ASSAY
INDIVIDUAL MOUSE DATA

Compound No.: 71-15

Organism: TA-1530

Treatment: (-) CONTROL

A. Acute

Mouse No.	Ave. No. Mutant Colonies or Recombinants/ml	Ave. No. Colony Forming Units/ml	Mutation or Recombination Frequency
1	.121666666666ex 03	.660000000000ex 09	.184343434342ex-06
2	.180000000000ex 03	.921666666665ex 09	.195298372513ex-06
3	.950000000000ex 02	.653333333330ex 09	.145408163266ex-06
4	.966666666665ex 02	.950000000000ex 09	.101754385964ex-06
5	.160000000000ex 04	.221666666666ex 10	.721804511280ex-06
6	.300000000000ex 02	.520000000000ex 09	.576923076923ex-07
7	.516666666665ex 02	.768333333330ex 09	.672451193059ex-07
			.210506613478ex-06

B. Subacute

Mouse No.	Ave. No. Mutant Colonies or Recombinants/ml	Ave. No. Colony Forming Units/ml	Mutation or Recombination Frequency
1	.483333333333ex 02	.915000000000ex 09	.528233151183ex-07
2	.550000000000ex 02	.147166666666ex 10	.373725934316ex-07
3	.477500000000ex 03	.121333333333ex 10	.393543956045ex-06
4	.475000000000ex 02	.128833333333ex 10	.368693402329ex-07
5	.291666666666ex 02	.408333333333ex 09	.714285714284ex-07
6	.541666666665ex 02	.119500000000ex 10	.453277545326ex-07
7	.333333333333ex 02	.109833333333ex 10	.303490136571ex-07
8	.591666666665ex 02	.118166666666ex 10	.500705218619ex-07
			.897231332880ex-07

Table 2 (continued)

HOST MEDIATED ASSAY
INDIVIDUAL MOUSE DATA

Compound No.: 71-15

Organism: TA-1530

Treatment: MAXIMUM

A. Acute

Mouse No.	Ave. No. Mutant Colonies or Recombinants/ml	Ave. No. Colony Forming Units/ml	Mutation or Recombination Frequency
1	.148333333333ex 03	.413333333333ex 10	.358870967741ex-07
2	.900000000000ex 03	.550000000000ex 10	.163636363636ex-06
3	.625000000000ex 03	.673333333330ex 09	.928217821786ex-06
4	.283333333333ex 02	.991666666665ex 09	.285714285714ex-07
5	.250000000000ex 02	.423333333333ex 09	.590551181102ex-07
6	.200000000000ex 02	.335000000000ex 09	.597014925373ex-07
			.212511553566ex-06

B. Subacute

Mouse No.	Ave. No. Mutant Colonies or Recombinants/ml	Ave. No. Colony Forming Units/ml	Mutation or Recombination Frequency
1	.370000000000ex 02	.940000000000ex 09	.393617021276ex-07
2	.266666666666ex 02	.491666666666ex 09	.542372881355ex-07
3	.483333333333ex 02	.536666666665ex 09	.900621118014ex-07
4	.491666666665ex 02	.541666666665ex 09	.907692307693ex-07
5	.316666666666ex 02	.791666666665ex 09	.400000000000ex-07
6	.550000000000ex 02	.458333333333ex 09	.120000000000ex-06
7	.287500000000ex 02	.866666666665ex 09	.331730769231ex-07
8	.366666666666ex 02	.836666666665ex 09	.438247011952ex-07
9	.383333333333ex 02	.426666666666ex 09	.898437500000ex-07
10	.620000000000ex 02	.738333333330ex 09	.839729119642ex-07
			.683244772915ex-07

Table 2 (continued)

HOST MEDIATED ASSAY
INDIVIDUAL MOUSE DATA

Compound No.: 71-15

Organism: TA-1530

Treatment: INTERMEDIATE

A. Acute

Mouse No.	Ave. No. Mutant Colonies or Recombinants/ml	Ave. No. Colony Forming Units/ml	Mutation or Recombination Frequency
1	.533333333330ex 02	.811666666665ex 09	.657084188908ex-07
2	.333333333333ex 02	.328333333333ex 09	.101522842639ex-06
3	.550000000000ex 02	.471666666666ex 09	.116607773851ex-06
4	.800000000000ex 02	.181666666666ex 09	.440366972478ex-06
5	.300000000000ex 02	.171666666666ex 09	.174757281554ex-06
6	.283333333333ex 02	.208333333333ex 09	.136000000000ex-06
7	.183333333333ex 02	.345000000000ex 09	.531400966182ex-07
8	.150000000000ex 02	.115000000000ex 09	.130434782608ex-06
9	.483333333333ex 02	.175000000000ex 09	.276190476190ex-06
			.166080960534ex-06

B. Subacute

Mouse No.	Ave. No. Mutant Colonies or Recombinants/ml	Ave. No. Colony Forming Units/ml	Mutation or Recombination Frequency
1	.408333333333ex 02	.695000000000ex 09	.587529976018ex-07
2	.235000000000ex 03	.103666666666ex 10	.226688102895ex-06
3	.366666666666ex 02	.875000000000ex 09	.419047619046ex-07
4	.175000000000ex 03	.533333333330ex 09	.328125000002ex-06
5	.291666666666ex 02	.668333333330ex 09	.436408977557ex-07
6	.766666666665ex 02	.973333333330ex 09	.787671232877ex-07
7	.583333333330ex 02	.102500000000ex 10	.569105691053ex-07
			.119255636078ex-06

Table 2 (continued)

HOST MEDIATED ASSAY
INDIVIDUAL MOUSE DATA

Compound No.: 71-15

Organism: TA-1530

Treatment: LOW

A. Acute

Mouse No.	Ave. No. Mutant Colonies or Recombinants/ml	Ave. No. Colony Forming Units/ml	Mutation or Recombination Frequency
1	.350000000000ex 02	.315000000000ex 09	.111111111111ex-06
2	.516666666665ex 02	.468333333333ex 09	.110320284697ex-06
3	.800000000000ex 02	.178333333333ex 09	.448598130841ex-06
4	.533333333330ex 02	.820000000000ex 09	.650406504060ex-07
5	.200000000000ex 02	.211666666666ex 09	.944881889766ex-07
6	.200000000000ex 02	.166666666666ex 09	.120000000000ex-06
7	.133333333333ex 02	.116666666666ex 09	.114285714286ex-06
8	.483333333333ex 02	.178333333333ex 09	.271028037383ex-06
9	.166666666666ex 02	.346666666666ex 09	.480769230768ex-07
10	.450000000000ex 02	.535000000000ex 09	.841121495327ex-07
			.146706119029ex-06

B. Subacute

Mouse No.	Ave. No. Mutant Colonies or Recombinants/ml	Ave. No. Colony Forming Units/ml	Mutation or Recombination Frequency
1	.450000000000ex 02	.573333333330ex 09	.784883720934ex-07
2	.107500000000ex 03	.575000000000ex 09	.186956521739ex-06
3	.550000000000ex 02	.116000000000ex 10	.474137931034ex-07
4	.407500000000ex 03	.575000000000ex 09	.708695652173ex-06
5	.341666666666ex 02	.676666666665ex 09	.504926108374ex-07
6	.475000000000ex 02	.800000000000ex 09	.593750000000ex-07
7	.191666666666ex 02	.531666666665ex 09	.360501567397ex-07
8	.458333333333ex 02	.108833333333ex 10	.421133231241ex-07
9	.562500000000ex 02	.878333333330ex 09	.640417457307ex-07
			.141514130612ex-06

Table 2 (continued)

HOST MEDIATED ASSAY
INDIVIDUAL MOUSE DATA

Compound No.: 71-15

Organism: D-3

Treatment: (+)CONTROL

A. Acute

Mouse No.	Ave. No. Mutant Colonies or Recombinants/ml	Ave. No. Colony Forming Units/ml	Mutation or Recombination Frequency
1	.340000000000ex 05	.540000000000ex 08	.629629629629ex-03
2	.355000000000ex 05	.388333333333ex 08	.914163090129ex-03
3	.333333333333ex 04	.112500000000ex 07	.296296296296ex-02
4	.570000000000ex 05	.785000000000ex 08	.726114649681ex-03
5	.380000000000ex 05	.428333333333ex 08	.887159533074ex-03
6	.485000000000ex 05	.571666666665ex 08	.848396501460ex-03
7	.330000000000ex 05	.305000000000ex 08	.108196721311ex-02
8	.115000000000ex 05	.751666666665ex 08	.152993348115ex-03
9	.415000000000ex 05	.208333333333ex 08	.199200000000ex-02
			.113282076978ex-02

B. Subacute

Mouse No.	Ave. No. Mutant Colonies or Recombinants/ml	Ave. No. Colony Forming Units/ml	Mutation or Recombination Frequency

18

Table 2 (continued)

HOST MEDIATED ASSAY
INDIVIDUAL MOUSE DATA

Compound No.: 71-15

Organism: D-3

Treatment: (-) CONTROL

A. Acute

Mouse No.	Ave. No. Mutant Colonies or Recombinants/ml	Ave. No. Colony Forming Units/ml	Mutation or Recombination Frequency
1	.300000000000ex 04	.440000000000ex 08	.681818181818ex-04
2	.250000000000ex 04	.506666666665ex 08	.493421052633ex-04
3	.150000000000ex 04	.228333333333ex 08	.656934306570ex-04
4	.450000000000ex 04	.516666666665ex 08	.870967741938ex-04
5	.350000000000ex 04	.413333333333ex 08	.846774193549ex-04
6	.450000000000ex 04	.271666666666ex 08	.165644171779ex-03
7	.500000000000ex 04	.463333333333ex 08	.107913669064ex-03
8	.350000000000ex 04	.206666666666ex 08	.169354838710ex-03
9	.200000000000ex 04	.363333333333ex 08	.550458715596ex-04
10	.200000000000ex 04	.328333333333ex 08	.609137055838ex-04
			.913863804344ex-04

B. Subacute

Mouse No.	Ave. No. Mutant Colonies or Recombinants/ml	Ave. No. Colony Forming Units/ml	Mutation or Recombination Frequency
1	.500000000000ex 04	.546666666665ex 08	.914634146344ex-04
2	.400000000000ex 04	.468333333333ex 08	.854092526690ex-04
3	.350000000000ex 04	.581666666665ex 08	.601719197709ex-04
4	.300000000000ex 04	.521666666665ex 08	.575079872206ex-04
5	.300000000000ex 04	.666666666665ex 08	.450000000001ex-04
6	.550000000000ex 04	.871666666665ex 08	.630975143404ex-04
7	.350000000000ex 04	.591666666665ex 08	.591549295776ex-04
8	.650000000000ex 04	.104833333333ex 09	.620031796504ex-04
9	.500000000000ex 04	.713333333330ex 08	.700934579442ex-04
10	.550000000000ex 04	.878333333330ex 08	.626185958256ex-04
			.656520251629ex-04

Table 2 (continued)

HOST MEDIATED ASSAY
INDIVIDUAL MOUSE DATA

Compound No.: 71-15

Organism: D-3

Treatment: MAXIMUM

A. Acute

Mouse No.	Ave. No. Mutant Colonies or Recombinants/ml	Ave. No. Colony Forming Units/ml	Mutation or Recombination Frequency
1	.250000000000ex 04	.887500000000ex 07	.281590140845ex-03
2	.350000000000ex 04	.536666666665ex 08	.652173913045ex-04
3	.350000000000ex 04	.423333333333ex 08	.826771653543ex-04
4	.300000000000ex 04	.220000000000ex 08	.136363636363ex-03
5	.450000000000ex 04	.426666666666ex 08	.105468750000ex-03
6	.150000000000ex 04	.200000000000ex 08	.750000000000ex-04
7	.100000000000ex 04	.947500000000ex 07	.105540897097ex-03
			.121708282994ex-03

B. Subacute

Mouse No.	Ave. No. Mutant Colonies or Recombinants/ml	Ave. No. Colony Forming Units/ml	Mutation or Recombination Frequency
1	.250000000000ex 04	.340000000000ex 08	.735294117647ex-04
2	.300000000000ex 04	.390000000000ex 08	.769230769230ex-04
3	.250000000000ex 04	.525000000000ex 08	.476190476190ex-04
4	.750000000000ex 04	.661666666665ex 08	.113350125944ex-03
5	.750000000000ex 04	.376666666666ex 08	.199115044248ex-03
6	.250000000000ex 04	.493333333333ex 08	.506756756757ex-04
7	.550000000000ex 04	.610000000000ex 08	.901639344262ex-04
8	.300000000000ex 04	.493333333333ex 08	.608108108108ex-04
9	.200000000000ex 04	.533333333330ex 08	.375000000002ex-04
10	.300000000000ex 04	.280000000000ex 08	.107142857142ex-03
			.856829984551ex-04

Table 2 (continued)

HOST MEDIATED ASSAY
INDIVIDUAL MOUSE DATA

Compound No.: 71-15

Organism: D-3

Treatment: INTERMEDIATE

A. Acute

Mouse No.	Ave. No. Mutant Colonies or Recombinants/ml	Ave. No. Colony Forming Units/ml	Mutation or Recombination Frequency
1	.150000000000ex 04	.291666666666ex 08	.514285714286ex-04
2	.150000000000ex 04	.441666666666ex 08	.339622641509ex-04
3	.500000000000ex 03	.120000000000ex 08	.416666666666ex-04
4	.300000000000ex 04	.608333333330ex 08	.493150684934ex-04
5	.350000000000ex 04	.533333333330ex 08	.656250000004ex-04
6	.200000000000ex 04	.766666666665ex 08	.260869565217ex-04
7	.100000000000ex 04	.109500000000ex 08	.913242009132ex-04
8	.250000000000ex 04	.441666666666ex 08	.566037735849ex-04
			.520015627196ex-04

B. Subacute

Mouse No.	Ave. No. Mutant Colonies or Recombinants/ml	Ave. No. Colony Forming Units/ml	Mutation or Recombination Frequency
1	.150000000000ex 04	.591666666665ex 08	.253521126761ex-04
2	.250000000000ex 04	.306666666666ex 08	.815217391306ex-04
3	.800000000000ex 04	.328333333333ex 08	.243654822335ex-03
4	.250000000000ex 04	.375000000000ex 08	.666666666666ex-04
5	.400000000000ex 04	.158333333333ex 08	.252631578947ex-03
6	.700000000000ex 04	.525000000000ex 08	.133333333333ex-03
7	.650000000000ex 04	.720000000000ex 08	.902777777777ex-04
8	.300000000000ex 04	.515000000000ex 08	.582524271844ex-04
9	.400000000000ex 04	.311666666666ex 08	.128342245989ex-03
10	.250000000000ex 04	.286666666666ex 08	.872093023257ex-04
			.116724200635ex-03

21

Table 2 (concluded)

HOST MEDIATED ASSAY
INDIVIDUAL MOUSE DATA

Compound No.: 71-15

Organism: D-3

Treatment: LOW

A. Acute

Mouse No.	Ave. No. Mutant Colonies or Recombinants/ml	Ave. No. Colony Forming Units/ml	Mutation or Recombination Frequency
1	.400000000000ex 04	.491666666666ex 08	.813559322035ex-04
2	.200000000000ex 04	.338333333333ex 08	.591133004926ex-04
3	.150000000000ex 04	.371666666666ex 08	.403587443946ex-04
4	.150000000000ex 04	.817500000000ex 07	.183486238532ex-03
5	.200000000000ex 04	.208333333333ex 08	.960000000001ex-04
6	.200000000000ex 04	.436666666666ex 08	.458015267176ex-04
7	.300000000000ex 04	.571666666665ex 08	.524781341109ex-04
8	.300000000000ex 04	.335000000000ex 08	.895522388059ex-04
9	.500000000000ex 04	.596666666665ex 08	.837988826817ex-04
			.813272219927ex-04

B. Subacute

Mouse No.	Ave. No. Mutant Colonies or Recombinants/ml	Ave. No. Colony Forming Units/ml	Mutation or Recombination Frequency
1	.300000000000ex 04	.283333333333ex 08	.105882352941ex-03
2	.350000000000ex 04	.515000000000ex 08	.679611650485ex-04
3	.200000000000ex 04	.371666666666ex 08	.538116591929ex-04
4	.350000000000ex 04	.443333333333ex 08	.789473684211ex-04
5	.600000000000ex 04	.360000000000ex 08	.166666666666ex-03
6	.250000000000ex 04	.535000000000ex 08	.467289719626ex-04
7	.500000000000ex 04	.591666666665ex 08	.845070422537ex-04
8	.400000000000ex 04	.536666666665ex 08	.745341614909ex-04
9	.500000000000ex 04	.341666666666ex 08	.146341463414ex-03
			.917089834874ex-04

ERRATUM

Table 3

HOST-MEDIATED ASSAY
IN VITRO MUTAGENICITY OF COMPOUND 71-15 (GUM ARABIC)

Salmonella typhimurium G-46

5% w/v 71-15	EMS
negative	positive

Salmonella typhimurium TA-1530

5% w/v 71-15	EMS
negative	positive

Saccharomyces cerevisiae D-3

Compound	Concentration	Survival (%)	Recombinants/10^5 Survivors	RFt/RFc
71-15	5% w/v	16%	2.57	1.15
EMS	1% w/v	62%	89.60	38.62
Control (-)	--	100%	2.32 ✓	1

Table

CYTOGENETIC ASSAY
METAPHASE SUMMARY SHEET BY TIME OF SACRIFICE
Compound 71-15

Dosage (mg/kg)	Time*	Mitotic Index (%)	No. of Animals	No. of Cells	Cells with Breaks (%)	Cells with Rearrangements (%)	Cells with More than One Type of Aber. (%)	Cells with Aber. (%)
TEM (0.4 mg/kg)	6	0.55%	4	172	14.0%	2.9%	1.2%	15.7%
Negative Control	6	1.53	3	150	0.7	0	0	0.7
30 mg/kg	6	1.57	5	228	0.9	0	0	0.9
2500 mg/kg	6	1.77	5	228	4.8	0.4	0	5.3
5000 mg/kg	6	1.74	5	191	5.2	0	0	5.2
Negative Control	24	1.3	3	99	4.0	0	0	4.0
30 mg/kg	24	2.02	5	250	2.4	0.4	0	2.8
2500 mg/kg	24	1.69	5	237	2.2	0.4	0	2.5
5000 mg/kg	24	2.31	5	250	0.4	0.4	0	0.8
Negative Control	48	2.23	3	150	2.7	0	0	2.7
30 mg/kg	48	2.14	5	250	1.2	0	0	1.2
2500 mg/kg	48	1.79	5	250	2.0	0	0	2.0
5000 mg/kg	48	2.05	5	250	1.2	0	0	1.2
Negative Control	SA**	1.83	3	150	2.7	0	0	2.7
30 mg/kg	SA	2.78	5	250	2.4	0.8	0	3.2
2500 mg/kg	SA	1.95	5	250	2.4	0	0	2.4
5000 mg/kg	SA	1.93	5	250	1.2	0.4	0	1.6

* Time of sacrifice after treatment (hours)
** SA = subacute

Table 5

CYTOGENETIC ASSAY
METAPHASE SUMMARY SHEET BY DOSE LEVELS
Compound 71-15

Dosage (mg/kg)	Time*	Mitotic Index (%)	No. of Animals	No. of Cells	Cells with Breaks (%)	Cells with Rearrangements (%)	Cells with More than One Type of Aber. (%)	Cells with Aber. (%)
TEM (0.4 mg/kg)	6	0.55%	4	172	14.0%	2.9%	1.2%	15.7%
Negative Control	6	1.53	3	150	0.7	0	0	0.7
	24	1.30	3	9[illegible]	4.0	0	0	4.0
	48	2.23	3	150	2.7	0	0	2.7
	SA	1.83	3	150	2.7	0	0	2.7
30 mg/kg	6	1.57	5	228	0.9	0	0	0.9
	24	2.02	5	250	2.4	0.4	0	2.8
	48	2.14	5	250	1.2	0	0	1.2
	SA	2.78	5	250	2.4	0.8	0	3.2
2500 mg/kg	6	1.77	5	228	4.8	0.4	0	5.3
	24	1.69	5	237	2.2	0.4	0	2.5
	48	1.79	5	250	2.0	0	0	2.0
	SA	1.95	5	250	2.4	0	0	2.4
5000 mg/kg	6	1.74	5	191	5.2	0	0	5.2
	24	2.31	5	250	0.4	0.4	0	0.8
	48	2.05	5	250	1.2	0	0	1.2
	SA	1.93	5	250	1.2	0.4	0	1.6

* Time of sacrifice after treatment (hours)

Table 6

CYTOGENETIC ASSAY
ANAPHASE SUMMARY SHEET
Compound 71-15

Dosage	Time*	No. of Cells	Cells with Acentric Fragments (%)	Cells with Bridges (%)	Multipolar Cells (%)	Cells with More than One Type Aber. (%)	Cells with Aber. (%)
Negative Control	48	83	12.0%	6.0%	--	2.4%	15.7%
1.25 µg/ml	48	101	9.9	15.8	1.0	5.9	20.8
12.5 µg/ml	48	138	19.6	15.9	--	7.2	28.1
125 µg/ml	48	101	14.9	15.8	--	8.9	21.8
Positive Control (TEM @ 0.5 µg/ml and 0.1 µg/ml)		No anaphases at either concentration					

* Time of harvest after treatment

Table 8

AVERAGE IMPLANTATIONS PER PREGNANT FEMALE

Summary

Compound: Gum Arabic
FDA No: 71-15

Week of Study	Control (10 ml/kg)	TEM (0.2 mg/kg)	71-15 (30 mg/kg)	71-15 (2.5 g/kg)	71-15 (5 g/kg)
Acute-Single Dose					
1	90/9=10.0	86/11= 7.8	217/18=12.1	123/11=11.2	208/18=11.6
2	176/20= 8.8	193/20= 9.7	168/15=11.2	226/19=11.9**I	233/20=11.7*I
3	199/18=11.1	166/17= 9.8	177/15=11.8	205/18=11.4	232/19=12.2
4	194/19=10.2	94/14= 6.7*	212/18=11.8	195/17=11.5	201/18=11.2
5	163/16=10.2	199/17=11.7	241/20=12.1*I	207/18=11.5	205/19=10.8
6	151/12=12.6	238/20=11.9	251/20=12.6	193/17=11.4	202/20=10.1
7	176/17=10.4	197/18=10.9	208/19=10.9	199/19=10.5	188/15=12.5*I
8	240/20=12.0	248/20=12.4	262/20=13.1	255/20=12.8	241/19=12.7
Subacute-Multiple Dose					
1	134/11=12.2		234/20=11.7	166/14=11.9	198/16=12.4
2	184/16=11.5		223/20=11.2	238/20=11.9	169/15=11.3
3	171/15=11.4		245/20=12.3	218/19=11.5	212/19=11.2
4	199/18=11.1		214/18=11.9	225/19=11.8	179/16=11.2
5	165/14=11.8		209/18=11.6	226/20=11.3	195/18=10.8
6	203/17=11.9		228/19=12.0	198/18=11.0	189/15=12.6
7	224/19=11.8		225/19=11.8	240/20=12.0	256/20=12.8

* Significant at $P < 0.05$
** Significant at $P < 0.01$
I Increase above control

Table 9

AVERAGE DEAD IMPLANTS PER PREGNANT FEMALE

Summary

Compound: Gum Arabic
FDA No: 71-15

Week of Study	Control (10 ml/kg)	TEM (0.2 mg/kg)	71-15 (30 mg/kg)	71-15 (2.5 g/kg)	71-15 (5 g/kg)
Acute-Single Dose					
1	5/9=0.56	31/11=2.82*	23/18=1.27	6/11=0.55	16/18=0.89
2	9/20=0.45	125/20=6.25**	13/15=0.87	9/19=0.47	18/20=0.90
3	8/18=0.44	109/17=6.41**	27/15=1.80*	22/18=1.22	32/19=1.68*
4	15/19=0.79	50/14=3.57**	14/18=0.78	21/17=1.24	29/18=1.61
5	9/16=0.56	62/17=3.65**	14/20=0.70	14/18=0.78	15/19=0.79
6	11/12=0.92	14/20=0.70	25/20=1.25	12/17=0.71	13/20=0.65
7	11/17=0.65	9/18=0.50	13/19=0.68	19/19=1.00	16/15=1.07
8	14/20=0.70	9/20=0.45	26/20=1.30	9/20=0.45	12/19=0.63
Subacute-Multiple Dose					
1	10/11=0.91		19/20=0.95	13/14=0.93	7/16=0.44
2	10/16=0.63		14/20=0.70	24/20=1.20	10/15=0.67
3	17/15=1.13		18/20=0.90	19/19=1.00	21/19=1.11
4	16/18=0.89		13/18=0.72	21/19=1.11	10/16=0.63
5	9/14=0.64		15/18=0.83	17/20=0.85	13/18=0.72
6	26/17=1.53		14/19=0.74	14/18=0.78	19/15=1.27
7	11/19=0.58		8/19=0.42	16/20=0.80	17/20=0.85

* Significant at $P < 0.05$
** Significant at $P < 0.01$

Table 10

DEAD IMPLANTS/TOTAL IMPLANTS

Summary

Compound: Gum Arabic
FDA No: 71-15

Week of Study	Control (10 ml/kg)	TEM (0.2 mg/kg)	71-15 (30 mg/kg)	71-15 (2.5 g/kg)	71-15 (5 g/kg)
Acute-Single Dose					
1	5/90=0.06	31/86=0.36**	23/217=0.11	6/123=0.05	16/208=0.08
2	9/176=0.05	125/193=0.65**	13/168=0.08	9/226=0.04	18/233=0.08
3	8/199=0.04	109/166=0.66**	27/177=0.15	22/205=0.11	32/232=0.14*
4	15/194=0.08	50/94=0.53**	14/212=0.07	21/195=0.11	29/201=0.14
5	9/163=0.06	62/199=0.31*	14/241=0.06	14/207=0.07	15/205=0.07
6	11/151=0.07	14/238=0.06	25/251=0.10	12/193=0.06	13/202=0.06
7	11/176=0.06	9/197=0.05	13/208=0.06	19/199=0.10	16/188=0.09
8	14/240=0.06	9/248=0.04	26/262=0.10	9/255=0.04	12/241=0.05
Subacute-Multiple Dose					
1	10/134=0.07		19/234=0.08	13/166=0.08	7/198=0.04
2	10/184=0.05		14/223=0.06	24/238=0.10	10/169=0.06
3	17/171=0.10		18/245=0.07	19/218=0.09	21/212=0.10
4	16/199=0.08		13/214=0.06	21/225=0.09	10/179=0.06
5	9/165=0.05		15/209=0.07	17/226=0.08	13/195=0.07
6	26/203=0.13		14/228=0.06	14/198=0.07	19/189=0.10
7	11/224=0.05		8/225=0.04	16/240=0.07	17/256=0.07

* Significant at $P < 0.05$
** Significant at $P < 0.01$

DOMINANT LETHAL GENE-RAT

Table 11

AVERAGE CORPORA LUTEA PER PREGNANT FEMALE

Summary

Compound: Gum Arabic
FDA No: 71-15

Week of Study	Control (10 ml/kg)	TEM (0.2 mg/kg)	71-15 (30 mg/kg)	71-15 (2.5 g/kg)	71-15 (5 g/kg)
Acute-Single Dose					
1	123/9=13.7	138/11=12.5	238/18=13.2	146/11=13.3	280/18=15.6
2	228/20=11.4	247/20=12.4	191/15=12.7	247/19=13.0**I	256/20=12.8*I
3	216/18=12.0	196/17=11.5	184/15=12.3	235/18=13.1	244/19=12.8
4	244/19=12.8	161/14=11.5*	231/18=12.8	235/17=13.8	229/18=12.7
5	198/16=12.4	228/17=13.4	266/20=13.3	227/18=12.6	240/19=12.6
6	163/12=13.6	249/20=12.5	262/20=13.1	206/17=12.1	229/20=11.5*
7	213/17=12.5	234/18=13.0	243/19=12.8	235/19=12.4	202/15=13.5
8	271/20=13.6	264/20=13.2	279/20=14.0	275/20=13.8	262/19=13.8
Subacute-Multiple Dose					
1	141/11=12.8		264/20=13.2	179/14=12.8	217/16=13.6
2	190/16=11.9		238/20=11.9	244/20=12.2	185/15=12.3
3	189/15=12.6		270/20=13.5	251/19=13.2	244/19=12.8
4	217/18=12.1		235/18=13.1	241/19=12.7	194/16=12.1
5	183/14=13.1		230/18=12.8	245/20=12.3	212/18=11.8
6	245/17=14.4		251/19=13.2	222/18=12.3*	196/15=13.1
7	251/19=13.2		241/19=12.7	283/20=14.2	281/20=14.1

* Significant at P < 0.05
** Significant at P < 0.01
I Increase above control

Table 12

AVERAGE PREIMPLANTATION LOSS PER PREGNANT FEMALE

Summary

Compound: Gum Arabic
FDA No: 71-15

Week of Study	Control (10 ml/kg)	TEM (0.2 mg/kg)	71-15 (30 mg/kg)	71-15 (2.5 g/kg)	71-15 (5 g/kg)
Acute-Single Dose					
1	33/9=3.67	52/11=4.73	21/18=1.17	23/11=2.09	72/18=4.00
2	52/20=2.60	54/20=2.70	23/15=1.53	21/19=1.10*D	23/20=1.15*D
3	17/18=0.94	30/17=1.76	7/15=0.47	30/18=1.67	12/19=0.63
4	50/19=2.63	67/14=4.79*	19/18=1.06	40/17=2.35	28/18=1.56
5	35/16=2.19	29/17=1.71	25/20=1.25	20/18=1.11	35/19=1.84
6	12/12=1.00	11/20=0.55	11/20=0.55	13/17=0.76	27/20=1.35
7	37/17=2.18	37/18=2.06	35/19=1.84	36/19=1.89	14/15=0.93
8	31/20=1.55	16/20=0.80	17/20=0.85	20/20=1.00	21/19=1.11
Subacute-Multiple Dose					
1	7/11=0.64		30/20=1.50	13/14=0.93	19/16=1.19
2	6/16=0.38		15/20=0.75	6/20=0.30	16/15=1.07
3	18/15=1.20		25/20=1.25	33/19=1.74	32/19=1.68
4	18/18=1.00		21/18=1.17	16/19=0.84	15/16=0.94
5	18/14=1.29		21/18=1.17	19/20=0.95	17/18=0.94
6	42/17=2.47		23/19=1.21	24/18=1.33	7/15=0.47
7	27/19=1.42		16/19=0.84	43/20=2.15	25/20=1.25

** Significant at $P < 0.01$
D Decrease below control

DOMINANT LETHAL GENE-RAT

Table 7

ORAL LD_{50}

Compound: Gum Arabic
FDA NO: 71-15

Single Dose[a]	> 10 g/kg
Multiple Dose[b]	> 5 g/kg

[a] Five male, Sprague-Dawley rats, weighing 200-250 g each, were fasted overnight and then administered orally specified amounts of the candidate compound suspended in water.

[b] Five male, nonfasted Sprague-Dawley rats, weighing 200-250g each, were administered orally specified amounts of the candidate compound as a partial suspension in water.

DOMINANT LETHAL GENE-RAT

Table 8

AVERAGE IMPLANTATIONS PER PREGNANT FEMALE

Summary

Compound: Gum Arabic
FDA No: 71-15

Week of Study	Control (10 ml/kg)	TEM (0.2 mg/kg)	71-15 (30 mg/kg)	71-15 (2.5 g/kg)	71-15 (5 g/kg)
Acute-Single Dose					
1	90/9=10.0	86/11= 7.8	217/18=12.1	123/11=11.2	208/18=11.6
2	176/20= 8.8	193/20= 9.7	168/15=11.2	226/19=11.9**I	233/20=11.7*I
3	199/18=11.1	166/17= 9.8	177/15=11.8	205/18=11.4	232/19=12.2
4	194/19=10.2	94/14= 6.7*	212/18=11.8	195/17=11.5	201/18=11.2
5	163/16=10.2	199/17=11.7	241/20=12.1	207/18=11.5	205/19=10.8
6	151/12=12.6	238/20=11.9	251/20=12.6	193/17=11.4	202/20=10.1
7	176/17=10.4	197/18=10.9	208/19=10.9	199/19=10.5	188/15=12.5
8	240/20=12.0	248/20=12.4	262/20=13.1	255/20=12.8	241/19=12.7
Subacute-Multiple Dose					
1	134/11=12.2		234/20=11.7	166/14=11.9	198/16=12.4
2	184/16=11.5		223/20=11.2	238/20=11.9	169/15=11.3
3	171/15=11.4		245/20=12.3	218/19=11.5	212/19=11.2
4	199/18=11.1		214/18=11.9	225/19=11.8	179/16=11.2
5	165/14=11.8		209/18=11.6	226/20=11.3	195/18=10.8
6	203/17=11.9		228/19=12.0	198/18=11.0	189/15=12.6
7	224/19=11.8		225/19=11.8	240/20=12.0	256/20=12.8

* Significant at P < 0.05
** Significant at P < 0.01
I Increase above control

DOMINANT LETHAL GENE-RAT

Table 9

AVERAGE DEAD IMPLANTS PER PREGNANT FEMALE

Summary

Compound: Gum Arabic
FDA No: 71-15

Week of Study	Control (10 ml/kg)	TEM (0.2 mg/kg)	71-15 (30 mg/kg)	71-15 (2.5 g/kg)	71-15 (5 g/kg)
Acute-Single Dose					
1	5/9=0.56	31/11=2.82	23/18=1.27	6/11=0.55	16/18=0.89
2	9/20=0.45	125/20=6.25**	13/15=0.87	9/19=0.47	18/20=0.90
3	8/18=0.44	109/17-6.41**	27/15=1.80	22/18=1.22	32/19=1.68*
4	15/19=0.79	50/14=3.57**	14/18=0.78	21/17=1.24	29/18=1.61
5	9/16=0.56	62/17=3.65**	14/20=0.70	14/18=0.78	15/19=0.79
6	11/12=0.92	14/20=0.70	25/20=1.25	12/17=0.71	13/20=0.65
7	11/17-0.65	9/18=0.50	13/19=0.68	19/19=1.00	16/15=1.07
8	14/20=0.70	9/20-0.45	26/20=1.30	9/20=0.45	12/19=0.63
Subacute-Multiple Dose					
1	10/11=0.91		19/20=0.95	13/14=0.93	7/16=0.44
2	10/16=0.63		14/20=0.70	24/20=1.20	10/15-0.67
3	17/15=1.13		18/20=0.90	19/19=1.00	21/19=1.11
4	16/18=0.89		13/18=0.72	21/19=1.11	10/16=0.63
5	9/14=0.64		15/18=0.83	17/20=0.85	13/18=0.72
6	26/17=1.53		14/19=0.74	14/18=0.78	19/15=1.27
7	11/19=0.58		8/19=0.42	16/20-0.80	17/20=0.85

* Significant at P < 0.05
** Significant at P < 0.01

DOMINANT LETHAL GENE-RAT

Table 10

DEAD IMPLANTS/TOTAL IMPLANTS

Summary

Compound: Gum Arabic
FDA No: 71-15

Week of Study	Control (10 ml/kg)	TEM (0.2 mg/kg)	71-15 (30 mg/kg)	71-15 (2.5 g/kg)	71-15 (5 g/kg)
Acute-Single Dose					
1	5/90=0.06	31/86=0.36**	23/217=0.11	6/123=0.05	16/208=0.08
2	9/176=0.05	125/193=0.65**	13/168=0.08	9/226=0.04	18/233=0.08
3	8/199=0.04	109/166=0.66**	27/177=0.15*	22/205=0.11	32/232=0.14*
4	15/194=0.08	50/94=0.53**	14/212=0.07	21/195=0.11	29/201=0.14
5	9/163=0.06	62/199=0.31*	14/241=0.06	14/207=0.07	15/205=0.07
6	11/151=0.07	14/238=0.06	25/251=0.10	12/193=0.06	13/202=0.06
7	11/176=0.06	9/197=0.05	13/208=0.06	19/199=0.10	16/188=0.09
8	14/240=0.06	9/248=0.04	26/262=0.10	9/255=0.04	12/241=0.05
Subacute-Multiple Dose					
1	10/134=0.07		19/234=0.08	13/166=0.08	7/198=0.04
2	10/184=0.05		14/223=0.06	24/238=0.10	10/169=0.06
3	17/171=0.10		18/245=0.07	19/218=0.09	21/212=0.10
4	16/199=0.08		13/214=0.06	21/225=0.09	10/179=0.06
5	9/165=0.05		15/209=0.07	17/226=0.08	13/195=0.07
6	26/203=0.13		14/228=0.06	14/198=0.07	19/189=0.10
7	11/224=0.05		8/225=0.04	16/240=0.07	17/256=0.07

* Significant at P < 0.05
** Significant at P < 0.01

Table 11

AVERAGE CORPORA LUTEA PER PREGNANT FEMALE

Summary

Compound: Gum Arabic
FDA No: 71-15

Week of Study	Control (10 ml/kg)	TEM (0.2 mg/kg)	71-15 (30 mg/kg)	71-15 (2.5 g/kg)	71-15 (5 g/kg)
Acute-Single Dose					
1	123/9=13.7	138/11=12.5	238/18=13.2	146/11=13.3	280/18=15.6
2	228/20=11.4	247/20=12.4	191/15=12.7	247/19=13.0*I	256/20=12.8*I
3	216/18=12.0	196/17=11.5	184/15=12.3	235/18=13.1	244/19=12.8
4	244/19=12.8	161/14=11.5*	231/18=12.8	235/17=13.8	229/18=12.7
5	198/16=12.4	228/17=13.4	266/20=13.3	227/18=12.6	240/19=12.6
6	163/12=13.6	249/20=12.5	262/20=13.1	206/17=12.1	229/20=11.5*
7	213/17=12.5	234/18=13.0	243/19=12.8	235/19=12.4	202/15=13.5
8	271/20=13.0	264/20=13.2	279/20=14.0	275/20=13.8	262/19=13.8
Subacute-Multiple Dose					
1	141/11=12.8		264/20=13.2	179/14=12.8	217/16=13.6
2	190/16=11.9		238/20=11.9	244/20=12.2	185/15=12.3
3	189/15=12.6		270/20=13.5	251/19=13.2	244/19=12.8
4	217/18=12.1		235/18=13.1	241/19=12.7	194/16=12.1
5	183/14=13.1		230/18=12.8	245/20=12.3	212/18=11.8
6	245/17=14.4		251/19=13.2	222/18=12.3*	196/15=13.1
7	251/19=13.2		241/19=12.7	283/20=14.2	281/20=14.1

* Significant at $P < 0.05$
** Significant at $P < 0.01$
I Increase above control

DOMINANT LETHAL GENE-RAT

Table 12

AVERAGE PREIMPLANTATION LOSS PER PREGNANT FEMALE

Summary

Compound: Gum Arabic
FDA No: 71-15

Week of Study	Control (10 ml/kg)	TEM (0.2 mg/kg)	71-15 (30 mg/kg)	71-15 (2.5 g/kg)	71-15 (5 g/kg)
Acute-Single Dose					
1	33/9=3.67	52/11=4.73	21/18=1.17	23/11=2.09	72/18=4.00
2	52/20=2.60	54/20=2.70	23/15=1.53	21/19=1.10**D	23/20=1.15**D
3	17/18=0.94	30/17=1.76	7/15=0.47	30/18=1.67	12/19=0.63
4	50/19=2.63	67/14=4.79	19/18=1.06	40/17=2.35	28/18=1.56
5	35/16=2.19	29/17=1.71	25/20=1.25	20/18=1.11	35/19=1.84
6	12/12=1.00	11/20=0.55	11/20=0.55	13/17=0.76	27/20=1.35
7	37/17=2.18	37/18=2.06	35/19=1.84	36/19=1.89	14/15=0.93
8	31/20=1.55	16/20=0.80	17/20=0.85	20/20=1.00	21/19=1.11
Subacute-Multiple Dose					
1	7/11=0.64		30/20=1.50	13/14=0.93	19/16=1.19
2	6/16=0.38		15/20=0.75	6/20=0.30	16/15=1.07
3	18/15=1.20		25/20=1.25	33/19=1.74	32/19=1.68
4	18/18=1.00		21/18=1.17	16/19=0.84	15/16=0.94
5	18/14=1.29		21/18=1.17	19/20=0.95	17/18=0.94
6	42/17=2.47		23/19=1.21	24/18=1.33	7/15=0.47
7	27/19=1.42		16/19=0.84	43/20=2.15	25/20=1.25

** Significant at P = 0.01
D = Decrease below control

Raw Data and Statistical Analyses

CONTENTS

Item	Page
1. Raw Data	
Week 1	1 - 5
Week 2	6 - 10
Week 3	11 - 15
Week 4	16 - 20
Week 5	21 - 25
Week 6	26 - 30
Week 7	31 - 35
Week 8	36 - 38
2. Chi-square test of the Fertility Index	39
3. Armitage test for a Linear Trend in Proportions for the Fertility Index - Dose Levels	40
4. Armitage Test for a Linear Trend in Proportions for the Fertility Index - Log of Dose Levels	41
5. Armitage Test for a Linear Trend in Proportions for the Fertility Index - Dose Levels and Controls	42
6. T-Test of number of Implantations	43
7. Regression Fits of the Number, U, of Implantations Dose and Log Dose - Control Exluded	44
8. Regression Fits of the Number, U, of Implantations Dose - Control Group Included	45
9. T-Test of the (Transformed) Pre-Implantation Loses	46
10. T-Test of the (Transformed) Number of Dead Implants	47
11. Chi-square Test of the Death Index	48
12. Armitage Test for a Linear Trend in Proportions for the Death Index - Dose Levels	49
13. Armitage Test for a Linear Trend in Proportions for the Death Index - Log of Dose Levels	50
14. Armitage Test for a Linear Trend in Proportions for the Fertility Index - Dose Levels including Control	51
15. Probit Analysis of the Proportions of Females with one or more Dead Implants	52
16. T-Test of the (transformed) Number of Dead Implants over Total Implants	53
17. Control Group ANOVA for the Number of Pregnant Females	54
18. Control Group ANOVA for the Number of Implantations Per Pregnant Females	55
19. Control Group ANOVA for the Pre-Implantation Loss per Pregnant Female	56
20. Control Group ANOVA for the Number of Dead Implants per Female	57
21. Control Group ANOVA for the Ratio of Dead Implants to Total Implants per Female	58
22. T-Test of the Number of Corpora Lutea in Pregnant Females	59

DOMINANT LETHAL GENE STUDY OF COMPOUND 71-15 GUM ARABIC

TEST MATERIAL	WEEK	S/M	DOSE	MALE NO.	FEMALE NO.	PREG.	IMPLANTS L	IMPLANTS R	EARLY DEATHS L	EARLY DEATHS R	LATE DEATHS L	LATE DEATHS R	CORPORA LUTEA L	CORPORA LUTEA R
CNTRL15	1	S	0.0000	1	1	Y	7	6	0	0	0	0	7	6
CNTRL15	1	S	0.0000	1	2	Y	7	9	0	0	0	1	7	9
CNTRL15	1	S	0.0000	2	3	Y	0	1	0	0	0	0	6	5
CNTRL15	1	S	0.0000	2	4	N	-0	-0	-0	-0	-0	-0	-0	-0
CNTRL15	1	S	0.0000	3	5	Y	7	6	1	0	0	0	7	5
CNTRL15	1	S	0.0000	3	6	Y	2	1	0	0	0	0	10	3
CNTRL15	1	S	0.0000	4	7	Y	7	6	1	0	0	0	7	9
CNTRL15	1	S	0.0000	4	8	Y	5	7	0	0	1	0	6	8
CNTRL15	1	S	0.0000	5	9	Y	4	10	0	0	0	1	4	10
CNTRL15	1	S	0.0000	5	10	N	-0	-0	-0	-0	-0	-0	-0	-0
CNTRL15	1	S	0.0000	6	11	Y	2	3	0	0	0	0	4	9
CNTRL15	1	S	0.0000	6	12	N	-0	-0	-0	-0	-0	-0	-0	-0
CNTRL15	1	S	0.0000	7	13	N	-0	-0	-0	-0	-0	-0	-0	-0
CNTRL15	1	S	0.0000	7	14	N	-0	-0	-0	-0	-0	-0	-0	-0
CNTRL15	1	S	0.0000	8	15	N	-0	-0	-0	-0	-0	-0	-0	-0
CNTRL15	1	S	0.0000	8	16	N	-0	-0	-0	-0	-0	-0	-0	-0
CNTRL15	1	S	0.0000	9	17	N	-0	-0	-0	-0	-0	-0	-0	-0
CNTRL15	1	S	0.0000	9	18	N	-0	-0	-0	-0	-0	-0	-0	-0
CNTRL15	1	S	0.0000	10	19	N	-0	-0	-0	-0	-0	-0	-0	-0
CNTRL15	1	S	0.0000	10	20	N	-0	-0	-0	-0	-0	-0	-0	-0
71-15	1	S	.0300	51	101	Y	8	6	0	0	0	0	8	6
71-15	1	S	.0300	51	102	Y	6	5	0	0	0	0	6	6
71-15	1	S	.0300	52	103	Y	6	7	0	0	0	0	6	7
71-15	1	S	.0300	52	104	Y	3	8	1	0	0	0	3	9
71-15	1	S	.0300	53	105	Y	6	8	0	0	2	0	6	8
71-15	1	S	.0300	53	106	Y	9	5	0	0	4	2	9	5
71-15	1	S	.0300	54	107	Y	6	6	0	0	0	1	6	6
71-15	1	S	.0300	54	108	N	-0	-0	-0	-0	-0	-0	-0	-0
71-15	1	S	.0300	55	109	Y	6	7	0	1	0	0	6	7
71-15	1	S	.0300	55	110	Y	3	11	0	1	0	0	3	11
71-15	1	S	.0300	56	111	Y	6	5	0	0	0	0	6	5
71-15	1	S	.0300	56	112	Y	4	4	0	0	0	0	5	8
71-15	1	S	.0300	57	113	Y	5	7	0	0	0	3	5	7
71-15	1	S	.0300	57	114	Y	1	1	1	0	0	1	7	5
71-15	1	S	.0300	58	115	Y	5	8	0	0	0	0	5	8
71-15	1	S	.0300	58	116	Y	4	6	0	0	0	1	7	7
71-15	1	S	.0300	59	117	Y	10	5	0	0	2	0	10	5
71-15	1	S	.0300	59	118	Y	7	9	0	1	1	0	7	9
71-15	1	S	.0300	60	119	Y	7	7	1	0	0	0	7	7
71-15	1	S	.0300	60	120	N	-0	-0	-0	-0	-0	-0	-0	-0

TEST MATERIAL	WEEK	S/M	DOSE	MALE NO.	FEMALE NO.	PREG.	IMPLANTS L	IMPLANTS R	EARLY DEATHS L	EARLY DEATHS R	LATE DEATHS L	LATE DEATHS R	CORPORA LUTEA L	CORPORA LUTEA R
71-15	1	S	2.5000	61	121	N	-0	-0	-0	-0	-0	-0	-0	-0
71-15	1	S	2.5000	61	122	N	-0	-0	-0	-0	-0	-0	-0	-0
71-15	1	S	2.5000	62	123	N	-0	-0	-0	-0	-0	-0	-0	-0
71-15	1	S	2.5000	62	124	N	-0	-0	-0	-0	-0	-0	-0	-0
71-15	1	S	2.5000	63	125	Y	5	6	0	1	0	1	6	8
71-15	1	S	2.5000	63	126	Y	5	3	0	0	0	0	6	9
71-15	1	S	2.5000	64	127	N	-0	-0	-0	-0	-0	-0	-0	-0
71-15	1	S	2.5000	64	128	Y	4	8	0	0	0	0	6	9
71-15	1	S	2.5000	65	129	Y	8	3	0	0	0	0	10	5
71-15	1	S	2.5000	65	130	N	-0	-0	-0	-0	-0	-0	-0	-0
71-15	1	S	2.5000	66	131	N	-0	-0	-0	-0	-0	-0	-0	-0
71-15	1	S	2.5000	66	132	Y	7	5	0	1	0	0	7	6
71-15	1	S	2.5000	67	133	Y	6	6	2	0	0	0	6	6
71-15	1	S	2.5000	67	134	N	-0	-0	-0	-0	-0	-0	-0	-0
71-15	1	S	2.5000	68	135	Y	4	8	0	0	0	0	4	8
71-15	1	S	2.5000	68	136	Y	4	7	0	0	0	1	4	8
71-15	1	S	2.5000	69	137	Y	3	6	0	0	0	0	4	6
71-15	1	S	2.5000	69	138	Y	6	5	0	0	0	0	8	5
71-15	1	S	2.5000	70	139	Y	5	9	0	0	0	0	6	9
71-15	1	S	2.5000	70	140	N	-0	-0	-0	-0	-0	-0	-0	-0
71-15	1	S	5.0000	71	141	Y	5	7	1	0	0	0	5	8
71-15	1	S	5.0000	71	142	Y	5	6	0	0	0	0	5	6
71-15	1	S	5.0000	72	143	Y	6	7	0	0	0	0	6	7
71-15	1	S	5.0000	72	144	Y	7	2	0	0	2	0	10	2
71-15	1	S	5.0000	73	145	Y	5	7	0	0	0	0	5	7
71-15	1	S	5.0000	73	146	Y	8	5	1	0	0	0	9	12
71-15	1	S	5.0000	74	147	Y	4	7	0	0	0	0	4	9
71-15	1	S	5.0000	74	148	Y	4	8	0	0	0	0	4	8
71-15	1	S	5.0000	75	149	Y	5	7	0	0	0	0	6	7
71-15	1	S	5.0000	75	150	Y	9	4	0	0	0	0	10	4
71-15	1	S	5.0000	76	151	Y	4	7	0	0	0	0	8	12
71-15	1	S	5.0000	76	152	Y	0	1	0	1	0	0	13	12
71-15	1	S	5.0000	77	153	Y	8	4	0	0	0	0	9	4
71-15	1	S	5.0000	77	154	Y	7	6	0	0	3	3	8	7
71-15	1	S	5.0000	78	155	Y	5	9	1	0	0	0	6	9
71-15	1	S	5.0000	78	156	N	-0	-0	-0	-0	-0	-0	-0	-0
71-15	1	S	5.0000	79	157	Y	4	6	0	0	0	0	10	9
71-15	1	S	5.0000	79	158	Y	8	7	0	0	0	0	8	7
71-15	1	S	5.0000	80	159	Y	7	7	3	1	0	0	12	12
71-15	1	S	5.0000	80	160	N	-0	-0	-0	-0	-0	-0	-0	-0

TEST MATERIAL	WEEK	S/M	DOSE	MALE NO.	FEMALE NO.	PREG.	IMPLANTS L	IMPLANTS R	EARLY DEATHS L	EARLY DEATHS R	LATE DEATHS L	LATE DEATHS R	CORPORA LUTEA L	CORPORA LUTEA R
TEM15	1	S	.0002	11	21	N	-0	-0	-0	-0	-0	-0	-0	-0
TEM15	1	S	.0002	11	22	N	-0	-0	-0	-0	-0	-0	-0	-0
TEM15	1	S	.0002	12	23	N	-0	-0	-0	-0	-0	-0	-0	-0
TEM15	1	S	.0002	12	24	N	-0	-0	-0	-0	-0	-0	-0	-0
TEM15	1	S	.0002	13	25	Y	2	6	0	0	2	4	7	5
TEM15	1	S	.0002	13	26	N	-0	-0	-0	-0	-0	-0	-0	-0
TEM15	1	S	.0002	14	27	N	-0	-0	-0	-0	-0	-0	-0	-0
TEM15	1	S	.0002	14	28	N	-0	-0	-0	-0	-0	-0	-0	-0
TEM15	1	S	.0002	15	29	Y	10	2	0	0	0	0	11	3
TEM15	1	S	.0002	15	30	Y	6	6	0	0	3	4	7	6
TEM15	1	S	.0002	16	31	Y	10	3	2	0	0	0	10	3
TEM15	1	S	.0002	16	32	N	-0	-0	-0	-0	-0	-0	-0	-0
TEM15	1	S	.0002	17	33	Y	0	2	0	0	0	2	4	6
TEM15	1	S	.0002	17	34	Y	3	5	1	0	0	2	3	10
TEM15	1	S	.0002	18	35	Y	0	4	0	1	0	0	7	4
TEM15	1	S	.0002	18	36	Y	1	0	0	0	0	0	6	6
TEM15	1	S	.0002	19	37	Y	0	1	0	1	0	0	4	7
TEM15	1	S	.0002	19	38	N	-0	-0	-0	-0	-0	-0	-0	-0
TEM15	1	S	.0002	20	39	Y	5	5	0	0	4	5	7	7
TEM15	1	S	.0002	20	40	Y	7	8	0	0	0	0	7	8
CNTRL15	1	M	0.0000	1	1	Y	7	5	0	0	0	0	7	6
CNTRL15	1	M	0.0000	1	2	Y	6	6	0	0	0	0	6	6
CNTRL15	1	M	0.0000	2	3	Y	5	8	0	0	1	0	6	8
CNTRL15	1	M	0.0000	2	4	N	-0	-0	-0	-0	-0	-0	-0	-0
CNTRL15	1	M	0.0000	3	5	N	-0	-0	-0	-0	-0	-0	-0	-0
CNTRL15	1	M	0.0000	3	6	N	-0	-0	-0	-0	-0	-0	-0	-0
CNTRL15	1	M	0.0000	4	7	N	-0	-0	-0	-0	-0	-0	-0	-0
CNTRL15	1	M	0.0000	4	8	N	-0	-0	-0	-0	-0	-0	-0	-0
CNTRL15	1	M	0.0000	5	9	Y	6	5	0	0	0	0	6	5
CNTRL15	1	M	0.0000	5	10	Y	3	8	0	0	0	0	3	8
CNTRL15	1	M	0.0000	6	11	Y	0	9	0	0	0	1	3	9
CNTRL15	1	M	0.0000	6	12	Y	8	4	0	0	0	0	9	4
CNTRL15	1	M	0.0000	7	13	Y	8	6	0	0	4	1	8	6
CNTRL15	1	M	0.0000	7	14	Y	8	6	0	1	0	0	8	6
CNTRL15	1	M	0.0000	8	15	N	-0	-0	-0	-0	-0	-0	-0	-0
CNTRL15	1	M	0.0000	8	16	Y	7	6	0	0	0	0	7	7
CNTRL15	1	M	0.0000	9	17	N	-0	-0	-0	-0	-0	-0	-0	-0
CNTRL15	1	M	0.0000	9	18	Y	8	5	1	1	0	0	8	5
CNTRL15	1	M	0.0000	10	19	N	-0	-0	-0	-0	-0	-0	-0	-0
CNTRL15	1	M	0.0000	10	20	N	-0	-0	-0	-0	-0	-0	-0	-0

TEST MATERIAL	WEEK	S/M	DOSE	MALE NO.	FEMALE NO.	PREG.	IMPLANTS L	IMPLANTS R	EARLY DEATHS L	EARLY DEATHS R	LATE DEATHS L	LATE DEATHS R	CORPORA LUTEA L	CORPORA LUTEA R
71-15	1	M	.0300	51	101	Y	1	0	1	0	0	0	6	9
71-15	1	M	.0300	51	102	Y	9	5	0	0	0	0	9	6
71-15	1	M	.0300	52	103	Y	7	5	0	0	4	1	7	5
71-15	1	M	.0300	52	104	Y	12	3	0	1	0	0	12	3
71-15	1	M	.0300	53	105	Y	5	5	0	0	1	0	7	8
71-15	1	M	.0300	53	106	Y	5	6	0	0	0	0	5	6
71-15	1	M	.0300	54	107	Y	2	8	0	0	1	1	2	8
71-15	1	M	.0300	54	108	Y	9	3	1	0	0	0	9	3
71-15	1	M	.0300	55	109	Y	2	7	0	0	1	0	3	9
71-15	1	M	.0300	55	110	Y	3	8	0	0	0	0	3	8
71-15	1	M	.0300	56	111	Y	3	12	0	0	0	0	3	12
71-15	1	M	.0300	56	112	Y	5	7	0	0	0	0	6	7
71-15	1	M	.0300	57	113	Y	9	3	0	0	0	0	9	3
71-15	1	M	.0300	57	114	Y	7	4	0	0	0	1	7	5
71-15	1	M	.0300	58	115	Y	6	5	1	0	0	0	6	5
71-15	1	M	.0300	58	116	Y	8	9	0	0	0	0	8	9
71-15	1	M	.0300	59	117	Y	6	8	0	0	1	0	9	8
71-15	1	M	.0300	59	118	Y	5	5	0	0	0	0	8	5
71-15	1	M	.0300	60	119	Y	6	6	0	1	1	0	6	6
71-15	1	M	.0300	60	120	Y	9	5	2	0	0	0	9	5
71-15	1	M	2.5000	61	121	Y	3	10	0	0	0	0	3	11
71-15	1	M	2.5000	61	122	Y	7	6	0	0	0	0	7	6
71-15	1	M	2.5000	62	123	N	-0	-0	-0	-0	-0	-0	-0	-0
71-15	1	M	2.5000	62	124	N	-0	-0	-0	-0	-0	-0	-0	-0
71-15	1	M	2.5000	63	125	Y	5	5	0	0	2	1	5	6
71-15	1	M	2.5000	63	126	Y	4	6	0	1	0	0	4	7
71-15	1	M	2.5000	64	127	Y	5	7	0	0	2	2	5	8
71-15	1	M	2.5000	64	128	N	-0	-0	-0	-0	-0	-0	-0	-0
71-15	1	M	2.5000	65	129	Y	5	7	0	0	0	0	7	7
71-15	1	M	2.5000	65	130	N	-0	-0	-0	-0	-0	-0	-0	-0
71-15	1	M	2.5000	66	131	N	-0	-0	-0	-0	-0	-0	-0	-0
71-15	1	M	2.5000	66	132	Y	5	7	0	0	0	0	5	7
71-15	1	M	2.5000	67	133	Y	7	7	0	0	0	2	7	7
71-15	1	M	2.5000	67	134	Y	7	4	0	0	0	0	8	5
71-15	1	M	2.5000	68	135	N	-0	-0	-0	-0	-0	-0	-0	-0
71-15	1	M	2.5000	68	136	Y	3	10	0	1	0	0	3	10
71-15	1	M	2.5000	69	137	Y	5	5	0	0	0	0	7	6
71-15	1	M	2.5000	69	138	Y	5	7	1	0	0	0	5	7
71-15	1	M	2.5000	70	139	Y	5	6	0	1	0	0	5	7
71-15	1	M	2.5000	70	140	Y	2	11	0	0	0	0	2	12

TEST MATERIAL	WEEK	S/M	DOSE	MALE NO.	FEMALE NO.	PREG.	IMPLANTS L	IMPLANTS R	EARLY DEATHS L	EARLY DEATHS R	LATE DEATHS L	LATE DEATHS R	CORPORA LUTEA L	CORPORA LUTEA R
71-15	1	M	5.0000	71	141	Y	7	6	0	0	0	0	7	6
71-15	1	M	5.0000	71	142	Y	4	9	0	0	1	1	4	9
71-15	1	M	5.0000	72	143	N	-0	-0	-0	-0	-0	-0	-0	-0
71-15	1	M	5.0000	72	144	Y	7	8	0	0	0	0	8	8
71-15	1	M	5.0000	73	145	Y	6	6	1	0	0	0	7	6
71-15	1	M	5.0000	73	146	Y	1	11	0	1	0	0	1	11
71-15	1	M	5.0000	74	147	Y	9	8	0	0	0	0	9	8
71-15	1	M	5.0000	74	148	N	-0	-0	-0	-0	-0	-0	-0	-0
71-15	1	M	5.0000	75	149	Y	7	5	0	0	1	0	7	6
71-15	1	M	5.0000	75	150	Y	8	5	0	0	0	0	8	5
71-15	1	M	5.0000	76	151	Y	7	5	0	0	0	0	7	5
71-15	1	M	5.0000	76	152	N	-0	-0	-0	-0	-0	-0	-0	-0
71-15	1	M	5.0000	77	153	Y	8	3	0	0	0	0	8	3
71-15	1	M	5.0000	77	154	Y	11	2	0	0	1	0	11	2
71-15	1	M	5.0000	78	155	Y	8	6	0	0	0	0	8	6
71-15	1	M	5.0000	78	156	Y	7	5	0	0	0	0	8	5
71-15	1	M	5.0000	79	157	Y	9	5	1	0	0	0	10	5
71-15	1	M	5.0000	79	158	Y	2	0	0	0	0	0	5	10
71-15	1	M	5.0000	80	159	Y	5	8	0	0	0	0	5	9
71-15	1	M	5.0000	80	160	N	-0	-0	-0	-0	-0	-0	-0	-0

44

TEST MATERIAL	WEEK	S/M	DOSE	MALE NO.	FEMALE NO.	PREG.	IMPLANTS L	IMPLANTS R	EARLY DEATHS L	EARLY DEATHS R	LATE DEATHS L	LATE DEATHS R	CORPORA LUTEA L	CORPORA LUTEA R
CNTRL15	2	S	0.0000	1	1	Y	6	5	0	0	0	0	6	5
CNTRL15	2	S	0.0000	1	2	Y	8	6	0	0	0	0	8	6
CNTRL15	2	S	0.0000	2	3	Y	3	3	1	0	0	0	5	6
CNTRL15	2	S	0.0000	2	4	Y	0	1	0	0	0	0	8	3
CNTRL15	2	S	0.0000	3	5	Y	3	8	0	0	0	0	3	8
CNTRL15	2	S	0.0000	3	6	Y	8	4	0	0	1	1	3	4
CNTRL15	2	S	0.0000	4	7	Y	4	8	0	0	0	0	5	8
CNTRL15	2	S	0.0000	4	8	Y	4	0	0	0	0	0	4	5
CNTRL15	2	S	0.0000	5	9	Y	0	6	0	0	0	0	3	8
CNTRL15	2	S	0.0000	5	10	Y	5	4	0	0	0	1	6	4
CNTRL15	2	S	0.0000	6	11	Y	3	9	0	0	1	0	4	9
CNTRL15	2	S	0.0000	6	12	Y	1	4	0	0	0	2	5	6
CNTRL15	2	S	0.0000	7	13	Y	8	3	0	0	0	0	9	5
CNTRL15	2	S	0.0000	7	14	Y	3	2	0	0	0	0	6	4
CNTRL15	2	S	0.0000	8	15	Y	1	1	0	0	0	0	1	5
CNTRL15	2	S	0.0000	8	16	Y	3	9	0	0	1	0	3	9
CNTRL15	2	S	0.0000	9	17	Y	5	8	0	0	0	0	5	8
CNTRL15	2	S	0.0000	9	18	Y	5	7	0	0	0	0	8	7
CNTRL15	2	S	0.0000	10	19	Y	6	7	1	0	0	0	6	7
CNTRL15	2	S	0.0000	10	20	Y	5	0	0	0	0	0	5	3
71-15	2	S	.0300	51	101	Y	11	4	2	0	1	0	11	4
71-15	2	S	.0300	51	102	Y	4	7	0	3	0	1	5	8
71-15	2	S	.0300	52	103	Y	4	10	0	0	0	0	5	10
71-15	2	S	.0300	52	104	N	-0	-0	-0	-0	-0	-0	-0	-0
71-15	2	S	.0300	53	105	Y	6	8	0	1	0	0	6	8
71-15	2	S	.0300	53	106	Y	4	8	0	0	1	0	4	8
71-15	2	S	.0300	54	107	N	-0	-0	-0	-0	-0	-0	-0	-0
71-15	2	S	.0300	54	108	N	-0	-0	-0	-0	-0	-0	-0	-0
71-15	2	S	.0300	55	109	Y	1	1	0	0	0	0	5	6
71-15	2	S	.0300	55	110	Y	7	4	0	0	0	0	9	4
71-15	2	S	.0300	56	111	N	-0	-0	-0	-0	-0	-0	-0	-0
71-15	2	S	.0300	56	112	Y	4	0	0	0	0	0	4	5
71-15	2	S	.0300	57	113	Y	7	5	0	0	1	0	8	5
71-15	2	S	.0300	57	114	Y	6	4	0	0	0	0	6	4
71-15	2	S	.0300	58	115	Y	6	10	0	0	0	0	5	11
71-15	2	S	.0300	58	116	Y	5	7	0	0	0	1	5	7
71-15	2	S	.0300	59	117	Y	7	5	0	0	0	0	7	5
71-15	2	S	.0300	59	118	Y	6	5	2	0	0	0	7	5
71-15	2	S	.0300	60	119	N	-0	-0	-0	-0	-0	-0	-0	-0
71-15	2	S	.0300	60	120	Y	5	7	0	0	0	0	5	8

DOMINANT LETHAL GENE STUDY OF COMPOUND 71-15 GUM ARABIC

TEST MATERIAL	WEEK	S/M	DOSE	MALE NO.	FEMALE NO.	PREG.	IMPLANTS L	IMPLANTS R	EARLY DEATHS L	EARLY DEATHS R	LATE DEATHS L	LATE DEATHS R	CORPORA LUTEA L	CORPORA LUTEA R
71-15	2	S	2.5000	61	121	Y	7	4	0	0	0	0	7	4
71-15	2	S	2.5000	61	122	Y	3	8	0	0	0	0	3	8
71-15	2	S	2.5000	62	123	Y	5	6	0	0	0	0	7	7
71-15	2	S	2.5000	62	124	Y	9	5	0	0	0	0	9	5
71-15	2	S	2.5000	63	125	Y	7	5	0	0	0	0	7	5
71-15	2	S	2.5000	63	126	Y	7	7	1	0	0	0	7	7
71-15	2	S	2.5000	64	127	Y	8	4	0	0	0	0	8	5
71-15	2	S	2.5000	64	128	Y	3	8	0	0	0	0	3	8
71-15	2	S	2.5000	65	129	Y	6	7	0	0	1	0	6	7
71-15	2	S	2.5000	65	130	Y	7	5	0	0	1	0	7	5
71-15	2	S	2.5000	66	131	Y	1	7	0	0	0	1	5	8
71-15	2	S	2.5000	66	132	N	-0	-0	-0	-0	-0	-0	-0	-0
71-15	2	S	2.5000	67	133	Y	7	8	0	0	1	0	7	8
71-15	2	S	2.5000	67	134	Y	8	4	1	1	0	0	8	4
71-15	2	S	2.5000	68	135	Y	9	6	0	0	0	0	10	6
71-15	2	S	2.5000	68	136	Y	5	8	0	0	0	0	5	9
71-15	2	S	2.5000	69	137	Y	4	10	0	0	1	0	4	10
71-15	2	S	2.5000	69	138	Y	8	3	0	0	0	0	8	3
71-15	2	S	2.5000	70	139	Y	8	4	0	0	0	0	9	4
71-15	2	S	2.5000	70	140	Y	0	5	0	0	0	1	8	6
71-15	2	S	5.0000	71	141	Y	5	6	0	0	0	0	5	6
71-15	2	S	5.0000	71	142	Y	8	3	0	0	0	0	9	3
71-15	2	S	5.0000	72	143	Y	7	6	0	0	0	0	8	7
71-15	2	S	5.0000	72	144	Y	1	7	0	0	0	0	6	7
71-15	2	S	5.0000	73	145	Y	4	8	0	0	0	0	4	8
71-15	2	S	5.0000	73	146	Y	6	5	0	0	0	0	6	8
71-15	2	S	5.0000	74	147	Y	5	6	0	0	0	0	5	7
71-15	2	S	5.0000	74	148	Y	5	6	0	0	0	0	5	6
71-15	2	S	5.0000	75	149	Y	1	8	0	0	0	0	1	8
71-15	2	S	5.0000	75	150	Y	6	6	0	1	3	4	6	6
71-15	2	S	5.0000	76	151	Y	5	8	0	0	0	1	5	8
71-15	2	S	5.0000	76	152	Y	7	4	0	0	0	0	7	4
71-15	2	S	5.0000	77	153	Y	7	8	0	0	0	0	7	8
71-15	2	S	5.0000	77	154	Y	9	7	1	0	0	0	9	7
71-15	2	S	5.0000	78	155	Y	5	8	0	0	0	0	5	8
71-15	2	S	5.0000	78	156	Y	10	3	0	0	1	0	10	4
71-15	2	S	5.0000	79	157	Y	8	4	0	0	0	0	8	4
71-15	2	S	5.0000	79	158	Y	7	7	0	0	1	1	7	7
71-15	2	S	5.0000	80	159	Y	2	1	2	1	0	0	9	5
71-15	2	S	5.0000	80	160	Y	6	5	1	1	0	0	7	5

DOMINANT LETHAL GENE STUDY OF COMPOUND 71-15 GUM ARABIC

TEST MATERIAL	WEEK	S/M.	DOSE	MALE NO.	FEMALE NO.	PREG.	IMPLANTS L	IMPLANTS R	EARLY DEATHS L	EARLY DEATHS R	LATE DEATHS L	LATE DEATHS R	CORPORA LUTEA L	CORPORA LUTEA R
TEM15	2	S	.0002	11	21	Y	6	5	4	5	0	0	7	6
TEM15	2	S	.0002	11	22	Y	5	0	4	0	0	0	5	4
TEM15	2	S	.0002	12	23	Y	6	5	6	4	0	0	7	6
TEM15	2	S	.0002	12	24	Y	7	6	0	0	4	3	8	6
TEM15	2	S	.0002	13	25	Y	5	6	0	0	2	0	7	6
TEM15	2	S	.0002	13	26	Y	3	0	1	0	1	0	3	6
TEM15	2	S	.0002	14	27	Y	1	1	0	1	0	0	6	3
TEM15	2	S	.0002	14	28	Y	7	5	0	0	0	2	7	5
TEM15	2	S	.0002	15	29	Y	7	4	0	0	7	3	7	4
TEM15	2	S	.0002	15	30	Y	8	5	0	0	1	1	8	5
TEM15	2	S	.0002	16	31	Y	5	7	3	5	0	0	6	8
TEM15	2	S	.0002	16	32	Y	8	2	0	0	7	2	9	4
TEM15	2	S	.0002	17	33	Y	2	3	2	2	0	0	5	6
TEM15	2	S	.0002	17	34	Y	6	6	0	0	2	1	6	6
TEM15	2	S	.0002	18	35	Y	4	8	2	8	1	0	5	9
TEM15	2	S	.0002	18	36	Y	5	7	0	3	4	2	6	8
TEM15	2	S	.0002	19	37	Y	4	8	0	0	4	7	5	10
TEM15	2	S	.0002	19	38	Y	3	3	0	3	1	0	4	5
TEM15	2	S	.0002	20	39	Y	3	6	2	6	0	0	3	9
TEM15	2	S	.0002	20	40	Y	1	10	1	8	0	0	2	10
CNTRL15	2	M	0.0000	1	1	Y	5	5	0	0	0	0	5	5
CNTRL15	2	M	0.0000	1	2	Y	10	4	0	0	0	0	10	4
CNTRL15	2	M	0.0000	2	3	N	-0	-0	-0	-0	-0	-0	-0	-0
CNTRL15	2	M	0.0000	2	4	N	-0	-0	-0	-0	-0	-0	-0	-0
CNTRL15	2	M	0.0000	3	5	Y	6	3	0	0	0	0	6	4
CNTRL15	2	M	0.0000	3	6	Y	2	6	0	1	0	1	3	6
CNTRL15	2	M	0.0000	4	7	N	-0	-0	-0	-0	-0	-0	-0	-0
CNTRL15	2	M	0.0000	4	8	Y	10	3	0	0	0	0	10	3
CNTRL15	2	M	0.0000	5	9	Y	4	9	0	0	0	0	4	9
CNTRL15	2	M	0.0000	5	10	Y	8	6	0	0	1	0	8	6
CNTRL15	2	M	0.0000	6	11	N	-0	-0	-0	-0	-0	-0	-0	-0
CNTRL15	2	M	0.0000	6	12	Y	4	5	0	0	0	0	4	6
CNTRL15	2	M	0.0000	7	13	Y	5	6	0	0	0	0	5	6
CNTRL15	2	M	0.0000	7	14	Y	5	9	0	0	0	0	5	9
CNTRL15	2	M	0.0000	8	15	Y	11	2	1	1	3	1	11	2
CNTRL15	2	M	0.0000	8	16	Y	5	6	0	0	0	0	5	6
CNTRL15	2	M	0.0000	9	17	Y	6	0	0	0	0	0	6	3
CNTRL15	2	M	0.0000	9	18	Y	7	7	0	0	0	0	7	7
CNTRL15	2	M	0.0000	10	19	Y	7	6	0	0	0	0	7	6
CNTRL15	2	M	0.0000	10	20	Y	8	4	1	0	0	0	8	4

TEST MATERIAL	WEEK	S/M	DOSE	MALE NO.	FEMALE NO.	PREG.	IMPLANTS L	IMPLANTS R	EARLY DEATHS L	EARLY DEATHS R	LATE DEATHS L	LATE DEATHS R	CORPORA LUTEA L	CORPORA LUTEA R
71-15	2	M	.0300	41	81	Y	3	8	0	1	0	0	3	9
71-15	2	M	.0300	41	82	Y	4	9	0	1	0	0	4	9
71-15	2	M	.0300	42	83	Y	3	9	0	0	0	0	3	9
71-15	2	M	.0300	42	84	Y	7	3	1	0	1	2	8	3
71-15	2	M	.0300	43	85	Y	4	6	0	0	0	0	4	7
71-15	2	M	.0300	43	86	Y	3	11	0	0	0	0	3	11
71-15	2	M	.0300	44	87	Y	5	5	0	0	0	0	7	5
71-15	2	M	.0300	44	88	Y	5	6	0	0	0	0	5	6
71-15	2	M	.0300	45	89	Y	5	5	0	0	0	0	6	5
71-15	2	M	.0300	45	90	Y	5	9	0	0	0	0	5	9
71-15	2	M	.0300	46	91	Y	4	7	0	0	0	0	5	8
71-15	2	M	.0300	46	92	Y	6	8	0	1	1	0	6	8
71-15	2	M	.0300	47	93	Y	4	7	0	0	0	0	4	7
71-15	2	M	.0300	47	94	Y	5	6	0	0	1	0	5	6
71-15	2	M	.0300	48	95	Y	5	7	0	0	0	1	5	7
71-15	2	M	.0300	48	96	Y	6	5	0	0	0	0	6	5
71-15	2	M	.0300	49	97	Y	2	0	2	0	0	0	2	2
71-15	2	M	.0300	49	98	Y	6	9	0	0	0	0	6	9
71-15	2	M	.0300	50	99	Y	7	7	0	0	0	0	7	7
71-15	2	M	.0300	50	100	Y	5	2	2	0	0	0	7	5
71-15	2	M	2.5000	51	101	Y	5	6	1	0	0	0	5	6
71-15	2	M	2.5000	51	102	Y	6	8	0	0	0	0	6	9
71-15	2	M	2.5000	52	103	Y	6	7	1	0	3	3	6	7
71-15	2	M	2.5000	52	104	Y	6	7	1	0	0	0	6	7
71-15	2	M	2.5000	53	105	Y	1	1	0	1	0	0	2	1
71-15	2	M	2.5000	53	106	Y	7	5	0	0	0	0	7	6
71-15	2	M	2.5000	54	107	Y	10	5	0	0	2	0	10	5
71-15	2	M	2.5000	54	108	Y	6	5	0	1	0	0	6	5
71-15	2	M	2.5000	55	109	Y	10	2	1	0	0	0	10	2
71-15	2	M	2.5000	55	110	Y	5	4	0	0	0	0	5	4
71-15	2	M	2.5000	56	111	Y	7	7	0	0	0	0	7	7
71-15	2	M	2.5000	56	112	Y	9	5	0	0	0	0	9	5
71-15	2	M	2.5000	57	113	Y	6	9	0	3	1	0	6	9
71-15	2	M	2.5000	57	114	Y	7	5	0	0	1	1	7	5
71-15	2	M	2.5000	58	115	Y	5	7	0	0	0	0	5	7
71-15	2	M	2.5000	58	116	Y	4	8	0	0	2	1	4	8
71-15	2	M	2.5000	59	117	Y	8	5	0	0	0	0	8	5
71-15	2	M	2.5000	59	118	Y	8	4	1	0	0	0	8	5
71-15	2	M	2.5000	60	119	Y	5	6	0	0	0	0	7	6
71-15	2	M	2.5000	60	120	Y	4	7	0	0	0	0	4	7

48

DOMINANT LETHAL GENE STUDY OF COMPOUND 71-15 GUM ARABIC

TEST MATERIAL	WEEK	S/N	DOSE	MALE NO.	FEMALE NO.	PREG.	IMPLANTS L	IMPLANTS R	EARLY DEATHS L	EARLY DEATHS R	LATE DEATHS L	LATE DEATHS R	CORPORA LUTEA L	CORPORA LUTEA R
71-15	2	M	5.0000	61	121	Y	6	5	1	0	0	0	7	5
71-15	2	M	5.0000	61	122	Y	7	6	0	0	0	0	7	6
71-15	2	M	5.0000	62	123	Y	4	7	0	0	0	0	4	7
71-15	2	M	5.0000	62	124	N	-0	-0	-0	-0	-0	-0	-0	-0
71-15	2	M	5.0000	63	125	Y	4	8	0	0	1	0	4	9
71-15	2	M	5.0000	63	126	Y	5	7	0	0	1	0	5	7
71-15	2	M	5.0000	64	127	Y	8	4	0	0	0	0	8	4
71-15	2	M	5.0000	64	128	N	-0	-0	-0	-0	-0	-0	-0	-0
71-15	2	M	5.0000	65	129	Y	5	6	0	0	0	0	5	6
71-15	2	M	5.0000	65	130	Y	5	5	1	0	0	0	6	5
71-15	2	M	5.0000	66	131	N	-0	-0	-0	-0	-0	-0	-0	-0
71-15	2	M	5.0000	66	132	Y	8	5	0	0	0	0	8	5
71-15	2	M	5.0000	67	133	Y	4	7	0	1	0	0	7	7
71-15	2	M	5.0000	67	134	Y	3	1	0	0	0	0	3	6
71-15	2	M	5.0000	68	135	Y	9	4	2	0	0	0	10	4
71-15	2	M	5.0000	68	136	Y	6	4	0	1	0	0	9	4
71-15	2	M	5.0000	69	137	Y	9	6	0	0	0	0	9	6
71-15	2	M	5.0000	69	138	Y	7	4	0	0	2	0	7	5
71-15	2	M	5.0000	70	139	N	-0	-0	-0	-0	-0	-0	-0	-0
71-15	2	M	5.0000	70	140	N	-0	-0	-0	-0	-0	-0	-0	-0

TEST MATERIAL	WEEK	S/M	DOSE	MALE NO.	FEMALE NO.	PREG.	IMPLANTS L	IMPLANTS R	EARLY DEATHS L	EARLY DEATHS R	LATE DEATHS L	LATE DEATHS R	CORPORA LUTEA L	CORPORA LUTEA R
CNTRL15	3	S	0.0000	1	1	Y	7	4	1	1	0	0	7	5
CNTRL15	3	S	0.0000	1	2	Y	3	8	0	1	0	1	3	8
CNTRL15	3	S	0.0000	2	3	Y	5	6	0	0	0	0	5	6
CNTRL15	3	S	0.0000	2	4	Y	7	6	0	0	0	0	7	6
CNTRL15	3	S	0.0000	3	5	Y	3	5	0	0	0	0	3	7
CNTRL15	3	S	0.0000	3	6	Y	4	9	0	0	0	0	4	9
CNTRL15	3	S	0.0000	4	7	Y	2	10	0	0	0	0	2	11
CNTRL15	3	S	0.0000	4	8	Y	6	6	0	0	0	0	6	6
CNTRL15	3	S	0.0000	5	9	Y	3	0	0	0	0	0	4	2
CNTRL15	3	S	0.0000	5	10	Y	4	2	1	1	0	0	5	7
CNTRL15	3	S	0.0000	6	11	Y	5	8	0	0	0	0	5	8
CNTRL15	3	S	0.0000	6	12	N	-0	-0	-0	-0	-0	-0	-0	-0
CNTRL15	3	S	0.0000	7	13	Y	7	4	1	0	0	0	7	5
CNTRL15	3	S	0.0000	7	14	Y	4	7	0	0	0	0	5	7
CNTRL15	3	S	0.0000	8	15	Y	5	7	0	0	0	0	6	7
CNTRL15	3	S	0.0000	8	16	Y	8	6	0	0	1	0	8	6
CNTRL15	3	S	0.0000	9	17	Y	4	9	0	0	0	0	4	10
CNTRL15	3	S	0.0000	9	18	Y	6	6	0	0	0	0	6	6
CNTRL15	3	S	0.0000	10	19	Y	5	8	0	0	0	0	5	8
CNTRL15	3	S	0.0000	10	20	N	-0	-0	-0	-0	-0	-0	-0	-0
71-15	3	S	.0300	51	101	Y	1	7	0	1	0	0	3	7
71-15	3	S	.0300	51	102	Y	7	7	1	1	0	0	7	7
71-15	3	S	.0300	52	103	Y	7	4	0	0	0	1	7	4
71-15	3	S	.0300	52	104	Y	5	7	0	0	0	0	5	7
71-15	3	S	.0300	53	105	Y	7	4	0	0	0	0	7	4
71-15	3	S	.0300	53	106	Y	4	6	0	2	3	3	4	6
71-15	3	S	.0300	54	107	N	-0	-0	-0	-0	-0	-0	-0	-0
71-15	3	S	.0300	54	108	Y	6	5	0	0	0	0	6	5
71-15	3	S	.0300	55	109	Y	4	6	0	0	0	0	4	7
71-15	3	S	.0300	55	110	Y	6	5	1	0	0	0	6	5
71-15	3	S	.0300	56	111	Y	5	10	0	0	2	2	5	11
71-15	3	S	.0300	56	112	N	-0	-0	-0	-0	-0	-0	-0	-0
71-15	3	S	.0300	57	113	Y	3	12	0	1	0	0	3	13
71-15	3	S	.0300	57	114	Y	6	6	0	0	0	0	6	6
71-15	3	S	.0300	58	115	N	-0	-0	-0	-0	-0	-0	-0	-0
71-15	3	S	.0300	58	116	N	-0	-0	-0	-0	-0	-0	-0	-0
71-15	3	S	.0300	59	117	Y	7	6	0	1	0	0	7	6
71-15	3	S	.0300	59	118	Y	4	9	0	0	0	1	4	9
71-15	3	S	.0300	60	119	Y	5	6	3	4	0	0	6	6
71-15	3	S	.0300	60	120	N	-0	-0	-0	-0	-0	-0	-0	-0

50

DOMINANT LETHAL GENE STUDY OF COMPOUND 71-15 GUM ARABIC

TEST MATERIAL	WEEK	S/M	DOSE	MALE NO.	FEMALE NO.	PREG.	IMPLANTS L	IMPLANTS R	EARLY DEATHS L	EARLY DEATHS R	LATE DEATHS L	LATE DEATHS R	CORPORA LUTEA L	CORPORA LUTEA R
71-15	3	S	2.5000	61	121	Y	8	6	0	0	0	1	8	6
71-15	3	S	2.5000	61	122	Y	8	4	0	0	0	0	8	4
71-15	3	S	2.5000	62	123	Y	8	4	0	0	0	0	8	4
71-15	3	S	2.5000	62	124	Y	10	4	0	0	0	0	10	4
71-15	3	S	2.5000	63	125	Y	1	2	0	0	0	0	5	7
71-15	3	S	2.5000	63	126	Y	5	7	0	1	0	0	5	7
71-15	3	S	2.5000	64	127	Y	5	6	1	0	0	0	5	7
71-15	3	S	2.5000	64	128	N	-0	-0	-0	-0	-0	-0	-0	-0
71-15	3	S	2.5000	65	129	Y	4	8	0	0	2	2	4	8
71-15	3	S	2.5000	65	130	Y	1	0	0	0	1	0	7	4
71-15	3	S	2.5000	66	131	Y	5	6	0	0	2	4	8	8
71-15	3	S	2.5000	66	132	[illegible]	5	5	1	0	0	0	5	5
71-15	3	S	2.5000	67	133	Y	9	5	0	0	0	0	10	5
71-15	3	S	2.5000	67	134	Y	10	5	1	1	0	0	10	5
71-15	3	S	2.5000	68	135	Y	5	6	0	0	0	0	5	8
71-15	3	S	2.5000	68	136	N	-0	-0	-0	-0	-0	-0	-0	-0
71-15	3	S	2.5000	69	137	Y	6	6	0	0	2	0	8	6
71-15	3	S	2.5000	69	138	Y	7	8	0	0	0	0	7	8
71-15	3	S	2.5000	70	139	Y	7	6	1	1	0	0	7	6
71-15	3	S	2.5000	70	140	Y	8	5	1	0	0	0	8	5
71-15	3	S	5.0000	71	141	Y	4	10	0	5	0	1	5	10
71-15	3	S	5.0000	71	142	Y	5	6	0	0	0	0	5	6
71-15	3	S	5.0000	72	143	Y	9	5	0	0	1	1	9	5
71-15	3	S	5.0000	72	144	Y	7	6	2	0	0	0	7	6
71-15	3	S	5.0000	73	145	Y	4	7	0	0	1	0	5	7
71-15	3	S	5.0000	73	146	Y	5	5	0	1	0	0	5	5
71-15	3	S	5.0000	74	147	Y	7	6	0	0	0	0	7	6
71-15	3	S	5.0000	74	148	Y	6	0	1	0	0	0	6	4
71-15	3	S	5.0000	75	149	Y	3	10	0	0	0	0	3	11
71-15	3	S	5.0000	75	150	Y	5	6	0	0	0	0	5	6
71-15	3	S	5.0000	76	151	Y	5	[illegible]	0	2	3	1	5	7
71-15	3	S	5.0000	76	152	Y	7	9	0	1	0	0	7	9
71-15	3	S	5.0000	77	153	Y	5	7	0	0	0	1	7	7
71-15	3	S	5.0000	77	154	Y	10	5	0	0	0	0	10	5
71-15	3	S	5.0000	78	155	Y	7	9	0	0	0	1	7	10
71-15	3	S	5.0000	78	156	Y	4	5	0	1	0	0	6	5
71-15	3	S	5.0000	79	157	Y	5	6	0	0	0	0	5	6
71-15	3	S	5.0000	79	158	Y	5	8	1	0	1	1	5	8
71-15	3	S	5.0000	80	159	Y	7	5	0	1	3	2	7	5
71-15	3	S	5.0000	80	160	N	-0	-0	-0	-0	-0	-0	-0	-0

51

TEST MATERIAL	WEEK	S/M	DOSE	MALE NO.	FEMALE NO.	PREG.	IMPLANTS L	IMPLANTS R	EARLY DEATHS L	EARLY DEATHS R	LATE DEATHS L	LATE DEATHS R	CORPORA LUTEA L	CORPORA LUTEA R
TEM15	3	S	.0002	11	21	Y	6	4	1	2	0	0	5	5
TEM15	3	S	.0002	11	22	Y	6	5	4	4	1	0	5	5
TEM15	3	S	.0002	12	23	Y	2	1	2	1	0	0	6	2
TEM15	3	S	.0002	12	24	Y	1	0	1	0	0	0	8	5
TEM15	3	S	.0002	13	25	Y	4	6	2	3	0	0	6	6
TEM15	3	S	.0002	13	26	Y	7	7	6	5	0	1	7	7
TEM15	3	S	.0002	14	27	Y	5	8	0	0	1	0	5	8
TEM15	3	S	.0002	14	28	N	-0	-0	-0	-0	-0	-0	-0	-0
TEM15	3	S	.0002	15	29	Y	6	5	0	0	3	3	7	5
TEM15	3	S	.0002	15	30	Y	6	5	0	0	5	4	8	5
TEM15	3	S	.0002	16	31	Y	6	7	3	4	1	0	6	7
TEM15	3	S	.0002	16	32	N	-0	-0	-0	-0	-0	-0	-0	-0
TEM15	3	S	.0002	17	33	Y	9	3	0	0	7	1	9	3
TEM15	3	S	.0002	17	34	N	-0	-0	-0	-0	-0	-0	-0	-0
TEM15	3	S	.0002	18	35	Y	5	6	0	0	5	6	5	6
TEM15	3	S	.0002	18	36	Y	1	5	1	4	0	0	4	6
TEM15	3	S	.0002	19	37	Y	4	6	0	0	1	1	4	6
TEM15	3	S	.0002	19	38	Y	5	2	5	2	0	0	6	3
TEM15	3	S	.0002	20	39	Y	4	8	0	0	4	5	4	8
TEM15	3	S	.0002	20	40	Y	6	5	6	4	0	0	6	5
CNTRL15	3	M	0.0000	1	1	Y	9	4	0	0	2	0	10	4
CNTRL15	3	M	0.0000	1	2	Y	7	5	0	0	0	0	8	6
CNTRL15	3	M	0.0000	2	3	N	-0	-0	-0	-0	-0	-0	-0	-0
CNTRL15	3	M	0.0000	2	4	Y	6	5	0	0	0	0	8	6
CNTRL15	3	M	0.0000	3	5	Y	6	3	1	0	0	0	7	3
CNTRL15	3	M	0.0000	3	6	N	-0	-0	-0	-0	-0	-0	-0	-0
CNTRL15	3	M	0.0000	4	7	Y	6	8	0	0	0	0	6	9
CNTRL15	3	M	0.0000	4	8	N	-0	-0	-0	-0	-0	-0	-0	-0
CNTRL15	3	M	0.0000	5	9	Y	7	4	1	0	0	0	8	4
CNTRL15	3	M	0.0000	5	10	Y	6	8	0	1	1	0	6	8
CNTRL15	3	M	0.0000	6	11	Y	7	4	0	0	0	1	7	5
CNTRL15	3	M	0.0000	6	12	Y	8	6	0	0	0	0	9	6
CNTRL15	3	M	0.0000	7	13	N	-0	-0	-0	-0	-0	-0	-0	-0
CNTRL15	3	M	0.0000	7	14	Y	8	3	0	0	2	0	9	3
CNTRL15	3	M	0.0000	8	15	Y	8	4	0	0	1	0	8	4
CNTRL15	3	M	0.0000	8	16	Y	6	3	0	1	0	0	8	3
CNTRL15	3	M	0.0000	9	17	Y	4	4	1	0	2	1	5	4
CNTRL15	3	M	0.0000	9	18	Y	5	7	0	0	1	0	5	8
CNTRL15	3	M	0.0000	10	19	N	-0	-0	-0	-0	-0	-0	-0	-0
CNTRL15	3	M	0.0000	10	20	Y	6	4	1	0	0	0	6	6

52

TEST MATERIAL	WEEK	S/M	DOSE	MALE NO.	FEMALE NO.	PREG.	IMPLANTS L	IMPLANTS R	EARLY DEATHS L	EARLY DEATHS R	LATE DEATHS L	LATE DEATHS R	CORPORA LUTEA L	CORPORA LUTEA R
71-15	3	M	.0300	41	81	Y	5	2	0	0	1	0	9	3
71-15	3	M	.0300	41	82	Y	7	5	0	0	0	0	9	6
71-15	3	M	.0300	42	83	Y	7	6	0	0	0	0	7	6
71-15	3	M	.0300	42	84	Y	8	6	0	0	0	0	8	6
71-15	3	M	.0300	43	85	Y	6	4	0	0	0	0	6	4
71-15	3	M	.0300	43	86	Y	6	8	0	0	1	1	6	8
71-15	3	M	.0300	44	87	Y	7	6	1	0	0	0	7	7
71-15	3	M	.0300	44	88	Y	5	6	1	0	0	0	7	6
71-15	3	M	.0300	45	89	Y	4	8	0	0	1	0	4	8
71-15	3	M	.0300	45	90	Y	4	9	0	0	0	0	4	11
71-15	3	M	.0300	46	91	Y	4	6	0	0	0	1	4	7
71-15	3	M	.0300	46	92	Y	6	5	0	0	1	0	8	5
71-15	3	M	.0300	47	93	Y	6	7	0	0	0	0	6	7
71-15	3	M	.0300	47	94	Y	4	8	0	0	2	1	4	9
71-15	3	M	.0300	48	95	Y	8	7	0	0	2	1	9	8
71-15	3	M	.0300	48	96	Y	7	6	1	0	0	0	7	6
71-15	3	M	.0300	49	97	Y	9	4	0	0	1	0	10	5
71-15	3	M	.0300	49	98	Y	10	5	0	0	2	0	11	7
71-15	3	M	.0300	50	99	Y	6	5	0	0	0	0	6	5
71-15	3	M	.0300	50	100	Y	6	7	0	0	0	0	7	7
71-15	3	M	2.5000	51	101	Y	5	7	0	0	0	0	5	7
71-15	3	M	2.5000	51	102	Y	7	4	1	1	0	0	7	5
71-15	3	M	2.5000	52	103	Y	10	2	0	0	0	0	13	3
71-15	3	M	2.5000	52	104	Y	6	6	0	0	0	0	6	6
71-15	3	M	2.5000	53	105	Y	2	9	0	1	0	0	3	9
71-15	3	M	2.5000	53	106	Y	4	7	0	0	0	3	4	7
71-15	3	M	2.5000	54	107	Y	6	6	0	0	0	0	7	6
71-15	3	M	2.5000	54	108	Y	7	4	0	0	0	0	7	4
71-15	3	M	2.5000	55	109	Y	1	3	0	0	0	0	5	6
71-15	3	M	2.5000	55	110	Y	5	8	0	0	0	1	5	8
71-15	3	M	2.5000	56	111	Y	4	7	0	0	0	0	5	8
71-15	3	M	2.5000	56	112	Y	10	5	2	1	0	1	10	5
71-15	3	M	2.5000	57	113	Y	7	7	0	0	0	0	7	7
71-15	3	M	2.5000	57	114	Y	4	8	0	0	2	2	9	11
71-15	3	M	2.5000	58	115	Y	5	5	0	0	1	0	7	5
71-15	3	M	2.5000	58	116	Y	1	6	0	0	0	0	2	8
71-15	3	M	2.5000	59	117	Y	7	8	0	0	0	0	7	8
71-15	3	M	2.5000	59	118	Y	6	6	0	0	1	1	8	6
71-15	3	M	2.5000	60	119	N	-0	-0	-0	-0	-0	-0	-0	-0
71-15	3	M	2.5000	60	120	Y	9	4	1	0	0	0	10	5

53

TEST MATERIAL	WEEK	S/M	DOSE	MALE NO.	FEMALE NO.	PREG.	IMPLANTS L	IMPLANTS R	EARLY DEATHS L	EARLY DEATHS R	LATE DEATHS L	LATE DEATHS R	CORPORA LUTEA L	CORPORA LUTEA R
71-15	3	M	5.0000	61	121	Y	8	3	0	0	1	0	9	5
71-15	3	M	5.0000	61	122	Y	7	5	0	0	0	0	8	6
71-15	3	M	5.0000	62	123	N	-0	-0	-0	-0	-0	-0	-0	-0
71-15	3	M	5.0000	62	124	Y	7	6	1	1	1	1	7	6
71-15	3	M	5.0000	63	125	Y	5	6	0	0	0	0	6	7
71-15	3	M	5.0000	63	126	Y	5	3	1	0	1	0	7	4
71-15	3	M	5.0000	64	127	Y	6	6	0	0	0	0	7	7
71-15	3	M	5.0000	64	128	Y	5	9	0	0	2	3	5	9
71-15	3	M	5.0000	65	129	Y	6	4	0	0	0	0	6	5
71-15	3	M	5.0000	65	130	Y	5	6	0	0	0	0	5	6
71-15	3	M	5.0000	66	131	Y	9	4	1	0	0	0	9	4
71-15	3	M	5.0000	66	132	Y	7	7	1	1	0	0	8	7
71-15	3	M	5.0000	67	133	Y	2	9	0	0	0	0	2	10
71-15	3	M	5.0000	67	134	Y	3	8	0	0	0	0	3	9
71-15	3	M	5.0000	68	135	Y	5	4	0	0	0	0	9	5
71-15	3	M	5.0000	68	136	Y	4	5	0	0	0	0	7	5
71-15	3	M	5.0000	69	137	Y	6	7	0	0	0	0	6	7
71-15	3	M	5.0000	69	138	Y	4	1	0	0	2	1	5	6
71-15	3	M	5.0000	70	139	Y	7	4	0	0	0	0	8	5
71-15	3	M	5.0000	70	140	Y	7	7	1	1	0	1	7	7

TEST MATERIAL	WEEK	S/M	DOSE	MALE NO.	FEMALE NO.	PREG.	IMPLANTS L	IMPLANTS R	EARLY DEATHS L	EARLY DEATHS R	LATE DEATHS L	LATE DEATHS R	CORPORA LUTEA L	CORPORA LUTEA R
CNTRL15	4	S	0.0000	1	1	Y	2	1	0	0	0	0	6	7
CNTRL15	4	S	0.0000	1	2	Y	9	7	0	0	0	0	9	7
CNTRL15	4	S	0.0000	2	3	Y	7	5	0	0	0	1	7	6
CNTRL15	4	S	0.0000	2	4	N	-0	-0	-0	-0	-0	-0	-0	-0
CNTRL15	4	S	0.0000	3	5	Y	5	2	0	0	1	2	4	8
CNTRL15	4	S	0.0000	3	6	Y	8	6	0	0	0	2	8	6
CNTRL15	4	S	0.0000	4	7	Y	4	7	0	0	0	0	4	9
CNTRL15	4	S	0.0000	4	8	Y	2	0	0	0	0	0	8	5
CNTRL15	4	S	0.0000	5	9	Y	9	8	0	0	1	2	7	8
CNTRL15	4	S	0.0000	5	10	Y	7	5	0	0	0	0	7	5
CNTRL15	4	S	0.0000	6	11	Y	8	3	0	0	0	0	8	4
CNTRL15	4	S	0.0000	6	12	Y	8	4	0	1	0	0	8	5
CNTRL15	4	S	0.0000	7	13	Y	3	5	0	0	1	0	7	5
CNTRL15	4	S	0.0000	7	14	Y	3	8	0	0	0	0	3	8
CNTRL15	4	S	0.0000	8	15	Y	8	6	0	0	1	0	9	7
CNTRL15	4	S	0.0000	8	16	Y	0	1	0	0	0	0	4	6
CNTRL15	4	S	0.0000	9	17	Y	2	9	0	0	0	1	2	10
CNTRL15	4	S	0.0000	9	18	Y	8	4	0	1	0	0	8	4
CNTRL15	4	S	0.0000	10	19	Y	6	5	0	0	0	0	8	5
CNTRL15	4	S	0.0000	10	20	Y	6	7	0	1	0	0	6	7
71-15	4	S	.0300	51	101	Y	3	6	0	0	0	0	3	7
71-15	4	S	.0300	51	102	Y	5	7	0	0	0	0	6	7
71-15	4	S	.0300	52	103	Y	5	4	0	0	0	0	7	7
71-15	4	S	.0300	52	104	N	-0	-0	-0	-0	-0	-0	-0	-0
71-15	4	S	.0300	53	105	Y	6	5	0	0	0	0	6	6
71-15	4	S	.0300	53	106	Y	8	4	0	0	3	0	8	4
71-15	4	S	.0300	54	107	Y	6	4	0	0	2	1	6	5
71-15	4	S	.0300	54	108	Y	9	4	0	2	0	0	11	4
71-15	4	S	.0300	55	109	Y	7	6	0	0	0	0	9	6
71-15	4	S	.0300	55	110	Y	8	5	0	0	0	0	8	5
71-15	4	S	.0300	56	111	Y	6	4	0	0	0	0	8	4
71-15	4	S	.0300	56	112	Y	1	10	0	0	0	1	1	10
71-15	4	S	.0300	57	113	Y	8	5	0	0	1	0	9	5
71-15	4	S	.0300	57	114	Y	5	8	0	0	0	1	5	8
71-15	4	S	.0300	58	115	Y	4	9	0	0	0	0	4	9
71-15	4	S	.0300	58	116	Y	10	4	0	1	0	1	10	6
71-15	4	S	.0300	59	117	Y	8	4	0	0	0	0	8	5
71-15	4	S	.0300	59	118	Y	8	2	0	0	0	0	8	2
71-15	4	S	.0300	60	119	N	-0	-0	-0	-0	-0	-0	-0	-0
71-15	4	S	.0300	60	120	Y	9	5	0	0	1	0	9	5

55

TEST MATERIAL	WEEK	S/M	DOSE	MALE NO.	FEMALE NO.	PREG.	IMPLANTS L	IMPLANTS R	EARLY DEATHS L	EARLY DEATHS R	LATE DEATHS L	LATE DEATHS R	CORPORA LUTEA L	CORPORA LUTEA R
71-15	4	S	2.5000	61	121	Y	5	8	0	0	0	0	5	9
71-15	4	S	2.5000	61	122	Y	5	6	0	0	0	0	5	6
71-15	4	S	2.5000	62	123	Y	7	8	0	0	1	0	7	9
71-15	4	S	2.5000	62	124	Y	9	4	4	0	0	0	10	5
71-15	4	S	2.5000	63	125	Y	9	2	-0	0	1	0	10	3
71-15	4	S	2.5000	63	126	Y	7	5	0	0	6	2	8	5
71-15	4	S	2.5000	64	127	Y	5	7	0	0	0	0	7	7
71-15	4	S	2.5000	64	128	N	-0	-0	-0	-0	-0	-0	-0	-0
71-15	4	S	2.5000	65	129	Y	5	6	0	0	0	1	5	6
71-15	4	S	2.5000	65	130	Y	0	1	0	0	0	1	2	12
71-15	4	S	2.5000	66	131	Y	4	7	0	0	0	3	4	7
71-15	4	S	2.5000	66	132	Y	2	10	0	1	0	0	2	10
71-15	4	S	2.5000	67	133	Y	4	7	0	0	0	0	4	13
71-15	4	S	2.5000	67	134	N	-0	-0	-0	-0	-0	-0	-0	-0
71-15	4	S	2.5000	68	135	Y	8	7	0	0	0	0	8	8
71-15	4	S	2.5000	68	136	N	-0	-0	-0	-0	-0	-0	-0	-0
71-15	4	S	2.5000	69	137	Y	8	4	0	0	0	0	8	5
71-15	4	S	2.5000	69	138	Y	8	6	0	0	0	1	9	7
71-15	4	S	2.5000	70	139	Y	9	2	0	0	0	0	9	3
71-15	4	S	2.5000	70	140	Y	4	6	0	0	0	0	10	6
71-15	4	S	5.0000	71	141	Y	7	5	0	0	0	0	9	6
71-15	4	S	5.0000	71	142	Y	6	6	0	0	0	0	6	6
71-15	4	S	5.0000	72	143	Y	3	7	0	1	0	0	3	9
71-15	4	S	5.0000	72	144	Y	7	6	1	0	0	0	12	8
71-15	4	S	5.0000	73	145	Y	2	10	0	0	0	2	2	10
71-15	4	S	5.0000	73	146	Y	4	9	0	0	2	4	4	9
71-15	4	S	5.0000	74	147	Y	5	8	0	0	0	1	6	8
71-15	4	S	5.0000	74	148	Y	9	4	0	0	0	0	9	4
71-15	4	S	5.0000	75	149	Y	6	5	0	0	1	0	8	5
71-15	4	S	5.0000	75	150	Y	7	5	0	0	0	1	7	5
71-15	4	S	5.0000	76	151	Y	9	4	0	0	1	0	9	5
71-15	4	S	5.0000	76	152	Y	8	7	1	0	3	4	8	7
71-15	4	S	5.0000	77	153	Y	6	4	0	2	0	0	6	6
71-15	4	S	5.0000	77	154	Y	4	6	0	0	0	1	4	6
71-15	4	S	5.0000	78	155	Y	0	7	0	0	0	0	4	7
71-15	4	S	5.0000	78	156	N	-0	-0	-0	-0	-0	-0	-0	-0
71-15	4	S	5.0000	79	157	Y	7	5	0	0	0	0	7	5
71-15	4	S	5.0000	79	158	Y	4	8	0	0	0	3	4	8
71-15	4	S	5.0000	80	159	Y	1	0	1	0	0	0	4	3
71-15	4	S	5.0000	80	160	N	-0	-0	-0	-0	-0	-0	-0	-0

56

TEST MATERIAL	WEEK	S/M	DOSE	MALE NO.	FEMALE NO.	PREG.	IMPLANTS L	IMPLANTS R	EARLY DEATHS L	EARLY DEATHS R	LATE DEATHS L	LATE DEATHS R	CORPORA LUTEA L	CORPORA LUTEA R
TEM15	4	S	.0002	11	21	Y	4	4	0	0	0	2	5	9
TEM15	4	S	.0002	11	22	N	-0	-0	-0	-0	-0	-0	-0	-0
TEM15	4	S	.0002	12	23	Y	0	1	0	0	0	1	3	3
TEM15	4	S	.0002	12	24	N	-0	-0	-0	-0	-0	-0	-0	-0
TEM15	4	S	.0002	13	25	Y	3	7	0	0	2	5	4	8
TEM15	4	S	.0002	13	26	Y	3	3	0	0	0	0	4	8
TEM15	4	S	.0002	14	27	Y	1	0	1	0	0	0	9	1
TEM15	4	S	.0002	14	28	N	-0	-0	-0	-0	-0	-0	-0	-0
TEM15	4	S	.0002	15	29	Y	2	10	0	0	0	9	2	10
TEM15	4	S	.0002	15	30	N	-0	-0	-0	-0	-0	-0	-0	-0
TEM15	4	S	.0002	16	31	Y	2	2	2	2	0	0	4	7
TEM15	4	S	.0002	16	32	Y	3	5	0	0	3	4	5	6
TEM15	4	S	.0002	17	33	Y	5	5	0	0	1	0	5	6
TEM15	4	S	.0002	17	34	Y	1	1	0	0	1	1	5	6
TEM15	4	S	.0002	18	35	N	-0	-0	-0	-0	-0	-0	-0	-0
TEM15	4	S	.0002	18	36	Y	4	5	4	5	0	0	7	7
TEM15	4	S	.0002	19	37	Y	2	3	0	0	0	0	8	3
TEM15	4	S	.0002	19	38	Y	5	2	1	0	0	0	7	5
TEM15	4	S	.0002	20	39	N	-0	-0	-0	-0	-0	-0	-0	-0
TEM15	4	S	.0002	20	40	Y	3	3	3	3	0	0	8	5
CNTRL15	4	M	0.0000	1	1	Y	7	3	0	0	0	1	8	3
CNTRL15	4	M	0.0000	1	2	Y	6	6	0	0	0	0	6	6
CNTRL15	4	M	0.0000	2	3	Y	5	0	0	0	0	0	5	5
CNTRL15	4	M	0.0000	2	4	Y	6	7	0	0	0	0	5	7
CNTRL15	4	M	0.0000	3	5	Y	5	7	0	0	0	1	5	7
CNTRL15	4	M	0.0000	3	6	Y	6	5	0	0	0	0	7	5
CNTRL15	4	M	0.0000	4	7	Y	7	5	1	0	3	0	8	5
CNTRL15	4	M	0.0000	4	8	N	-0	-0	-0	-0	-0	-0	-0	-0
CNTRL15	4	M	0.0000	5	9	Y	3	6	0	0	0	0	4	6
CNTRL15	4	M	0.0000	5	10	Y	6	6	0	0	0	0	6	6
CNTRL15	4	M	0.0000	6	11	N	-0	-0	-0	-0	-0	-0	-0	-0
CNTRL15	4	M	0.0000	6	12	Y	7	4	0	0	0	0	7	4
CNTRL15	4	M	0.0000	7	13	Y	9	7	0	0	1	1	9	7
CNTRL15	4	M	0.0000	7	14	Y	5	6	0	0	2	0	5	7
CNTRL15	4	M	0.0000	8	15	Y	5	7	0	0	0	1	5	8
CNTRL15	4	M	0.0000	8	16	Y	4	5	0	0	0	0	5	5
CNTRL15	4	M	0.0000	9	17	Y	6	6	0	0	0	1	7	8
CNTRL15	4	M	0.0000	9	18	Y	5	6	1	0	1	2	5	6
CNTRL15	4	M	0.0000	10	19	Y	3	7	0	0	0	0	4	7
CNTRL15	4	M	0.0000	10	20	Y	4	6	0	0	0	0	5	6

57

DOMINANT LETHAL GENE STUDY OF COMPOUND 71-15 GUM ARABIC

TEST MATERIAL	WEEK	S/M	DOSE	MALE NO.	FEMALE NO.	PREG.	IMPLANTS L	IMPLANTS R	EARLY DEATHS L	EARLY DEATHS R	LATE DEATHS L	LATE DEATHS R	CORPORA LUTEA L	CORPORA LUTEA R
71-15	4	M	.0300	41	81	Y	5	9	0	0	0	0	5	9
71-15	4	M	.0300	41	82	Y	8	6	0	0	1	2	8	6
71-15	4	M	.0300	42	83	Y	8	5	0	0	0	0	8	6
71-15	4	M	.0300	42	84	Y	3	8	1	0	0	0	3	8
71-15	4	M	.0300	43	85	Y	8	3	0	3	0	0	8	6
71-15	4	M	.0300	43	86	Y	8	5	0	0	0	0	8	5
71-15	4	M	.0300	44	87	Y	3	7	0	0	0	0	4	7
71-15	4	M	.0300	44	88	N	-0	-0	-0	-0	-0	-0	-0	-0
71-15	4	M	.0300	45	89	Y	5	6	1	0	1	0	5	8
71-15	4	M	.0300	45	90	Y	5	5	0	0	0	0	7	5
71-15	4	M	.0300	46	91	Y	8	7	1	0	0	0	8	7
71-15	4	M	.0300	46	92	N	-0	-0	-0	-0	-0	-0	-0	-0
71-15	4	M	.0300	47	93	Y	6	6	0	0	0	0	8	6
71-15	4	M	.0300	47	94	Y	8	5	0	0	1	1	8	5
71-15	4	M	.0300	48	95	Y	4	9	0	0	0	0	5	11
71-15	4	M	.0300	48	96	Y	5	7	0	0	0	0	5	7
71-15	4	M	.0300	49	97	Y	8	3	0	0	0	0	8	3
71-15	4	M	.0300	49	98	Y	4	8	0	0	0	0	4	9
71-15	4	M	.0300	50	99	Y	7	3	1	0	0	0	9	3
71-15	4	M	.0300	50	100	Y	5	6	0	0	0	0	7	6
71-15	4	M	2.5000	51	101	Y	8	4	0	1	0	0	8	5
71-15	4	M	2.5000	51	102	Y	7	7	1	0	0	0	7	7
71-15	4	M	2.5000	52	103	Y	9	5	1	0	0	1	9	5
71-15	4	M	2.5000	52	104	Y	8	6	0	0	0	0	8	6
71-15	4	M	2.5000	53	105	Y	4	5	0	0	0	0	4	7
71-15	4	M	2.5000	53	106	Y	7	7	0	0	0	1	7	7
71-15	4	M	2.5000	54	107	Y	6	6	0	0	0	0	6	6
71-15	4	M	2.5000	54	108	Y	6	8	0	0	0	0	6	8
71-15	4	M	2.5000	55	109	Y	6	7	1	3	0	0	6	8
71-15	4	M	2.5000	55	110	Y	8	4	0	0	0	0	8	4
71-15	4	M	2.5000	56	111	Y	6	5	1	2	0	0	6	5
71-15	4	M	2.5000	56	112	Y	4	9	0	0	0	2	4	9
71-15	4	M	2.5000	57	113	Y	1	1	1	1	0	0	7	3
71-15	4	M	2.5000	57	114	Y	6	5	0	0	1	0	6	5
71-15	4	M	2.5000	58	115	Y	7	7	1	0	0	0	9	7
71-15	4	M	2.5000	58	116	Y	4	7	1	0	0	0	4	7
71-15	4	M	2.5000	59	117	Y	3	10	0	0	0	0	3	11
71-15	4	M	2.5000	59	118	Y	9	3	0	0	0	0	9	3
71-15	4	M	2.5000	60	119	Y	2	8	1	1	0	0	2	9
71-15	4	M	2.5000	60	120	N	-0	-0	-0	-0	-0	-0	-0	-0

TEST MATERIAL	WEEK	S/M	DOSE	MALE NO.	FEMALE NO.	PREG.	IMPLANTS L	IMPLANTS R	EARLY DEATHS L	EARLY DEATHS R	LATE DEATHS L	LATE DEATHS R	CORPORA LUTEA L	CORPORA LUTEA R
71-15	4	M	5.0000	61	121	Y	4	7	0	0	0	0	4	7
71-15	4	M	5.0000	61	122	Y	4	9	0	0	0	2	4	9
71-15	4	M	5.0000	62	123	Y	3	7	0	1	0	0	4	9
71-15	4	M	5.0000	62	124	Y	5	7	0	0	0	0	5	7
71-15	4	M	5.0000	63	125	Y	5	7	0	0	1	0	5	7
71-15	4	M	5.0000	63	126	Y	6	7	0	0	0	0	6	8
71-15	4	M	5.0000	64	127	N	-0	-0	-0	-0	-0	-0	-0	-0
71-15	4	M	5.0000	64	128	Y	10	1	0	1	0	0	10	1
71-15	4	M	5.0000	65	129	Y	2	8	0	1	0	0	3	9
71-15	4	M	5.0000	65	130	N	-0	-0	-0	-0	-0	-0	-0	-0
71-15	4	M	5.0000	66	131	N	-0	-0	-0	-0	-0	-0	-0	-0
71-15	4	M	5.0000	66	132	Y	6	7	0	1	0	0	6	8
71-15	4	M	5.0000	67	133	Y	8	2	0	0	0	0	9	2
71-15	4	M	5.0000	67	134	Y	5	7	0	0	0	0	5	7
71-15	4	M	5.0000	68	135	Y	5	7	0	0	0	1	5	8
71-15	4	M	5.0000	68	136	N	-0	-0	-0	-0	-0	-0	-0	-0
71-15	4	M	5.0000	69	137	Y	3	9	0	0	0	0	3	9
71-15	4	M	5.0000	69	138	Y	1	1	1	0	0	0	3	3
71-15	4	M	5.0000	70	139	Y	9	4	0	0	0	0	11	4
71-15	4	M	5.0000	70	140	Y	9	4	1	0	0	0	9	4

TEST MATERIAL	WEEK	S/M	DOSE	MALE NO.	FEMALE NO.	PREG.	IMPLANTS L	IMPLANTS R	EARLY DEATHS L	EARLY DEATHS R	LATE DEATHS L	LATE DEATHS R	CORPORA LUTEA L	CORPORA LUTEA R
CNTRL15	5	S	0.0000	1	1	N	-0	-0	-0	-0	-0	-0	-0	-0
CNTRL15	5	S	0.0000	1	2	Y	8	4	0	0	1	0	8	5
CNTRL15	5	S	0.0000	2	3	Y	4	8	0	0	0	0	4	10
CNTRL15	5	S	0.0000	2	4	Y	7	6	1	0	0	0	7	6
CNTRL15	5	S	0.0000	3	5	N	-0	-0	-0	-0	-0	-0	-0	-0
CNTRL15	5	S	0.0000	3	6	Y	4	7	0	0	0	0	4	10
CNTRL15	5	S	0.0000	4	7	Y	8	5	0	1	0	0	8	6
CNTRL15	5	S	0.0000	4	8	Y	6	.	0	0	0	0	6	7
CNTRL15	5	S	0.0000	5	9	Y	5	0	0	0	0	0	7	3
CNTRL15	5	S	0.0000	5	10	Y	0	2	0	2	0	0	6	2
CNTRL15	5	S	0.0000	6	11	Y	1	5	0	0	0	0	8	5
CNTRL15	5	S	0.0000	6	12	Y	5	6	0	0	0	0	5	6
CNTRL15	5	S	0.0000	7	13	Y	6	5	0	0	0	0	6	5
CNTRL15	5	S	0.0000	7	14	Y	10	4	0	0	0	0	10	4
CNTRL15	5	S	0.0000	8	15	Y	6	2	0	0	0	0	9	5
CNTRL15	5	S	0.0000	8	16	N	-0	-0	-0	-0	-0	-0	-0	-0
CNTRL15	5	S	0.0000	9	17	Y	4	8	0	0	0	0	4	8
CNTRL15	5	S	0.0000	9	18	Y	4	8	0	0	0	0	5	8
CNTRL15	5	S	0.0000	10	19	Y	2	6	2	2	0	0	5	6
CNTRL15	5	S	0.0000	10	20	N	-0	-0	-0	-0	-0	-0	-0	-0
71-15	5	S	.0300	51	101	Y	5	8	1	0	0	0	5	8
71-15	5	S	.0300	51	102	Y	8	5	0	0	0	0	11	6
71-15	5	S	.0300	52	103	Y	4	5	0	0	0	0	4	6
71-15	5	S	.0300	52	104	Y	9	5	0	0	0	0	9	5
71-15	5	S	.0300	53	105	Y	4	8	0	0	0	0	4	8
71-15	5	S	.0300	53	106	Y	7	5	0	0	0	0	8	5
71-15	5	S	.0300	54	107	Y	5	4	0	0	0	0	5	6
71-15	5	S	.0300	54	108	Y	5	4	1	0	0	0	7	5
71-15	5	S	.0300	55	109	Y	5	7	0	0	0	0	5	7
71-15	5	S	.0300	55	110	Y	6	6	0	0	0	0	6	6
71-15	5	S	.0300	56	111	Y	5	8	2	0	1	0	5	8
71-15	5	S	.0300	56	112	Y	5	5	0	0	2	2	6	6
71-15	5	S	.0300	57	113	Y	2	11	0	0	0	0	3	11
71-15	5	S	.0300	57	114	Y	6	5	0	1	0	0	7	7
71-15	5	S	.0300	58	115	Y	8	6	0	0	0	0	8	6
71-15	5	S	.0300	58	116	Y	5	8	0	0	0	0	5	9
71-15	5	S	.0300	59	117	Y	1	11	0	0	0	0	2	12
71-15	5	S	.0300	59	118	Y	7	5	0	1	1	0	11	7
71-15	5	S	.0300	60	119	Y	7	6	0	1	0	0	7	6
71-15	5	S	.0300	60	120	Y	4	9	0	0	0	1	4	9

TEST MATERIAL	WEEK	S/A	DOSE	MALE NO.	FEMALE NO.	PREG.	IMPLANTS L	IMPLANTS R	EARLY DEATHS L	EARLY DEATHS R	LATE DEATHS L	LATE DEATHS R	CORPORA LUTEA L	CORPORA LUTEA R
71-15	5	S	2.5000	61	121	Y	4	7	0	0	0	0	5	7
71-15	5	S	2.5000	61	122	Y	6	7	0	0	0	0	6	7
71-15	5	S	2.5000	62	123	Y	2	8	0	0	0	0	4	8
71-15	5	S	2.5000	62	124	N	-0	-0	-0	-0	-0	-0	-0	-0
71-15	5	S	2.5000	63	125	Y	8	3	0	0	0	0	10	3
71-15	5	S	2.5000	63	126	Y	6	6	0	0	0	0	6	6
71-15	5	S	2.5000	64	127	Y	3	5	1	1	0	0	8	5
71-15	5	S	2.5000	64	128	N	-0	-0	-0	-0	-0	-0	-0	-0
71-15	5	S	2.5000	65	129	Y	7	7	1	0	0	0	8	7
71-15	5	S	2.5000	65	130	Y	6	4	1	1	0	0	6	4
71-15	5	S	2.5000	66	131	Y	6	4	2	0	0	1	6	4
71-15	5	S	2.5000	66	132	Y	5	9	1	0	0	0	5	9
71-15	5	S	2.5000	67	133	Y	7	7	0	0	0	0	7	7
71-15	5	S	2.5000	67	134	Y	8	3	0	0	0	0	9	3
71-15	5	S	2.5000	68	135	Y	5	7	0	0	0	1	6	7
71-15	5	S	2.5000	68	136	Y	8	5	0	0	0	0	8	5
71-15	5	S	2.5000	69	137	Y	11	2	0	0	0	0	11	2
71-15	5	S	2.5000	69	138	Y	3	9	0	1	0	0	3	9
71-15	5	S	2.5000	70	139	Y	8	6	0	1	1	0	9	6
71-15	5	S	2.5000	70	140	Y	5	0	0	0	1	0	5	6
71-15	5	S	5.0000	71	141	Y	5	8	0	0	1	0	8	8
71-15	5	S	5.0000	71	142	Y	1	0	0	0	0	0	7	3
71-15	5	S	5.0000	72	143	Y	8	4	0	0	0	0	8	4
71-15	5	S	5.0000	72	144	Y	8	8	0	1	0	0	7	7
71-15	5	S	5.0000	73	145	Y	4	6	0	0	0	0	4	6
71-15	5	S	5.0000	73	146	Y	6	6	0	0	0	0	7	6
71-15	5	S	5.0000	74	147	Y	3	0	1	0	0	0	8	8
71-15	5	S	5.0000	74	148	N	-0	-0	-0	-0	-0	-0	-0	-0
71-15	5	S	5.0000	75	149	Y	10	2	2	0	1	0	10	2
71-15	5	S	5.0000	75	150	Y	8	5	1	0	0	0	9	5
71-15	5	S	5.0000	76	151	Y	8	3	2	2	1	0	8	3
71-15	5	S	5.0000	76	152	Y	4	6	0	0	0	0	4	7
71-15	5	S	5.0000	77	153	Y	5	7	0	0	0	1	5	8
71-15	5	S	5.0000	77	154	Y	3	8	0	0	0	0	3	8
71-15	5	S	5.0000	78	155	Y	7	2	0	0	0	0	11	2
71-15	5	S	5.0000	78	156	Y	4	10	0	0	0	0	4	10
71-15	5	S	5.0000	79	157	Y	6	6	0	0	1	0	6	6
71-15	5	S	5.0000	79	158	Y	6	6	0	0	0	0	6	6
71-15	5	S	5.0000	80	159	Y	5	8	0	0	0	1	5	8
71-15	5	S	5.0000	80	160	Y	7	6	0	0	0	0	7	6

61

TEST MATERIAL	WEEK	S/M	DOSE	MALE NO.	FEMALE NO.	PREG.	IMPLANTS L	IMPLANTS R	EARLY DEATHS L	EARLY DEATHS R	LATE DEATHS L	LATE DEATHS R	CORPORA LUTEA L	CORPORA LUTEA R
TEM15	5	S	.0002	11	21	Y	7	3	1	1	0	0	8	3
TEM15	5	S	.0002	11	22	Y	6	7	0	0	0	0	6	7
TEM15	5	S	.0002	12	23	N	-0	-0	-0	-0	-0	-0	-0	-0
TEM15	5	S	.0002	12	24	Y	7	7	2	2	0	0	8	8
TEM15	5	S	.0002	13	25	Y	7	6	1	0	0	0	7	6
TEM15	5	S	.0002	13	26	Y	7	7	0	0	0	0	8	7
TEM15	5	S	.0002	14	27	Y	5	6	1	2	0	0	6	7
TEM15	5	S	.0002	14	28	Y	5	6	0	0	0	0	6	8
TEM15	5	S	.0002	15	29	Y	4	4	0	0	1	3	7	6
TEM15	5	S	.0002	15	30	Y	8	4	6	3	0	0	8	4
TEM15	5	S	.0002	16	31	Y	7	8	3	1	0	0	7	8
TEM15	5	S	.0002	16	32	Y	4	7	3	3	0	1	4	7
TEM15	5	S	.0002	17	33	N	-0	-0	-0	-0	-0	-0	-0	-0
TEM15	5	S	.0002	17	34	Y	3	9	2	3	0	2	5	9
TEM15	5	S	.0002	18	35	Y	2	10	1	5	0	0	2	10
TEM15	5	S	.0002	18	36	Y	7	6	0	0	0	0	7	8
TEM15	5	S	.0002	19	37	Y	3	5	2	3	0	0	4	9
TEM15	5	S	.0002	19	38	Y	7	2	7	2	0	0	8	5
TEM15	5	S	.0002	20	39	Y	9	4	0	1	0	0	9	6
TEM15	5	S	.0002	20	40	N	-0	-0	-0	-0	-0	-0	-0	-0
CNTRL15	5	M	0.0000	1	1	Y	6	8	0	0	1	0	6	8
CNTRL15	5	M	0.0000	1	2	N	-0	-0	-0	-0	-0	-0	-0	-0
CNTRL15	5	M	0.0000	2	3	Y	3	9	0	1	0	0	3	9
CNTRL15	5	M	0.0000	2	4	N	-0	-0	-0	-0	-0	-0	-0	-0
CNTRL15	5	M	0.0000	3	5	Y	8	5	0	0	0	0	8	5
CNTRL15	5	M	0.0000	3	6	N	-0	-0	-0	-0	-0	-0	-0	-0
CNTRL15	5	M	0.0000	4	7	N	-0	-0	-0	-0	-0	-0	-0	-0
CNTRL15	5	M	0.0000	4	8	Y	7	5	1	0	0	0	8	6
CNTRL15	5	M	0.0000	5	9	Y	12	1	0	0	0	0	12	7
CNTRL15	5	M	0.0000	5	10	Y	2	0	0	0	0	0	2	9
CNTRL15	5	M	0.0000	6	11	Y	6	8	0	0	0	0	6	8
CNTRL15	5	M	0.0000	6	12	Y	6	6	0	1	0	0	6	6
CNTRL15	5	M	0.0000	7	13	Y	6	7	0	0	0	1	6	7
CNTRL15	5	M	0.0000	7	14	Y	9	7	1	0	0	0	9	7
CNTRL15	5	M	0.0000	8	15	N	-0	-0	-0	-0	-0	-0	-0	-0
CNTRL15	5	M	0.0000	8	16	Y	9	3	1	0	0	0	9	3
CNTRL15	5	M	0.0000	9	17	N	-0	-0	-0	-0	-0	-0	-0	-0
CNTRL15	5	M	0.0000	9	18	Y	4	6	0	0	0	0	4	6
CNTRL15	5	M	0.0000	10	19	Y	7	5	1	1	0	0	7	5
CNTRL15	5	M	0.0000	10	20	Y	6	4	0	0	0	0	7	4

62

TEST MATERIAL	WEEK	S/M	DOSE	MALE NO.	FEMALE NO.	PREG.	IMPLANTS L	IMPLANTS R	EARLY DEATHS L	EARLY DEATHS R	LATE DEATHS L	LATE DEATHS R	CORPORA LUTEA L	CORPORA LUTEA R
71-15	5	M	.0300	41	81	Y	5	6	0	0	0	0	5	6
71-15	5	M	.0300	41	82	Y	5	6	1	0	0	0	5	6
71-15	5	M	.0300	42	83	Y	6	8	0	0	0	0	6	9
71-15	5	M	.0300	42	84	Y	3	10	0	2	0	0	3	10
71-15	5	M	.0300	43	85	Y	3	7	0	0	0	0	3	10
71-15	5	M	.0300	43	86	Y	5	6	2	0	0	0	6	7
71-15	5	M	.0300	44	87	N	-0	-0	-0	-0	-0	-0	-0	-0
71-15	5	M	.0300	44	88	Y	2	2	0	0	0	0	2	10
71-15	5	M	.0300	45	89	Y	8	5	0	0	0	0	9	5
71-15	5	M	.0300	45	90	Y	5	7	1	0	0	0	5	7
71-15	5	M	.0300	46	91	N	-0	-0	-0	-0	-0	-0	-0	-0
71-15	5	M	.0300	46	92	Y	5	11	0	1	0	0	5	12
71-15	5	M	.0300	47	93	Y	3	7	0	0	0	0	3	9
71-15	5	M	.0300	47	94	Y	4	7	0	0	0	0	4	7
71-15	5	M	.0300	48	95	Y	7	9	0	0	0	0	7	9
71-15	5	M	.0300	48	96	Y	2	11	2	0	0	0	3	11
71-15	5	M	.0300	49	97	Y	5	4	0	0	0	0	5	5
71-15	5	M	.0300	49	98	Y	4	7	0	0	0	0	4	7
71-15	5	M	.0300	50	99	Y	8	5	0	0	3	3	8	5
71-15	5	M	.0300	50	100	Y	4	7	0	0	0	0	4	8
71-15	5	M	2.5000	51	101	Y	4	5	0	0	0	0	5	5
71-15	5	M	2.5000	51	102	Y	6	7	0	0	0	0	6	7
71-15	5	M	2.5000	52	103	Y	9	3	0	0	2	1	10	4
71-15	5	M	2.5000	52	104	Y	8	4	0	0	0	0	9	5
71-15	5	M	2.5000	53	105	Y	7	7	0	0	0	0	7	7
71-15	5	M	2.5000	53	106	Y	6	4	0	0	0	0	6	4
71-15	5	M	2.5000	54	107	Y	4	7	0	0	0	0	5	7
71-15	5	M	2.5000	54	108	Y	4	6	0	1	1	4	4	7
71-15	5	M	2.5000	55	109	Y	4	7	0	0	1	1	4	7
71-15	5	M	2.5000	55	110	Y	0	2	0	1	0	0	4	5
71-15	5	M	2.5000	56	111	Y	4	9	0	0	0	0	4	9
71-15	5	M	2.5000	56	112	Y	7	8	0	0	0	0	7	8
71-15	5	M	2.5000	57	113	Y	5	6	1	0	0	1	5	6
71-15	5	M	2.5000	57	114	Y	7	4	0	0	1	1	7	5
71-15	5	M	2.5000	58	115	Y	5	7	0	0	0	0	5	7
71-15	5	M	2.5000	58	116	Y	4	10	0	1	0	0	4	10
71-15	5	M	2.5000	59	117	Y	5	7	0	0	0	0	5	8
71-15	5	M	2.5000	59	118	Y	2	10	0	0	0	0	2	10
71-15	5	M	2.5000	60	119	Y	7	3	0	0	0	0	9	3
71-15	5	M	2.5000	60	120	Y	7	5	0	0	0	0	7	5

63

TEST MATERIAL	WEEK	S/M	DOSE	MALE NO.	FEMALE NO.	PREG.	IMPLANTS L	IMPLANTS R	EARLY DEATHS L	EARLY DEATHS R	LATE DEATHS L	LATE DEATHS R	CORPORA LUTEA L	CORPORA LUTEA R
71-15	5	M	5.0000	61	121	Y	6	8	0	1	0	4	6	8
71-15	5	M	5.0000	61	122	Y	7	4	0	0	0	1	7	4
71-15	5	M	5.0000	62	123	Y	6	6	0	0	0	0	6	6
71-15	5	M	5.0000	62	124	Y	2	9	0	0	0	0	2	9
71-15	5	M	5.0000	63	125	Y	5	4	0	0	0	0	5	4
71-15	5	M	5.0000	63	126	Y	5	9	0	0	0	0	5	9
71-15	5	M	5.0000	64	127	Y	7	5	0	0	0	0	7	5
71-15	5	M	5.0000	64	128	Y	5	7	0	0	0	0	5	7
71-15	5	M	5.0000	65	129	Y	8	2	1	0	0	0	8	3
71-15	5	M	5.0000	65	130	Y	4	0	3	0	0	0	4	5
71-15	5	M	5.0000	66	131	N	-0	-0	-0	-0	-0	-0	-0	-0
71-15	5	M	5.0000	66	132	Y	5	6	0	0	0	0	6	7
71-15	5	M	5.0000	67	133	Y	9	5	1	0	0	0	9	6
71-15	5	M	5.0000	67	134	Y	6	5	0	0	0	0	6	5
71-15	5	M	5.0000	68	135	Y	7	5	0	0	0	0	7	5
71-15	5	M	5.0000	68	136	N	-0	-0	-0	-0	-0	-0	-0	-0
71-15	5	M	5.0000	69	137	Y	2	3	1	1	0	0	5	6
71-15	5	M	5.0000	69	138	Y	5	8	0	0	0	0	5	8
71-15	5	M	5.0000	70	139	Y	6	3	0	0	0	0	6	4
71-15	5	M	5.0000	70	140	Y	5	6	0	0	0	0	5	7

64

TEST MATERIAL	WEEK	S/M	DOSE	MALE NO.	FEMALE NO.	PREG.	IMPLANTS L	IMPLANTS R	EARLY DEATHS L	EARLY DEATHS R	LATE DEATHS L	LATE DEATHS R	CORPORA LUTEA L	CORPORA LUTEA R
CNTRL15	6	S	0.0000	1	1	N	-0	-0	-0	-0	-0	-0	-0	-0
CNTRL15	6	S	0.0000	1	2	N	-0	-0	-0	-0	-0	-0	-0	-0
CNTRL15	6	S	0.0000	2	3	Y	7	6	0	0	1	0	8	6
CNTRL15	6	S	0.0000	2	4	Y	4	9	0	0	0	0	4	9
CNTRL15	6	S	0.0000	3	5	N	-0	-0	-0	-0	-0	-0	-0	-0
CNTRL15	6	S	0.0000	3	6	N	-0	-0	-0	-0	-0	-0	-0	-0
CNTRL15	6	S	0.0000	4	7	Y	4	7	0	0	0	0	4	7
CNTRL15	6	S	0.0000	4	8	Y	5	7	0	1	0	0	5	7
CNTRL15	6	S	0.0000	5	9	N	-0	-0	-0	-0	-0	-0	-0	-0
CNTRL15	6	S	0.0000	5	10	Y	5	10	0	0	0	1	5	10
CNTRL15	6	S	0.0000	6	11	Y	1	2	0	1	0	0	7	5
CNTRL15	6	S	0.0000	6	12	N	-0	-0	-0	-0	-0	-0	-0	-0
CNTRL15	6	S	0.0000	7	13	Y	6	8	0	0	0	0	6	8
CNTRL15	6	S	0.0000	7	14	Y	3	8	1	3	0	0	4	8
CNTRL15	6	S	0.0000	8	15	N	-0	-0	-0	-0	-0	-0	-0	-0
CNTRL15	6	S	0.0000	8	16	N	-0	-0	-0	-0	-0	-0	-0	-0
CNTRL15	6	S	0.0000	9	17	Y	9	7	0	0	1	1	9	7
CNTRL15	6	S	0.0000	9	18	Y	8	7	0	0	0	0	8	7
CNTRL15	6	S	0.0000	10	19	Y	8	6	0	0	0	1	8	6
CNTRL15	6	S	0.0000	10	20	Y	7	7	0	0	0	0	8	7
71-15	6	S	.0300	51	101	Y	8	6	0	0	0	1	8	6
71-15	6	S	.0300	51	102	Y	8	4	0	0	0	0	8	4
71-15	6	S	.0300	52	103	Y	5	7	0	0	0	0	5	7
71-15	6	S	.0300	52	104	Y	5	2	3	1	0	0	5	3
71-15	6	S	.0300	53	105	Y	8	5	1	0	1	0	8	5
71-15	6	S	.0300	53	106	Y	7	6	0	0	0	0	7	6
71-15	6	S	.0300	54	107	Y	9	5	0	0	0	0	9	5
71-15	6	S	.0300	54	108	Y	6	8	1	0	0	0	7	8
71-15	6	S	.0300	55	109	Y	4	9	0	0	0	0	4	9
71-15	6	S	.0300	55	110	Y	4	7	0	0	0	0	5	7
71-15	6	S	.0300	56	111	Y	8	7	0	0	2	3	8	7
71-15	6	S	.0300	56	112	Y	4	5	0	0	0	0	6	5
71-15	6	S	.0300	57	113	Y	8	5	0	0	0	0	8	6
71-15	6	S	.0300	57	114	Y	7	5	0	0	0	0	7	5
71-15	6	S	.0300	58	115	Y	5	8	0	1	0	0	5	8
71-15	6	S	.0300	58	116	Y	7	7	0	1	2	2	8	8
71-15	6	S	.0300	59	117	Y	9	4	0	0	0	0	9	4
71-15	6	S	.0300	59	118	Y	5	6	0	1	0	0	5	6
71-15	6	S	.0300	60	119	Y	8	5	0	0	0	1	8	5
71-15	6	S	.0300	60	120	Y	7	7	1	3	0	0	8	8

TEST MATERIAL	WEEK	S/M	DOSE	MALE NO.	FEMALE NO.	PREG.	IMPLANTS L	IMPLANTS R	EARLY DEATHS L	EARLY DEATHS R	LATE DEATHS L	LATE DEATHS R	CORPORA LUTEA L	CORPORA LUTEA R
71-15	6	S	2.5000	61	121	Y	6	8	0	0	0	0	6	8
71-15	6	S	2.5000	61	122	Y	5	8	0	0	0	2	5	8
71-15	6	S	2.5000	62	123	Y	4	5	0	0	0	0	4	7
71-15	6	S	2.5000	62	124	Y	7	6	0	0	0	0	8	6
71-15	6	S	2.5000	63	125	Y	2	7	0	0	0	1	6	5
71-15	6	S	2.5000	63	126	Y	7	3	0	0	1	0	7	3
71-15	6	S	2.5000	64	127	N	-0	-0	-0	-0	-0	-0	-0	-0
71-15	6	S	2.5000	64	128	Y	7	6	1	0	0	0	8	6
71-15	6	S	2.5000	65	129	Y	5	5	1	0	0	0	6	6
71-15	6	S	2.5000	65	130	Y	7	4	1	0	0	0	9	4
71-15	6	S	2.5000	66	131	N	-0	-0	-0	-0	-0	-0	-0	-0
71-15	6	S	2.5000	66	132	Y	6	6	0	0	0	0	5	6
71-15	6	S	2.5000	67	133	Y	5	8	0	0	0	0	6	8
71-15	6	S	2.5000	67	134	Y	5	9	0	0	0	0	5	9
71-15	6	S	2.5000	68	135	Y	6	6	0	0	0	0	6	6
71-15	6	S	2.5000	68	136	N	-0	-0	-0	-0	-0	-0	-0	-0
71-15	6	S	2.5000	69	137	Y	5	7	0	0	0	0	5	7
71-15	6	S	2.5000	69	138	Y	5	9	0	0	0	0	6	9
71-15	6	S	2.5000	70	139	Y	1	1	1	0	0	0	2	1
71-15	6	S	2.5000	70	140	Y	4	8	0	1	1	2	4	8
71-15	6	S	5.0000	71	141	Y	1	0	0	0	0	0	3	4
71-15	6	S	5.0000	71	142	Y	9	5	0	0	0	0	9	5
71-15	6	S	5.0000	72	143	Y	4	6	1	0	0	0	4	6
71-15	6	S	5.0000	72	144	Y	7	3	0	0	0	0	6	3
71-15	6	S	5.0000	73	145	Y	5	8	0	0	0	0	5	8
71-15	6	S	5.0000	73	146	Y	6	1	0	0	0	0	6	5
71-15	6	S	5.0000	74	147	Y	9	4	0	0	0	0	9	4
71-15	6	S	5.0000	74	148	Y	6	5	0	0	0	0	8	5
71-15	6	S	5.0000	75	149	Y	6	4	0	0	0	0	6	4
71-15	6	S	5.0000	75	150	Y	10	4	0	0	0	0	10	5
71-15	6	S	5.0000	76	151	Y	5	6	0	0	0	1	5	8
71-15	6	S	5.0000	76	152	Y	6	7	0	0	0	0	6	7
71-15	6	S	5.0000	77	153	Y	5	7	0	0	0	0	5	7
71-15	6	S	5.0000	77	154	Y	2	2	0	0	0	0	4	4
71-15	6	S	5.0000	78	155	Y	4	7	3	0	0	1	6	8
71-15	6	S	5.0000	78	156	Y	5	8	0	2	2	2	5	8
71-15	6	S	5.0000	79	157	Y	8	5	0	0	0	0	8	5
71-15	6	S	5.0000	79	158	Y	1	6	0	0	0	0	1	3
71-15	6	S	5.0000	80	159	Y	4	5	1	0	0	0	5	5
71-15	6	S	5.0000	80	160	Y	5	7	0	0	0	0	5	7

TEST MATERIAL	WEEK	S/M	DOSE	MALE NO.	FEMALE NO.	PREG.	IMPLANTS L	IMPLANTS R	EARLY DEATHS L	EARLY DEATHS R	LATE DEATHS L	LATE DEATHS R	CORPORA LUTEA L	CORPORA LUTEA R
TEM15	6	S	.0002	11	21	Y	5	6	0	0	0	0	7	7
TEM15	6	S	.0002	11	22	Y	3	9	0	1	0	0	4	9
TEM15	6	S	.0002	12	23	Y	6	7	0	0	1	0	6	7
TEM15	6	S	.0002	12	24	Y	6	4	0	0	0	0	6	4
TEM15	6	S	.0002	13	25	Y	5	0	0	2	0	0	5	7
TEM15	6	S	.0002	13	26	Y	5	4	0	0	0	0	6	4
TEM15	6	S	.0002	14	27	Y	5	9	0	0	0	1	5	10
TEM15	6	S	.0002	14	28	Y	7	8	0	1	0	0	7	8
TEM15	6	S	.0002	15	29	Y	6	6	0	0	0	1	6	6
TEM15	6	S	.0002	15	30	Y	7	3	3	0	0	0	7	3
TEM15	6	S	.0002	16	31	Y	8	3	0	0	0	0	9	3
TEM15	6	S	.0002	16	32	Y	3	4	0	1	0	0	5	5
TEM15	6	S	.0002	17	33	Y	10	4	1	1	0	0	10	4
TEM15	6	S	.0002	17	34	Y	7	8	1	0	0	0	7	8
TEM15	6	S	.0002	18	35	Y	6	8	0	0	0	0	6	8
TEM15	6	S	.0002	18	36	Y	3	8	0	0	0	0	3	8
TEM15	6	S	.0002	19	37	Y	6	6	0	0	0	0	6	6
TEM15	6	S	.0002	19	38	Y	6	7	0	0	0	0	6	7
TEM15	6	S	.0002	20	39	Y	7	5	0	0	0	0	7	5
TEM15	6	S	.0002	20	40	Y	7	5	0	0	0	0	7	5
CNTRL15	6	M	0.0000	1	1	Y	2	6	0	0	0	1	6	6
CNTRL15	6	M	0.0000	1	2	Y	2	6	0	0	0	0	8	6
CNTRL15	6	M	0.0000	2	3	Y	0	1	0	1	0	0	0	14
CNTRL15	6	M	0.0000	2	4	N	-0	-0	-0	-0	-0	-0	-0	-0
CNTRL15	6	M	0.0000	3	5	Y	5	6	0	0	1	0	5	6
CNTRL15	6	M	0.0000	3	6	N	-0	-0	-0	-0	-0	-0	-0	-0
CNTRL15	6	M	0.0000	4	7	Y	6	5	0	0	3	2	6	8
CNTRL15	6	M	0.0000	4	8	Y	9	6	0	0	3	3	9	6
CNTRL15	6	M	0.0000	5	9	Y	7	9	0	0	0	0	7	9
CNTRL15	6	M	0.0000	5	10	Y	6	10	0	0	0	1	8	10
CNTRL15	6	M	0.0000	6	11	N	-0	-0	-0	-0	-0	-0	-0	-0
CNTRL15	6	M	0.0000	6	12	Y	6	5	0	0	0	0	6	5
CNTRL15	6	M	0.0000	7	13	Y	5	6	0	0	0	2	5	7
CNTRL15	6	M	0.0000	7	14	Y	9	3	0	0	0	0	9	4
CNTRL15	6	M	0.0000	8	15	Y	9	4	1	0	0	0	9	4
CNTRL15	6	M	0.0000	8	16	Y	10	6	3	1	0	0	10	6
CNTRL15	6	M	0.0000	9	17	Y	6	7	0	0	0	0	6	9
CNTRL15	6	M	0.0000	9	18	Y	7	5	0	0	1	1	8	5
CNTRL15	6	M	0.0000	10	19	Y	3	9	0	0	0	0	4	9
CNTRL15	6	M	0.0000	10	20	Y	11	5	1	0	1	0	11	5

TEST MATERIAL	WEEK	S/M	DOSE	MALE NO.	FEMALE NO.	PREG.	IMPLANTS L	IMPLANTS R	EARLY DEATHS L	EARLY DEATHS R	LATE DEATHS L	LATE DEATHS R	CORPORA LUTEA L	CORPORA LUTEA R
71-15	6	M	.0300	41	81	Y	7	4	0	0	0	0	8	4
71-15	6	M	.0300	41	82	Y	8	3	0	1	1	0	13	9
71-15	6	M	.0300	42	83	Y	10	2	0	0	0	0	10	4
71-15	6	M	.0300	42	84	Y	7	4	0	0	0	0	7	4
71-15	6	M	.0300	43	85	Y	4	7	0	0	0	2	4	7
71-15	6	M	.0300	43	86	Y	7	7	0	0	0	0	7	8
71-15	6	M	.0300	44	87	Y	7	4	2	2	0	0	8	7
71-15	6	M	.0300	44	88	N	-0	-0	-0	-0	-0	-0	-0	-0
71-15	6	M	.0300	45	89	Y	5	7	0	0	1	1	6	7
71-15	6	M	.0300	45	90	Y	3	10	0	0	0	1	3	10
71-15	6	M	.0300	46	91	Y	8	4	0	0	0	0	8	4
71-15	6	M	.0300	46	92	Y	3	10	0	0	0	0	3	10
71-15	6	M	.0300	47	93	Y	4	9	0	0	0	2	4	10
71-15	6	M	.0300	47	94	Y	4	10	0	0	0	0	4	10
71-15	6	M	.0300	48	95	Y	5	7	0	0	0	0	6	7
71-15	6	M	.0300	48	96	Y	6	7	0	0	0	0	6	7
71-15	6	M	.0300	49	97	Y	3	8	0	1	0	0	3	8
71-15	6	M	.0300	49	98	Y	7	4	0	0	0	0	7	4
71-15	6	M	.0300	50	99	Y	5	8	0	0	0	0	5	8
71-15	6	M	.0300	50	100	Y	7	3	0	0	0	0	7	4
71-15	6	M	2.5000	51	101	Y	6	8	0	0	0	0	6	8
71-15	6	M	2.5000	51	102	Y	6	5	0	0	0	0	6	5
71-15	6	M	2.5000	52	103	N	-0	-0	-0	-0	-0	-0	-0	-0
71-15	6	M	2.5000	52	104	Y	5	6	1	0	0	0	6	9
71-15	6	M	2.5000	53	105	Y	5	6	0	0	0	0	5	6
71-15	6	M	2.5000	53	106	Y	9	5	0	0	0	0	9	5
71-15	6	M	2.5000	54	107	Y	2	12	0	0	0	0	2	13
71-15	6	M	2.5000	54	108	Y	7	4	0	0	0	0	7	4
71-15	6	M	2.5000	55	109	Y	4	9	0	0	0	0	4	9
71-15	6	M	2.5000	55	110	Y	2	7	0	0	0	0	3	7
71-15	6	M	2.5000	56	111	Y	4	7	0	0	1	1	8	9
71-15	6	M	2.5000	56	112	Y	7	2	2	0	0	0	7	2
71-15	6	M	2.5000	57	113	Y	7	5	0	0	0	0	7	5
71-15	6	M	2.5000	57	114	Y	8	5	0	0	0	0	8	5
71-15	6	M	2.5000	58	115	Y	9	5	0	0	0	0	9	5
71-15	6	M	2.5000	58	116	Y	0	-1	0	0	0	0	3	4
71-15	6	M	2.5000	59	117	Y	1	4	1	4	0	0	6	6
71-15	6	M	2.5000	59	118	Y	4	3	0	1	0	1	4	8
71-15	6	M	2.5000	60	119	N	-0	-0	-0	-0	-0	-0	-0	-0
71-15	6	M	2.5000	60	120	Y	8	4	1	1	0	0	8	4

DOMINANT LETHAL GENE STUDY OF COMPOUND 71-15 GUM ARABIC

TEST MATERIAL	WEEK	S/M	DOSE	MALE NO.	FEMALE NO.	PREG.	IMPLANTS L	IMPLANTS R	EARLY DEATHS L	EARLY DEATHS R	LATE DEATHS L	LATE DEATHS R	CORPORA LUTEA L	CORPORA LUTEA R
71-15	6	M	5.0000	61	121	Y	4	7	0	0	1	3	4	7
71-15	6	M	5.0000	61	122	Y	6	6	0	1	0	0	7	6
71-15	6	M	5.0000	62	123	Y	8	5	0	0	0	0	9	5
71-15	6	M	5.0000	62	124	Y	5	10	0	1	0	0	5	12
71-15	6	M	5.0000	63	125	N	-0	-0	-0	-0	-0	-0	-0	-0
71-15	6	M	5.0000	63	126	N	-0	-0	-0	-0	-0	-0	-0	-0
71-15	6	M	5.0000	64	127	Y	4	9	0	0	0	1	4	9
71-15	6	M	5.0000	64	128	Y	4	9	0	0	0	0	4	9
71-15	6	M	5.0000	65	129	Y	7	7	0	0	0	2	7	7
71-15	6	M	5.0000	65	130	N	-0	-0	-0	-0	-0	-0	-0	-0
71-15	6	M	5.0000	66	131	Y	6	6	0	0	0	0	6	6
71-15	6	M	5.0000	66	132	Y	5	7	0	0	0	0	5	7
71-15	6	M	5.0000	67	133	Y	8	6	0	0	0	0	8	6
71-15	6	M	5.0000	67	134	Y	9	2	2	0	2	0	9	2
71-15	6	M	5.0000	68	135	Y	8	5	1	1	0	0	8	5
71-15	6	M	5.0000	68	136	N	-0	-0	-0	-0	-0	-0	-0	-0
71-15	6	M	5.0000	69	137	Y	5	8	0	0	0	0	5	8
71-15	6	M	5.0000	69	138	N	-0	-0	-0	-0	-0	-0	-0	-0
71-15	6	M	5.0000	70	139	Y	7	5	0	0	0	3	7	5
71-15	6	M	5.0000	70	140	Y	7	4	1	0	0	0	8	6

69

TEST MATERIAL	WEEK	S/M	DOSE	MALE NO.	FEMALE NO.	PREG.	IMPLANTS L	IMPLANTS R	EARLY DEATHS L	EARLY DEATHS R	LATE DEATHS L	LATE DEATHS R	CORPORA LUTEA L	CORPORA LUTEA R
CNTRL15	7	S	0.0000	1	1	Y	5	9	0	0	0	0	5	9
CNTRL15	7	S	0.0000	1	2	Y	5	0	0	0	0	0	5	5
CNTRL15	7	S	0.0000	2	3	Y	8	6	0	0	0	0	8	6
CNTRL15	7	S	0.0000	2	4	N	-0	-0	-0	-0	-0	-0	-0	-0
CNTRL15	7	S	0.0000	3	5	Y	6	4	0	0	3	0	6	4
CNTRL15	7	S	0.0000	3	6	Y	5	9	0	0	1	0	5	9
CNTRL15	7	S	0.0000	4	7	N	-0	-0	-0	-0	-0	-0	-0	-0
CNTRL15	7	S	0.0000	4	8	Y	6	7	0	0	0	0	5	7
CNTRL15	7	S	0.0000	5	9	Y	4	0	1	0	0	0	8	6
CNTRL15	7	S	0.0000	5	10	Y	0	4	0	2	0	0	3	9
CNTRL15	7	S	0.0000	6	11	Y	10	3	0	0	0	0	10	3
CNTRL15	7	S	0.0000	6	12	Y	3	5	0	1	0	0	5	5
CNTRL15	7	S	0.0000	7	13	Y	3	7	0	1	0	0	3	7
CNTRL15	7	S	0.0000	7	14	Y	3	2	0	0	0	0	6	6
CNTRL15	7	S	0.0000	8	15	N	-0	-0	-0	-0	-0	-0	-0	-0
CNTRL15	7	S	0.0000	8	16	Y	6	7	0	0	0	0	8	7
CNTRL15	7	S	0.0000	9	17	Y	2	9	0	0	0	0	2	9
CNTRL15	7	S	0.0000	9	18	Y	8	5	0	0	0	0	9	5
CNTRL15	7	S	0.0000	10	19	Y	9	4	2	0	0	0	11	4
CNTRL15	7	S	0.0000	10	20	Y	4	8	0	0	0	0	4	8
71-15	7	S	.0300	51	101	Y	8	4	0	0	0	0	8	4
71-15	7	S	.0300	51	102	Y	6	9	1	1	0	0	6	9
71-15	7	S	.0300	52	103	Y	5	2	0	0	0	0	7	6
71-15	7	S	.0300	52	104	Y	2	6	0	0	0	0	6	6
71-15	7	S	.0300	53	105	Y	7	7	1	0	0	0	7	7
71-15	7	S	.0300	53	106	Y	7	4	1	0	1	0	7	4
71-15	7	S	.0300	54	107	Y	8	3	0	0	0	0	8	3
71-15	7	S	.0300	54	108	Y	2	5	0	0	0	0	5	7
71-15	7	S	.0300	55	109	Y	3	9	1	1	1	1	3	9
71-15	7	S	.0300	55	110	Y	6	7	0	0	0	0	6	7
71-15	7	S	.0300	56	111	Y	0	1	0	1	0	0	12	2
71-15	7	S	.0300	56	112	Y	6	6	1	0	0	0	8	6
71-15	7	S	.0300	57	113	Y	3	7	0	1	0	0	4	8
71-15	7	S	.0300	57	114	Y	4	6	0	0	0	0	4	6
71-15	7	S	.0300	58	115	Y	5	7	0	1	0	0	5	8
71-15	7	S	.0300	58	116	N	-0	-0	-0	-0	-0	-0	-0	-0
71-15	7	S	.0300	59	117	Y	10	5	0	0	0	0	10	5
71-15	7	S	.0300	59	118	Y	8	3	0	0	0	0	9	3
71-15	7	S	.0300	60	119	Y	4	7	0	0	0	0	4	8
71-15	7	S	.0300	60	120	Y	9	6	0	0	0	0	9	6

TEST MATERIAL	WEEK	S/M	DOSE	MALE NO.	FEMALE NO.	PREG.	IMPLANTS L	IMPLANTS R	EARLY DEATHS L	EARLY DEATHS R	LATE DEATHS L	LATE DEATHS R	CORPORA LUTEA L	CORPORA LUTEA R
71-15	7	S	2.5000	61	121	Y	8	5	0	0	2	2	8	5
71-15	7	S	2.5000	61	122	Y	8	5	0	0	0	0	8	5
71-15	7	S	2.5000	62	123	Y	6	5	0	0	0	0	6	5
71-15	7	S	2.5000	62	124	N	-0	-0	-0	-0	-0	-0	-0	-0
71-15	7	S	2.5000	63	125	Y	5	8	0	0	0	0	5	8
71-15	7	S	2.5000	63	126	Y	1	0	1	0	0	0	4	5
71-15	7	S	2.5000	64	127	Y	6	6	1	0	0	0	8	6
71-15	7	S	2.5000	64	128	Y	3	9	0	1	0	0	3	10
71-15	7	S	2.5000	65	129	Y	4	10	0	1	0	0	5	10
71-15	7	S	2.5000	65	130	Y	8	5	0	0	0	0	8	5
71-15	7	S	2.5000	66	131	Y	4	9	0	0	0	0	5	9
71-15	7	S	2.5000	66	132	Y	0	4	0	0	0	0	7	4
71-15	7	S	2.5000	67	133	Y	3	5	0	1	0	0	5	7
71-15	7	S	2.5000	67	134	Y	6	7	0	0	0	1	6	8
71-15	7	S	2.5000	68	135	Y	6	5	0	0	0	1	7	6
71-15	7	S	2.5000	68	136	Y	1	1	0	0	1	1	3	1
71-15	7	S	2.5000	69	137	Y	4	8	0	0	0	1	5	8
71-15	7	S	2.5000	69	138	Y	1	3	1	1	0	1	4	6
71-15	7	S	2.5000	70	139	Y	9	9	0	0	1	0	9	9
71-15	7	S	2.5000	70	140	Y	6	6	0	1	0	0	6	6
71-15	7	S	5.0000	71	141	Y	4	8	0	0	0	0	5	8
71-15	7	S	5.0000	71	142	Y	7	5	0	0	1	0	7	5
71-15	7	S	5.0000	72	143	Y	6	6	0	0	0	0	6	8
71-15	7	S	5.0000	72	144	Y	5	8	1	0	0	1	5	8
71-15	7	S	5.0000	73	145	N	-0	-0	-0	-0	-0	-0	-0	-0
71-15	7	S	5.0000	73	146	Y	6	6	0	0	0	0	6	6
71-15	7	S	5.0000	74	147	Y	10	6	0	0	0	0	10	6
71-15	7	S	5.0000	74	148	Y	5	5	0	0	1	0	5	8
71-15	7	S	5.0000	75	149	Y	10	4	0	0	0	0	10	4
71-15	7	S	5.0000	75	150	Y	6	6	0	0	1	2	8	6
71-15	7	S	5.0000	76	151	Y	6	9	0	0	0	0	6	10
71-15	7	S	5.0000	76	152	Y	4	8	0	1	1	0	4	8
71-15	7	S	5.0000	77	153	Y	4	6	0	0	0	2	4	7
71-15	7	S	5.0000	77	154	N	-0	-0	-0	-0	-0	-0	-0	-0
71-15	7	S	5.0000	78	155	Y	5	8	1	0	0	0	5	8
71-15	7	S	5.0000	78	156	N	-0	-0	-0	-0	-0	-0	-0	-0
71-15	7	S	5.0000	79	157	N	-0	-0	-0	-0	-0	-0	-0	-0
71-15	7	S	5.0000	79	158	N	-0	-0	-0	-0	-0	-0	-0	-0
71-15	7	S	5.0000	80	159	Y	4	8	0	0	0	0	4	10
71-15	7	S	5.0000	80	160	Y	4	9	0	3	0	1	4	11

TEST MATERIAL	WEEK	S/M	DOSE	MALE NO.	FEMALE NO.	PREG.	IMPLANTS L	IMPLANTS R	EARLY DEATHS L	EARLY DEATHS R	LATE DEATHS L	LATE DEATHS R	CORPORA LUTEA L	CORPORA LUTEA R
TEM15	7	S	.0002	11	21	Y	1	2	0	0	0	0	7	8
TEM15	7	S	.0002	11	22	Y	6	5	0	0	0	1	9	6
TEM15	7	S	.0002	12	23	Y	8	0	0	0	0	0	8	3
TEM15	7	S	.0002	12	24	Y	8	5	0	0	0	0	8	5
TEM15	7	S	.0002	13	25	Y	7	3	0	0	0	0	9	3
TEM15	7	S	.0002	13	26	Y	2	11	1	0	0	0	4	10
TEM15	7	S	.0002	14	27	Y	9	4	1	0	0	0	9	4
TEM15	7	S	.0002	14	28	N	-0	-0	-0	-0	-0	-0	-0	-0
TEM15	7	S	.0002	15	29	Y	4	9	0	0	0	0	4	9
TEM15	7	S	.0002	15	30	Y	5	7	1	0	0	0	5	7
TEM15	7	S	.0002	16	31	Y	8	3	0	0	0	1	8	3
TEM15	7	S	.0002	16	32	Y	5	9	0	0	0	0	6	9
TEM15	7	S	.0002	17	33	Y	7	3	0	0	0	0	8	3
TEM15	7	S	.0002	17	34	Y	6	7	0	0	1	0	6	8
TEM15	7	S	.0002	18	35	Y	7	5	0	1	0	0	7	5
TEM15	7	S	.0002	18	36	N	-0	-0	-0	-0	-0	-0	-0	-0
TEM15	7	S	.0002	19	37	Y	1	7	0	0	0	0	4	7
TEM15	7	S	.0002	19	38	Y	5	6	0	0	0	0	6	7
TEM15	7	S	.0002	20	39	Y	5	6	0	0	0	1	7	9
TEM15	7	S	.0002	20	40	Y	4	7	0	1	0	0	4	9
CNTRL15	7	M	0.0000	1	1	Y	6	6	0	1	1	0	6	6
CNTRL15	7	M	0.0000	1	2	Y	7	4	0	0	0	0	7	4
CNTRL15	7	M	0.0000	2	3	Y	6	6	0	0	0	0	6	7
CNTRL15	7	M	0.0000	2	4	Y	6	5	0	0	0	0	7	6
CNTRL15	7	M	0.0000	3	5	Y	1	8	0	0	0	0	5	8
CNTRL15	7	M	0.0000	3	6	Y	7	7	0	0	0	0	7	7
CNTRL15	7	M	0.0000	4	7	N	-0	-0	-0	-0	-0	-0	-0	-0
CNTRL15	7	M	0.0000	4	8	Y	4	8	0	0	0	0	6	8
CNTRL15	7	M	0.0000	5	9	Y	4	9	0	0	0	0	4	9
CNTRL15	7	M	0.0000	5	10	Y	5	6	0	0	0	0	9	6
CNTRL15	7	M	0.0000	6	11	Y	5	8	0	0	0	0	5	9
CNTRL15	7	M	0.0000	6	12	Y	7	5	1	0	1	0	8	5
CNTRL15	7	M	0.0000	7	13	Y	6	6	0	0	0	0	5	7
CNTRL15	7	M	0.0000	7	14	Y	6	8	1	0	0	0	7	8
CNTRL15	7	M	0.0000	8	15	Y	5	7	0	0	0	0	5	7
CNTRL15	7	M	0.0000	8	16	Y	5	1	3	0	0	0	5	6
CNTRL15	7	M	0.0000	9	17	Y	6	5	0	1	0	0	8	5
CNTRL15	7	M	0.0000	9	18	Y	4	10	0	0	0	0	6	10
CNTRL15	7	M	0.0000	10	19	Y	5	8	0	0	0	2	5	8
CNTRL15	7	M	0.0000	10	20	Y	7	5	0	0	0	0	7	6

72

TEST MATERIAL	WEEK	S/M	DOSE	MALE NO.	FEMALE NO.	PREG.	IMPLANTS L	IMPLANTS R	EARLY DEATHS L	EARLY DEATHS R	LATE DEATHS L	LATE DEATHS R	CORPORA LUTEA L	CORPORA LUTEA R
71-15	7	M	.0300	41	81	Y	6	6	0	0	0	0	6	10
71-15	7	M	.0300	41	82	Y	7	5	0	0	0	0	7	5
71-15	7	M	.0300	42	83	Y	10	5	0	0	0	0	10	6
71-15	7	M	.0300	42	84	Y	5	7	0	0	1	1	5	7
71-15	7	M	.0300	43	85	Y	4	7	0	0	0	0	4	8
71-15	7	M	.0300	43	86	Y	7	7	0	0	0	0	7	7
71-15	7	M	.0300	44	87	Y	6	5	0	0	0	0	6	5
71-15	7	M	.0300	44	88	Y	7	6	0	0	0	0	7	6
71-15	7	M	.0300	45	89	Y	4	9	0	2	0	0	4	11
71-15	7	M	.0300	45	90	Y	6	8	0	0	0	0	6	8
71-15	7	M	.0300	46	91	Y	6	6	0	0	0	0	6	6
71-15	7	M	.0300	46	92	Y	10	5	1	0	0	1	10	5
71-15	7	M	.0300	47	93	Y	4	5	0	0	0	0	4	6
71-15	7	M	.0300	47	94	Y	7	6	0	0	0	0	7	6
71-15	7	M	.0300	48	95	Y	5	6	1	0	0	0	5	6
71-15	7	M	.0300	48	96	N	-0	-0	-0	-0	-0	-0	-0	-0
71-15	7	M	.0300	49	97	Y	3	8	0	0	0	0	3	8
71-15	7	M	.0300	49	98	Y	4	7	1	0	0	0	4	7
71-15	7	M	.0300	50	99	Y	4	2	0	0	0	0	4	7
71-15	7	M	.0300	50	100	Y	8	2	0	0	0	0	9	2
71-15	7	M	2.5000	51	101	Y	5	5	2	0	1	0	5	7
71-15	7	M	2.5000	51	102	Y	4	8	0	1	0	0	4	8
71-15	7	M	2.5000	52	103	Y	6	5	0	0	0	0	7	6
71-15	7	M	2.5000	52	104	Y	6	7	0	0	0	0	6	7
71-15	7	M	2.5000	53	105	Y	4	9	0	0	0	0	5	9
71-15	7	M	2.5000	53	106	Y	8	6	0	0	1	0	8	8
71-15	7	M	2.5000	54	107	Y	1	7	0	0	0	0	9	7
71-15	7	M	2.5000	54	108	Y	7	4	0	0	0	0	10	4
71-15	7	M	2.5000	55	109	Y	8	7	0	0	1	2	8	7
71-15	7	M	2.5000	55	110	Y	7	8	0	0	0	0	7	8
71-15	7	M	2.5000	56	111	Y	8	3	0	1	0	0	9	4
71-15	7	M	2.5000	56	112	Y	6	6	0	0	0	1	9	6
71-15	7	M	2.5000	57	113	Y	7	8	0	1	0	0	9	10
71-15	7	M	2.5000	57	114	Y	10	5	0	0	0	0	10	5
71-15	7	M	2.5000	58	115	Y	9	7	0	0	0	0	9	8
71-15	7	M	2.5000	58	116	Y	6	6	1	0	2	2	7	8
71-15	7	M	2.5000	59	117	Y	5	4	0	0	0	0	5	6
71-15	7	M	2.5000	59	118	Y	7	7	0	0	0	0	7	7
71-15	7	M	2.5000	60	119	Y	7	4	0	0	0	0	8	4
71-15	7	M	2.5000	60	120	Y	1	0	0	0	0	0	5	6

73

TEST MATERIAL	WEEK	S/M	DOSE	MALE NO.	FEMALE NO.	PREG	IMPLANTS L	IMPLANTS R	EARLY DEATHS L	EARLY DEATHS R	LATE DEATHS L	LATE DEATHS R	CORPORA LUTEA L	CORPORA LUTEA R
71-15	7	M	5.0000	61	121	Y	7	8	0	0	0	0	8	8
71-15	7	M	5.0000	61	122	Y	5	5	0	0	0	0	7	5
71-15	7	M	5.0000	62	123	Y	6	6	1	0	0	0	7	6
71-15	7	M	5.0000	62	124	Y	9	5	0	1	0	0	9	5
71-15	7	M	5.0000	63	125	Y	6	7	0	0	0	0	6	7
71-15	7	M	5.0000	63	126	Y	9	3	0	0	0	0	11	3
71-15	7	M	5.0000	64	127	Y	6	7	0	0	0	0	6	7
71-15	7	M	5.0000	64	128	Y	8	7	0	0	0	0	8	7
71-15	7	M	5.0000	65	129	Y	4	10	1	0	0	0	4	10
71-15	7	M	5.0000	65	130	Y	6	6	0	0	0	0	6	7
71-15	7	M	5.0000	66	131	Y	6	8	0	1	0	0	6	9
71-15	7	M	5.0000	66	132	Y	6	5	0	0	0	0	7	6
71-15	7	M	5.0000	67	133	Y	6	5	2	0	0	0	9	5
71-15	7	M	5.0000	67	134	Y	4	0	0	0	1	1	4	9
71-15	7	M	5.0000	68	135	Y	7	7	1	1	0	0	8	8
71-15	7	M	5.0000	68	136	Y	6	7	0	0	0	0	7	8
71-15	7	M	5.0000	69	137	Y	6	8	0	0	0	2	8	9
71-15	7	M	5.0000	69	138	Y	6	7	0	0	0	1	6	7
71-15	7	M	5.0000	70	139	Y	7	4	0	0	1	2	8	5
71-15	7	M	5.0000	70	140	Y	7	5	0	1	0	0	8	7

74

TEST MATERIAL	WEEK	S/M	DOSE	MALE NO.	FEMALE NO.	PREG.	IMPLANTS L	IMPLANTS R	EARLY DEATHS L	EARLY DEATHS R	LATE DEATHS L	LATE DEATHS R	CORPORA LUTEA L	CORPORA LUTEA R
CNTRL15	8	S	0.0000	1	1	Y	2	9	0	1	1	1	10	10
CNTRL15	8	S	0.0000	1	2	Y	8	5	1	0	0	0	10	5
CNTRL15	8	S	0.0000	2	3	Y	6	7	0	0	0	0	6	7
CNTRL15	8	S	0.0000	2	4	Y	6	7	0	0	0	0	6	7
CNTRL15	8	S	0.0000	3	5	Y	4	8	0	0	0	0	4	9
CNTRL15	8	S	0.0000	3	6	Y	6	4	0	0	0	0	6	9
CNTRL15	8	S	0.0000	4	7	Y	5	8	0	0	0	0	5	10
CNTRL15	8	S	0.0000	4	8	Y	4	10	0	0	0	0	4	10
CNTRL15	8	S	0.0000	5	9	Y	5	3	0	0	0	0	10	4
CNTRL15	8	S	0.0000	5	10	Y	8	7	0	0	1	0	8	7
CNTRL15	8	S	0.0000	6	11	Y	5	1	1	0	0	0	8	4
CNTRL15	8	S	0.0000	6	12	Y	5	7	0	1	0	1	5	7
CNTRL15	8	S	0.0000	7	13	Y	9	4	0	0	3	0	10	4
CNTRL15	8	S	0.0000	7	14	Y	7	4	0	0	0	0	7	5
CNTRL15	8	S	0.0000	8	15	Y	7	5	0	0	0	0	7	5
CNTRL15	8	S	0.0000	8	16	Y	5	9	0	1	0	0	5	10
CNTRL15	8	S	0.0000	9	17	Y	9	4	0	0	1	0	9	4
CNTRL15	8	S	0.0000	9	18	Y	4	8	0	0	1	0	6	8
CNTRL15	8	S	0.0000	10	19	Y	7	5	0	0	0	0	7	5
CNTRL15	8	S	0.0000	10	20	Y	6	7	0	0	0	0	6	7
71-15	8	S	.0300	51	101	Y	3	9	0	0	0	1	3	10
71-15	8	S	.0300	51	102	Y	7	6	1	1	0	0	7	6
71-15	8	S	.0300	52	103	Y	7	7	0	2	2	1	7	7
71-15	8	S	.0300	52	104	Y	8	3	0	0	0	0	9	4
71-15	8	S	.0300	53	105	Y	7	6	1	0	0	1	7	6
71-15	8	S	.0300	53	106	Y	7	[illegible]	0	1	1	0	7	7
71-15	8	S	.0300	54	107	Y	7	5	0	1	0	0	7	5
71-15	8	S	.0300	54	108	Y	7	4	1	0	1	0	7	5
71-15	8	S	.0300	55	109	Y	7	4	1	1	0	0	9	6
71-15	8	S	.0300	55	110	Y	7	8	0	0	0	0	7	8
71-15	8	S	.0300	56	111	Y	10	6	0	0	0	0	10	6
71-15	8	S	.0300	56	112	Y	9	4	0	0	0	0	9	6
71-15	8	S	.0300	57	113	Y	7	7	0	0	1	0	8	8
71-15	8	S	.0300	57	114	Y	5	9	2	0	0	1	5	9
71-15	8	S	.0300	58	115	Y	6	9	1	0	0	0	7	9
71-15	8	S	.0300	58	116	Y	5	9	0	0	0	0	6	9
71-15	8	S	.0300	59	117	Y	7	6	2	1	0	0	7	6
71-15	8	S	.0300	59	118	Y	6	6	0	0	0	0	8	7
71-15	8	S	.0300	60	119	Y	8	4	0	0	0	0	8	4
71-15	8	S	.0300	60	120	Y	2	9	0	1	0	0	3	10

75

TEST MATERIAL	WEEK	S/M	DOSE	MALE NO.	FEMALE NO.	PREG.	IMPLANTS L	IMPLANTS R	EARLY DEATHS L	EARLY DEATHS R	LATE DEATHS L	LATE DEATHS R	CORPORA LUTEA L	CORPORA LUTEA R
71-15	8	S	2.5000	61	121	Y	9	5	0	0	0	0	10	6
71-15	8	S	2.5000	61	122	Y	3	8	0	1	0	0	5	8
71-15	8	S	2.5000	62	123	Y	11	4	0	0	0	0	11	4
71-15	8	S	2.5000	62	124	Y	8	7	0	0	0	1	8	7
71-15	8	S	2.5000	63	125	Y	5	6	0	0	0	0	5	7
71-15	8	S	2.5000	63	126	Y	7	5	1	1	0	0	7	5
71-15	8	S	2.5000	64	127	Y	7	7	1	0	0	0	7	7
71-15	8	S	2.5000	64	128	Y	6	7	0	0	0	0	6	7
71-15	8	S	2.5000	65	129	Y	7	8	0	0	0	0	7	9
71-15	8	S	2.5000	65	130	Y	8	5	0	0	0	0	9	5
71-15	8	S	2.5000	66	131	Y	7	6	1	1	0	0	7	6
71-15	8	S	2.5000	66	132	Y	8	5	0	0	0	0	8	5
71-15	8	S	2.5000	67	133	Y	6	7	0	0	0	1	7	7
71-15	8	S	2.5000	67	134	Y	5	0	0	0	0	0	5	7
71-15	8	S	2.5000	68	135	Y	4	8	0	0	0	0	4	9
71-15	8	S	2.5000	68	136	Y	5	9	0	0	0	0	5	9
71-15	8	S	2.5000	69	137	Y	4	8	0	0	0	0	4	9
71-15	8	S	2.5000	69	138	Y	3	9	0	0	0	1	3	9
71-15	8	S	2.5000	70	139	Y	4	10	0	0	0	0	6	10
71-15	8	S	2.5000	70	140	Y	9	5	0	0	0	0	9	6
71-15	8	S	5.0000	71	141	Y	4	3	0	1	0	0	6	7
71-15	8	S	5.0000	71	142	Y	8	6	0	0	0	0	8	6
71-15	8	S	5.0000	72	143	Y	6	6	0	0	0	0	7	8
71-15	8	S	5.0000	72	144	Y	9	4	0	0	0	0	9	4
71-15	8	S	5.0000	73	145	Y	4	9	0	0	0	0	5	9
71-15	8	S	5.0000	73	146	Y	3	2	0	0	0	0	7	6
71-15	8	S	5.0000	74	147	Y	5	9	0	1	0	1	5	9
71-15	8	S	5.0000	74	148	Y	5	10	0	0	1	0	5	10
71-15	8	S	5.0000	75	149	Y	8	6	0	0	2	0	8	6
71-15	8	S	5.0000	75	150	Y	7	6	0	0	1	1	7	6
71-15	8	S	5.0000	76	151	Y	7	5	1	0	0	0	8	6
71-15	8	S	5.0000	76	152	Y	6	10	0	0	0	0	6	10
71-15	8	S	5.0000	77	153	Y	7	6	0	0	0	0	7	6
71-15	8	S	5.0000	77	154	Y	6	8	0	0	0	0	6	8
71-15	8	S	5.0000	78	155	Y	5	10	1	0	0	0	5	10
71-15	8	S	5.0000	78	156	Y	6	8	0	0	0	0	6	8
71-15	8	S	5.0000	79	157	Y	5	8	0	0	0	0	5	8
71-15	8	S	5.0000	79	158	Y	5	8	0	0	0	0	5	9
71-15	8	S	5.0000	80	159	Y	7	4	1	1	0	0	7	4
71-15	8	S	5.0000	80	160	N	-0	-0	-0	-0	-0	-0	-0	-0

TEST MATERIAL	WEEK	S/M	DOSE	MALE NO.	FEMALE NO.	PREG.	IMPLANTS L	IMPLANTS R	EARLY DEATHS L	EARLY DEATHS R	LATE DEATHS L	LATE DEATHS R	CORPORA LUTEA L	CORPORA LUTEA R
TEM15	8	S	.0002	11	21	Y	5	8	0	0	0	0	5	8
TEM15	8	S	.0002	11	22	Y	7	6	1	0	0	0	7	8
TEM15	8	S	.0002	12	23	Y	8	5	0	0	0	0	8	5
TEM15	8	S	.0002	12	24	Y	7	8	0	0	0	0	7	8
TEM15	8	S	.0002	13	25	Y	4	10	0	0	0	0	4	10
TEM15	8	S	.0002	13	26	Y	8	7	0	0	0	0	8	7
TEM15	8	S	.0002	14	27	Y	0	3	0	0	0	0	10	3
TEM15	8	S	.0002	14	28	Y	7	4	1	0	0	0	7	4
TEM15	8	S	.0002	15	29	Y	7	5	0	0	0	0	7	5
TEM15	8	S	.0002	15	30	Y	7	5	0	0	0	0	7	5
TEM15	8	S	.0002	16	31	Y	8	6	0	0	0	0	8	6
TEM15	8	S	.0002	16	32	Y	5	5	0	1	0	0	5	5
TEM15	8	S	.0002	17	33	Y	8	5	0	0	0	0	8	6
TEM15	8	S	.0002	17	34	Y	9	3	0	0	0	0	9	3
TEM15	8	S	.0002	18	35	Y	3	9	0	0	0	0	4	9
TEM15	8	S	.0002	18	36	Y	9	5	0	0	0	0	11	5
TEM15	8	S	.0002	19	37	Y	7	9	0	0	0	0	7	9
TEM15	8	S	.0002	19	38	Y	6	4	3	2	0	0	6	4
TEM15	8	S	.0002	20	39	Y	8	6	0	0	0	0	8	6
TEM15	8	S	.0002	20	40	Y	6	6	1	0	0	0	6	6

CHI-SQUARE TEST OF THE FERTILITY INDEX (1 DEGREE OF FREEDOM)

WEEK	VEHICLE CONTROL				71-15 30 MG/KG				71-15 2.5 G/KG				71-15 5.0 G/KG				TEM .2 MG/KG			
	N PRG	N MTD	FERT. INDEX	CHISQ	N PRG	N MTD	FERT. INDEX	CHISQ	N PRG	N MTD	FERT. INDEX	CHISQ	N PRG	N MTD	FERT. INDEX	CHISQ	N PRG	N MTD	FERT. INDEX	CHISQ
SINGLE TREATMENT																				
1	9	20	.45	0.00	18	20	.90	7.29	11	20	.55	.10	18	20	.90	7.29	11	20	.55	.10
2	20	20	1.00	0.00	15	20	.75	3.66	19	20	.95	0.00	20	20	1.00	0.00	20	20	1.00	0.00
3	18	20	.90	0.00	15	20	.75	.69	18	20	.90	.28	19	20	.95	0.00	17	20	.85	0.00
4	19	20	.95	0.00	18	20	.90	0.00	17	20	.85	.28	18	20	.90	0.00	14	20	.70	2.77
5	16	20	.80	0.00	20	20	1.00	2.50	18	20	.90	.20	19	20	.95	.91	17	20	.85	0.00
6	12	20	.60	0.00	20	20	1.00	7.66	17	20	.85	2.01	20	20	1.00	7.66	20	20	1.00	7.66
7	17	20	.85	0.00	19	20	.95	.28	19	20	.95	.28	15	20	.75	.16	18	20	.90	0.00
8	20	20	1.00	0.00	20	20	1.00	0.00	20	20	1.00	0.00	19	20	.95	0.00	20	20	1.00	0.00
MULTIPLE TREATMENT																				
1	11	20	.55	0.00	20	20	1.00	9.18	14	20	.70	.43	16	20	.80	1.82				
2	16	20	.80	0.00	20	20	1.00	2.50	20	20	1.00	2.50	15	20	.75	0.00				
3	15	20	.75	0.00	20	20	1.00	3.66	19	20	.95	1.76	19	20	.95	1.76				
4	18	20	.90	0.00	18	20	.90	.28	19	20	.95	0.00	16	20	.80	.20				
5	14	20	.70	0.00	18	20	.90	1.41	20	20	1.00	4.90	18	20	.90	1.41				
6	17	20	.85	0.00	19	20	.95	.28	18	20	.90	0.00	15	20	.75	.16				
7	19	20	.95	0.00	19	20	.95	.53	20	20	1.00	0.00	20	20	1.00	0.00				

ARMITAGE TEST FOR A LINEAR TREND IN PROPORTIONS FOR THE FERTILITY INDEX
(1 DEGREE OF FREEDOM) BASED ON THE DOSE LEVELS

	30 MG/KG		2.5 G/KG		5.0 G/KG				
WEEK	N PRG	N MTD	N PRG	N MTD	N PRG	N MTD	CHISQ (C-1)	CHISQ (1)	ARMTG CHISQ
							SINGLE TREATMENT		
1	18	20	11	20	18	20	9.62	.00	9.62
2	15	20	19	20	20	20	7.78	6.93	.85
3	15	20	18	20	19	20	3.75	3.45	.30
4	18	20	17	20	18	20	.32	.00	.32
5	20	20	18	20	19	20	2.11	.52	1.59
6	20	20	17	20	20	20	6.32	.00	6.32
7	19	20	19	20	15	20	5.18	3.90	1.28
8	20	20	20	20	19	20	2.03	1.53	.50
							MULTIPLE TREATMENT		
1	20	20	14	20	16	20	6.72	2.86	3.86
2	20	20	20	20	15	20	10.91	8.21	2.69
3	20	20	19	20	19	20	1.03	.77	.26
4	18	20	19	20	16	20	2.26	.98	1.29
5	18	20	20	20	18	20	2.14	.00	2.14
6	19	20	18	20	15	20	3.75	3.47	.28
7	19	20	20	20	20	20	2.03	1.52	.51

79

ARMITAGE TEST FOR A LINEAR TREND IN PROPORTIONS FOR THE FERTILITY INDEX
(1 DEGREE OF FREEDOM) BASED ON THE LOGARITHMS OF THE DOSE LEVELS

WEEK	30 MG/KG N PRG	30 MG/KG N MTD	2.5 G/KG N PRG	2.5 G/KG N MTD	5.0 G/KG N PRG	5.0 G/KG N MTD	CHISQ (C-1)	CHISQ (1)	ARMTG CHISQ
								SINGLE TREATMENT	
1	18	20	11	20	18	20	9.62	1.45	8.18
2	15	20	19	20	20	20	7.78	7.75	.03
3	15	20	18	20	19	20	3.75	3.70	.05
4	18	20	17	20	18	20	.32	.05	.27
5	20	20	18	20	19	20	2.11	1.34	.77
6	20	20	17	20	20	20	6.32	.95	5.37
7	19	20	19	20	15	20	5.18	1.89	3.29
8	20	20	20	20	19	20	2.03	.74	1.29
								MULTIPLE TREATMENT	
1	20	20	14	20	16	20	6.72	5.40	1.32
2	20	20	20	20	15	20	10.91	3.98	6.93
3	20	20	19	20	19	20	1.04	1.02	.02
4	18	20	19	20	16	20	2.26	.22	2.05
5	18	20	20	20	18	20	2.14	.32	1.82
6	19	20	18	20	15	20	3.75	2.27	1.48
7	19	20	20	20	20	20	2.03	2.00	.03

ARMITAGE TEST FOR A LINEAR TREND IN PROPORTIONS FOR THE FERTILITY INDEX
(2 DEGREES OF FREEDOM) BASED ON THE DOSE LEVELS AND INCLUDING THE CONTROL GROUP

	CONTROL		30 MG/KG		2.5 G/KG		5.0 G/KG				
WEEK	N PRG	N MTD	N PRG	N MTD	N PRG	N MTD	N PRG	N MTD	CHISQ (C-1)	CHISQ (1)	ARMTG CHISQ
							SINGLE TREATMENT				
1	9	20	18	20	11	20	18	20	15.71	2.22	13.49
2	20	20	15	20	19	20	20	20	12.25	3.15	9.10
3	18	20	15	20	18	20	19	20	4.11	2.01	2.10
4	19	20	18	20	17	20	18	20	1.11	.20	.91
5	16	20	20	20	18	20	19	20	5.48	.37	5.11
6	12	20	20	20	17	20	20	20	18.02	4.31	13.72
7	17	20	19	20	19	20	15	20	5.03	2.03	3.00
8	20	20	20	20	20	20	19	20	3.04	2.31	.73
							MULTIPLE TREATMENT				
1	11	20	20	20	14	20	16	20	11.80	.01	11.79
2	16	20	20	20	20	20	15	20	10.39	1.90	8.49
3	15	20	20	20	19	20	19	20	9.24	1.18	8.05
4	18	20	18	20	19	20	16	20	2.38	.93	1.45
5	14	20	18	20	20	20	18	20	8.69	2.06	6.63
6	17	20	19	20	18	20	15	20	3.69	2.15	1.54
7	19	20	19	20	20	20	20	20	2.05	1.68	.38

T-TEST OF THE NUMBER OF IMPLANTATIONS IN PREGNANT FEMALES.

WEEK	CONTROL			71-15 30 MG/KG					71-15 2.5 G/KG					71-15 5.0 G/KG					TEM .2 MG/KG				
	N PRG	MEAN	STD DEV	N PRG	MEAN	STD DEV	DF	T	N PRG	MEAN	STD DEV	DF	T	N PRG	MEAN	STD DEV	DF	T	N PRG	MEAN	STD DEV	DF	T
											SINGLE TREATMENT												
1	9	10.00	5.45	18	12.06	3.17	25	1.245	11	11.18	1.60	18	.687	18	11.66	3.01	25	.962	11	7.82	5.10	18	.923
2	20	8.80	4.09	15	11.20	3.73	33	1.785	19	11.89	2.38	37	2.871	20	11.65	2.78	38	2.580	20	9.65	3.44	38	.712
3	18	11.06	2.78	15	11.80	1.93	31	.876	18	11.39	3.71	34	.305	19	12.21	2.42	35	1.352	17	9.76	3.54	33	1.203
4	19	10.21	4.17	18	11.78	1.63	35	1.489	17	11.47	3.06	34	1.022	18	11.17	3.07	35	.790	14	6.71	3.67	31	2.502
5	16	10.19	3.41	20	12.05	1.50	34	2.196	18	11.50	2.36	32	1.318	19	10.79	3.34	33	.526	17	11.71	2.05	31	1.590
6	12	12.58	3.40	20	12.55	1.90	30	.036	17	11.35	2.91	27	1.046	20	10.10	3.95	30	1.812	20	11.55	2.54	30	.981
7	17	10.35	3.72	19	10.95	3.34	34	.505	19	10.47	4.53	34	.087	15	12.53	1.60	30	2.100	18	10.94	2.60	33	.597
8	20	12.00	2.08	20	13.10	1.48	38	1.927	20	12.75	2.20	38	1.109	19	12.68	2.65	37	.901	20	12.40	2.72	38	.522
											MULTIPLE TREATMENT												
1	11	12.18	1.47	20	11.70	3.25	29	.464	14	11.86	1.29	23	.587	16	12.37	3.12	25	.191					
2	16	11.50	2.48	20	11.15	2.89	34	.384	20	11.90	2.77	34	.451	15	11.27	2.40	29	.266					
3	15	11.40	1.88	20	12.25	1.89	33	1.320	19	11.47	2.55	32	.094	19	11.16	2.29	32	.330					
4	18	11.06	2.15	18	12.00	1.50	34	1.528	19	11.84	2.81	35	.951	16	11.19	2.69	32	.159					
5	14	11.79	3.21	18	11.61	2.70	30	.167	20	11.30	2.66	32	.481	18	10.83	2.75	30	.903					
6	17	11.94	3.80	19	12.00	1.15	34	.064	18	11.00	3.36	33	.777	15	12.60	1.18	30	.644					
7	19	11.79	1.87	19	11.84	2.14	36	.081	20	12.00	3.46	37	.234	20	12.80	1.40	37	1.915					

82

REGRESSION FITS OF THE NUMBER, U, OF IMPLANTATIONS ON 1) DOSE, AND 2) LOG DOSE.
(PREDICTED U = A + B*X) CONTROL GROUP EXCLUDED

WEEK	X	N	XBAR	SD X	UBAR	SD U	B	A	TB	DF	VARU.X	CV U	VARB	VARA	VARUBAR
							SINGLE TREATMENT								
1	DOSE	47	2.51	2.20	11.66	2.76	-.100	11.911	-.533	45	7.6738	.2407	.0354	.3909	.1675
	LOG DOSE	47	-.51	2.40	11.66	2.76	-.124	11.596	-.721	45	7.8330	.2400	.0296	.1744	.1667
2	DOSE	54	2.74	2.01	11.61	2.90	.080	11.391	.402	52	8.5664	.2521	.0401	.4600	.1586
	LOG DOSE	54	-.06	2.18	11.61	2.90	.110	11.617	.500	52	8.5339	.2516	.0339	.1581	.1580
3	DOSE	52	2.70	2.02	11.81	2.79	.093	11.556	.478	50	7.9253	.2384	.0391	.4302	.1524
	LOG DOSE	52	-.11	2.21	11.81	2.79	.023	11.810	.131	50	7.9588	.2389	.0321	.1534	.1531
4	DOSE	53	2.51	2.07	11.47	2.63	-.123	11.780	-.694	51	6.9774	.2303	.0314	.3294	.1316
	LOG DOSE	53	-.35	2.30	11.47	2.63	-.102	11.436	-.642	51	6.9868	.2304	.0253	.1349	.1318
5	DOSE	57	2.47	2.07	11.46	2.51	-.253	12.081	-1.585	55	6.1578	.2169	.0256	.2637	.1080
	LOG DOSE	57	-.40	2.32	11.46	2.51	-.204	11.374	-1.418	55	6.2118	.2176	.0206	.1124	.1090
6	DOSE	57	2.51	2.10	11.33	3.16	-.493	12.571	-2.568	55	9.1025	.2662	.0369	.3920	.1597
	LOG DOSE	57	-.39	2.33	11.33	3.16	-.411	11.172	-2.354	55	9.2612	.2685	.0305	.1672	.1625
7	DOSE	53	2.32	2.00	11.23	3.52	.299	10.533	1.230	51	12.2498	.3118	.0589	.5487	.2311
	LOG DOSE	53	-.47	2.31	11.23	3.52	.134	11.290	.630	51	12.5161	.3151	.0453	.2463	.2362
8	DOSE	59	2.47	2.04	12.85	2.12	-.084	13.055	-.611	57	4.5601	.1662	.0189	.1927	.0773
	LOG DOSE	59	-.36	2.29	12.85	2.12	-.090	12.819	-.658	57	4.5554	.1661	.0150	.0791	.0772
							MULTIPLE TREATMENTS								
1	DOSE	50	2.31	2.12	11.96	2.76	.134	11.651	.717	48	7.6663	.2315	.0348	.3394	.1533
	LOG DOSE	50	-.63	2.39	11.96	2.76	.099	12.022	.596	48	7.6915	.2319	.0275	.1648	.1538
2	DOSE	55	2.28	1.99	11.45	2.69	.038	11.369	.202	53	7.3837	.2372	.0346	.3149	.1342
	LOG DOSE	55	-.50	2.31	11.45	2.69	.087	11.498	.543	53	7.3484	.2367	.0255	.1401	.1336
3	DOSE	58	2.47	2.05	11.64	2.26	-.220	12.182	-1.530	56	4.9948	.1920	.0208	.2124	.0861
	LOG DOSE	58	-.38	2.30	11.64	2.26	-.200	11.562	-1.556	56	4.9878	.1919	.0165	.0884	.0860
4	DOSE	53	2.42	2.01	11.70	2.38	-.152	12.089	-.981	51	5.6804	.2037	.0271	.2655	.1072
	LOG DOSE	53	-.38	2.29	11.70	2.38	-.109	11.657	-.754	51	5.7239	.2045	.0211	.1110	.1080
5	DOSE	56	2.51	2.01	11.25	2.67	-.157	11.643	-.872	54	7.1676	.2380	.0322	.3311	.1280
	LOG DOSE	56	-.28	2.26	11.25	2.67	-.121	11.216	-.756	54	7.1924	.2384	.0257	.1305	.1284
6	DOSE	52	2.32	2.02	11.83	2.25	.100	11.594	.640	50	5.1070	.1911	.0246	.2302	.0982
	LOG DOSE	52	-.50	2.32	11.83	2.25	-.024	11.815	-.173	50	5.1458	.1918	.0187	.1036	.0990
7	DOSE	59	2.55	2.04	12.22	2.48	.194	11.725	1.217	57	6.1239	.2025	.0254	.2695	.1038
	LOG DOSE	59	-.37	2.27	12.22	2.48	.134	12.257	.927	57	6.1897	.2035	.0208	.1065	.1049

43

REGRESSION FITS OF THE NUMBER, U, OF IMPLANTATIONS ON DOSE.
(PREDICTED U = A + B*X) CONTROL GROUP INCLUDED

WEEK	X	N	XBAR	SD X	UBAR	SD U	B	A	TB	DF	VARU.X	CV U	VARB	VARA	VARUBAR
							SINGLE TREATMENT								
1	DOSE	56	2.11	2.22	11.39	3.34	.034	11.321	.166	54	11.3897	.2962	.0422	.3908	.2034
2	DOSE	74	2.00	2.10	10.85	3.47	.401	10.049	2.127	72	11.4913	.3124	.0356	.2975	.1553
3	DOSE	70	2.01	2.10	11.61	2.79	.152	11.309	.955	68	7.7866	.2403	.0255	.2138	.1112
4	DOSE	72	1.85	2.09	11.14	3.13	.055	11.038	.305	70	9.9098	.2825	.0319	.2466	.1376
5	DOSE	73	1.93	2.10	11.18	2.76	-.069	11.311	-.443	71	7.7066	.2484	.0243	.1958	.1056
6	DOSE	69	2.07	2.13	11.55	3.22	-.494	12.575	-2.839	67	9.3665	.2850	.0303	.2659	.1357
7	DOSE	70	1.76	2.01	11.01	3.56	.318	10.455	1.501	68	12.4549	.3204	.0449	.3167	.1779
8	DOSE	79	1.84	2.06	12.63	2.13	.033	12.572	.282	77	4.5973	.1697	.0139	.1053	.0582
							MULTIPLE TREATMENTS								
1	DOSE	61	1.90	2.12	12.00	2.56	.092	11.825	.588	59	6.6391	.2147	.0247	.1977	.1088
2	DOSE	71	1.77	1.99	11.46	2.63	.024	11.422	.152	69	7.0072	.2309	.0252	.1776	.0987
3	DOSE	73	1.96	2.09	11.59	2.18	-.147	11.877	-1.198	71	4.7170	.1874	.0151	.1225	.0646
4	DOSE	71	1.80	2.03	11.54	2.33	-.045	11.617	-.327	69	5.4939	.2032	.0191	.1394	.0774
5	DOSE	70	2.01	2.06	11.36	2.77	-.170	11.699	-1.052	68	7.6703	.2439	.0262	.2152	.1096
6	DOSE	69	1.75	2.07	11.86	2.68	.063	11.745	.389	67	7.2753	.2275	.0263	.1857	.1054
7	DOSE	76	1.93	2.08	12.12	2.35	.187	11.754	1.468	76	5.4245	.1922	.0162	.1300	.0695

T-TEST TEST OF THE (TRANSFORMED) PRE-IMPLANTATION LOSSES IN PREGNANT FEMALES.
(LOSSES TAKEN AS A SUBSET OF THE SET OF CORPORA LUTEA)

WEEK	CONTROL			71-15 30 MG/KG.					71-15 2.5 G/KG					71-15 5.0 G/KG					TEM .2 MG/KG				
	N PRG	MEAN	STD DEV	N PRG	MEAN	STD DEV	DF	T	N PRG	MEAN	STD DEV	DF	T	N PRG	MEAN	STD DEV	DF	T	N PRG	MEAN	STD DEV	DF	T
SINGLE TREATMENT																							
1	9	1.02	.87	18	.53	.54	25	1.781	11	.79	.36	18	.769	18	.88	.62	25	.477	11	1.33	.80	18	.846
2	20	.97	.67	15	.70	.56	33	1.301	19	.53	.44	37	2.443	20	.54	.48	38	2.371	20	.97	.54	38	.006
3	18	.59	.42	15	.44	.24	31	1.234	18	.65	.65	34	.326	19	.47	.31	35	.963	17	.74	.64	33	.832
4	19	.89	.69	18	.59	.29	35	1.689	17	.81	.52	34	.379	18	.68	.54	35	1.017	14	1.42	.63	31	2.251
5	16	.83	.58	20	.60	.33	34	1.496	18	.59	.41	32	1.436	19	.69	.63	33	.691	17	.71	.39	31	.728
6	12	.51	.52	20	.45	.27	30	.420	17	.57	.33	27	.401	20	.74	.61	30	1.081	20	.52	.41	30	.082
7	17	.76	.64	19	.70	.60	34	.311	19	.82	.64	34	.277	15	.55	.29	30	1.183	18	.76	.49	33	.000
8	23	.66	.45	20	.51	.28	38	1.243	20	.55	.35	38	.848	19	.52	.46	37	.999	20	.45	.43	38	1.482
MULTIPLE TREATMENT																							
1	11	.48	.27	20	.59	.56	29	.553	14	.58	.26	23	.909	16	.54	.51	25	.306					
2	16	.43	.30	20	.54	.40	34	.973	20	.41	.28	34	.147	15	.60	.40	29	1.384					
3	15	.69	.21	20	.61	.32	33	.803	19	.69	.45	32	.006	19	.73	.40	32	.381					
4	18	.62	.33	18	.58	.30	34	.335	19	.52	.45	35	.786	16	.59	.43	32	.190					
5	14	.55	.56	18	.60	.41	30	.304	20	.57	.44	32	.115	18	.56	.45	30	.053					
6	17	.72	.61	19	.54	.35	34	1.081	18	.61	.59	33	.540	15	.41	.24	30	1.857					
7	19	.67	.35	19	.52	.34	36	1.340	20	.77	.54	37	.681	20	.62	.29	37	.504					

85

T-TEST OF THE (TRANSFORMED) NUMBER OF DEAD IMPLANTS.

WEEK	CONTROL			71-15 30 MG/KG					71-15 2.5 G/KG					71-15 5.0 G/KG					TEM .2 MG/KG				
	N PRG	MEAN	STD DEV	N PRG	MEAN	STD DEV	DF	T	N PRG	MEAN	STD DEV	DF	T	N PRG	MEAN	STD DEV	DF	T	N PRG	MEAN	STD DEV	DF	T
SINGLE TREATMENT																							
1	9	.47	.18	18	.64	.33	25	1.414	11	.45	.26	18	.182	18	.46	.32	25	.056	11	.93	.56	18	2.315
2	20	.46	.24	15	.53	.31	33	.796	19	.44	.21	37	.181	20	.51	.41	38	.470	20	1.56	.51	38	8.670
3	18	.43	.25	15	.75	.54	31	2.228	18	.62	.34	34	1.844	19	.72	.43	35	2.458	17	1.70	.62	33	7.980
4	19	.53	.27	18	.51	.30	35	.158	17	.59	.43	34	.517	18	.71	.40	35	1.678	14	1.12	.59	31	3.874
5	16	.46	.33	20	.48	.30	34	.156	18	.54	.30	32	.672	19	.52	.33	33	.509	17	1.06	.61	31	3.471
6	12	.55	.30	20	.59	.39	30	.318	17	.55	.35	27	.036	20	.46	.34	30	.729	20	.52	.27	30	.331
7	17	.49	.30	19	.49	.29	34	.063	19	.64	.36	34	1.333	15	.58	.33	30	.747	18	.46	.20	33	.363
8	20	.48	.25	20	.63	.32	38	1.689	20	.42	.23	38	.725	19	.47	.26	37	.096	20	.41	.32	38	.667
MULTIPLE TREATMENT																							
1	11	.53	.34	20	.57	.31	29	.395	14	.56	.34	23	.223	16	.42	.22	25	.960					
2	16	.46	.35	20	.54	.38	34	.643	20	.64	.41	34	1.420	15	.52	.24	29	.569					
3	15	.66	.32	20	.55	.25	33	1.151	19	.54	.32	32	1.057	19	.56	.38	32	.796					
4	18	.54	.34	18	.49	.29	34	.529	19	.62	.31	35	.746	16	.53	.24	32	.131					
5	14	.51	.22	18	.51	.34	30	.031	20	.52	.39	32	.123	18	.50	.35	30	.101					
6	17	.65	.37	19	.48	.29	34	1.533	18	.50	.35	33	1.195	15	.64	.38	30	.073					
7	19	.45	.29	19	.41	.23	36	.452	20	.48	.31	37	.307	20	.52	.26	37	.848					

CHI-SQUARE TEST OF THE DEATH INDEX (1 DEGREE OF FREEDOM)

WEEK	VEHICLE CONTROL				71-15 30 MG/KG				71-15 2.5 G/KG				71-15 5.0 G/KG				TEM .2 MG/KG			
	N WDI	N PRG	DEATH INDEX	CHISQ	N WDI	N PRG	DEATH INDEX	CHISQ	N WDI	N PRG	DEATH INDEX	CHISQ	N WDI	N PRG	DEATH INDEX	CHISQ	N WDI	N PRG	DEATH INDEX	CHISQ
SINGLE TREATMENT																				
1	5	9	.56	0.00	12	18	.67	.02	4	11	.36	.17	7	18	.39	.17	8	11	.73	.11
2	7	20	.35	0.00	7	15	.47	.12	8	19	.42	.02	7	20	.35	.11	20	20	1.00	16.41
3	5	18	.28	0.00	10	15	.67	3.55	11	18	.61	2.81	13	19	.68	4.59	17	17	1.00	16.56
4	10	19	.53	0.00	8	18	.44	.03	9	17	.53	.10	13	18	.72	.79	12	14	.86	2.62
5	5	16	.31	0.00	8	20	.40	.04	9	18	.50	.58	9	19	.47	.39	13	17	.76	5.10
6	7	12	.58	0.00	10	20	.50	.01	8	17	.47	.05	5	20	.25	2.28	10	20	.50	.01
7	7	17	.41	0.00	8	19	.42	.08	13	19	.68	1.71	8	15	.53	.11	9	18	.50	.03
8	9	20	.45	0.00	13	20	.65	.91	7	20	.35	.10	8	19	.42	.02	5	20	.25	.99
MULTIPLE TREATMENT																				
1	5	11	.45	0.00	12	20	.60	.16	7	14	.50	.03	6	16	.38	.00				
2	4	16	.25	0.00	8	20	.40	.35	11	20	.55	2.17	8	15	.53	1.56				
3	11	15	.73	0.00	12	20	.60	.21	9	19	.47	1.38	8	19	.42	2.17				
4	8	18	.44	0.00	7	18	.39	0.00	12	19	.63	.66	9	16	.56	.12				
5	8	14	.57	0.00	7	18	.39	.45	7	20	.35	.86	6	18	.33	.98				
6	11	17	.65	0.00	7	19	.37	1.78	6	18	.33	2.30	9	15	.60	.01				
7	6	19	.32	0.00	5	19	.26	0.00	8	20	.40	.05	11	20	.55	1.33				

ARMITAGE TEST FOR A LINEAR TREND IN PROPORTIONS FOR THE DEATH INDEX
(1 DEGREE OF FREEDOM) BASED ON THE DOSE LEVELS

WEEK	30 MG/KG N WDI	30 MG/KG N PRG	2.5 G/KG N WDI	2.5 G/KG N PRG	5.0 G/KG N WDI	5.0 G/KG N PRG	CHISQ (C-1)	CHISQ (1)	ARMTG CHISQ
								SINGLE TREATMENT	
1	12	18	4	11	7	18	3.69	2.77	.92
2	7	15	8	19	7	20	.51	.50	.01
3	10	15	11	18	13	19	.23	.02	.21
4	8	18	9	17	13	18	2.96	2.83	.13
5	8	20	9	18	9	19	.42	.22	.20
6	10	20	8	17	5	20	3.05	2.60	.45
7	8	19	13	19	8	15	2.67	.57	2.11
8	13	20	7	20	8	19	3.93	2.09	1.84
								MULTIPLE TREATMENT	
1	12	20	7	14	6	16	1.80	1.79	.01
2	8	20	11	20	8	15	1.05	.69	.35
3	12	20	9	19	8	19	1.33	1.25	.07
4	7	18	12	19	9	16	2.29	1.10	1.20
5	7	18	7	20	6	18	.13	.12	.01
6	7	19	6	18	9	15	2.75	1.67	1.08
7	5	19	8	20	11	20	3.33	3.32	.00

ARMITAGE TEST FOR A LINEAR TREND IN PROPORTIONS FOR THE DEATH INDEX
(1 DEGREE OF FREEDOM) BASED ON THE LOGARITHMS OF THE DOSE LEVELS

	30 MG/KG		2.5 G/KG		5.0 G/KG				
WEEK	N WDI	N PRG	N WDI	N PRG	N WDI	N PRG	CHISQ (C-1)	CHISQ (1)	ARMIG CHISQ
							SINGLE TREATMENT		
1	12	18	4	11	7	18	3.69	3.57	.12
2	7	15	8	19	7	20	.51	.37	.14
3	10	15	11	18	13	19	.23	.00	.23
4	8	18	9	17	13	18	2.96	2.00	.97
5	8	20	9	18	9	19	.42	.36	.06
6	10	20	8	17	5	20	3.05	1.56	1.49
7	8	19	13	19	8	15	2.67	1.59	1.08
8	13	20	7	20	8	19	3.93	3.47	.46
							MULTIPLE TREATMENT		
1	12	20	7	14	6	16	1.80	1.50	.30
2	8	20	11	20	8	15	1.05	1.00	.05
3	12	20	9	19	8	19	1.33	1.29	.03
4	7	18	12	19	9	16	2.29	1.95	.34
5	7	18	7	20	6	18	.13	.12	.00
6	7	19	6	18	9	15	2.75	.62	2.13
7	5	19	8	20	11	20	3.33	2.75	.58

A9

ARMITAGE TEST FOR A LINEAR TREND IN PROPORTIONS FOR THE DEATH INDEX
(2 DEGREES OF FREEDOM) BASED ON THE DOSE LEVELS AND INCLUDING THE CONTROL GROUP

	CONTROL		30 MG/KG		2.5 G/KG		5.0 G/KG				
WEEK	N WDI	N PRG	N WDI	N PRG	N WDI	N PRG	N WDI	N PRG	CHISQ (C-1)	CHISQ (1)	ARMTG CHISQ
							SINGLE TREATMENT				
1	5	9	12	18	4	11	7	18	3.82	2.76	1.05
2	7	20	7	15	8	19	7	20	.71	.10	.61
3	5	18	10	15	11	18	13	19	7.88	2.81	5.07
4	10	19	8	18	9	17	13	18	3.04	2.49	.54
5	5	16	8	20	9	18	9	19	1.48	.83	.64
6	7	12	10	20	8	17	5	20	4.29	3.76	.53
7	7	17	8	19	13	19	8	15	3.59	1.29	2.31
8	9	20	13	20	7	20	8	19	3.97	1.29	2.69
							MULTIPLE TREATMENT				
1	5	11	12	20	7	14	6	16	1.88	1.21	.67
2	4	16	8	20	11	20	8	15	3.99	2.44	1.55
3	11	15	12	20	9	19	8	19	3.95	3.12	.84
4	8	18	7	18	12	19	9	16	2.66	1.47	1.19
5	9	14	7	18	7	20	6	18	2.27	1.03	1.24
6	11	17	7	19	6	18	9	15	5.27	.09	5.17
7	6	19	5	19	8	20	11	20	3.90	3.76	.14

90

PROBIT ANALYSIS OF THE PROPORTION OF PREGNANT FEMALES WITH 1 OR MORE DEAD IMPLANTS
PROBIT = A + B(LOG DOSE)

WEEK	B	A	CHISQ	DF
	SINGLE TREATMENT			
1	-.343	4.899	.12	1
2	-.111	4.762	.14	1
3	-.011	5.395	.23	1
4	.248	5.208	1.04	1
5	.101	4.907	.06	1
6	-.209	4.715	1.60	1
7	.220	5.165	1.11	1
8	-.313	4.888	.48	1
	MULTIPLE TREATMENT			
1	-.214	4.942	.31	1
2	.172	5.014	.05	1
3	-.190	4.969	.04	1
4	.247	5.112	.35	1
5	-.062	4.626	.00	1
6	.139	4.834	2.09	1
7	.293	4.787	.54	1

T-TEST OF THE (TRANSFORMED) NUMBER OF DEAD IMPLANTS.
(DEAD IMPLANTS TAKEN AS A SUBSET OF THE SET OF IMPLANTS)

WEEK	CONTROL			71-15 30 MG/KG					71-15 2.5 G/KG					71-15 5.0 G/KG					TEM .2 MG/KG				
	N PRG	MEAN	STD DEV	N PRG	MEAN	STD DEV	DF	T	N PRG	MEAN	STD DEV	DF	T	N PRG	MEAN	STD DEV	DF	T	N PRG	MEAN	STD DEV	DF	T
SINGLE TREATMENT																							
1	9	.58	.16	18	.74	.55	25	.836	11	.48	.27	18	.960	18	.62	.57	25	.192	11	1.43	.83	18	2.991
2	20	.56	.30	15	.58	.32	33	.199	19	.48	.26	37	.868	20	.60	.61	38	.263	20	1.89	.55	38	9.505
3	18	.47	.31	15	.77	.56	31	1.973	18	.75	.55	34	1.869	19	.74	.43	35	2.193	17	1.98	.62	33	9.290
4	19	.62	.31	18	.53	.31	35	.899	17	.72	.61	34	.601	18	.82	.55	35	1.380	14	1.80	.91	31	5.276
5	16	.59	.61	20	.51	.32	34	.545	18	.57	.34	32	.114	19	.59	.37	33	.006	17	1.19	.74	31	2.504
6	12	.61	.38	20	.52	.43	30	.038	17	.58	.39	27	.225	20	.53	.37	30	.625	20	.56	.33	30	.433
7	17	.59	.41	19	.60	.51	34	.069	19	.84	.69	34	1.330	15	.60	.35	30	.094	18	.51	.20	33	.776
8	20	.52	.30	20	.65	.33	38	1.307	20	.44	.23	38	1.008	19	.49	.27	37	.303	20	.43	.32	38	.908
MULTIPLE TREATMENT																							
1	11	.54	.34	20	.68	.51	29	.812	14	.58	.35	23	.255	16	.45	.22	25	.810					
2	16	.47	.36	20	.61	.56	34	.868	20	.66	.43	34	1.410	15	.55	.25	29	.744					
3	15	.70	.34	20	.58	.28	33	1.086	19	.59	.35	32	.901	19	.62	.45	32	.525					
4	18	.57	.34	18	.51	.31	34	.528	19	.71	.54	35	.989	16	.58	.35	32	.140					
5	14	.54	.21	18	.53	.34	30	.106	20	.58	.47	32	.287	18	.57	.50	30	.210					
6	17	.79	.55	19	.51	.33	34	1.829	18	.61	.60	33	.880	15	.65	.38	30	.808					
7	19	.49	.36	19	.42	.24	36	.644	20	.54	.35	37	.445	20	.55	.28	37	.624					

92

CONTROL GROUP ANOVA FOR THE NUMBER OF PREGNANT FEMALES

	BETWEEN MALES			WITHIN MALES			TOTAL		
WEEK	SUMSQ	DF	MEANSQ	SUMSQ	DF	MEANSQ	SUMSQ	DF	F
				SINGLE TREATMENT					
1	3.450	9	.383	1.500	10	.150	4.950	19	2.556
2	0.000	9	0.000	0.000	10	0.000	0.000	19	I
3	.800	9	.089	1.000	10	.100	1.800	19	.889
4	.450	9	.050	.500	10	.050	.950	19	1.000
5	1.200	9	.133	2.000	10	.200	3.200	19	.667
6	3.800	9	.422	1.000	10	.100	4.800	19	4.222
7	1.050	9	.117	1.500	10	.150	2.550	19	.778
8	0.000	9	0.000	0.000	10	0.000	0.000	19	I
				MULTIPLE TREATMENT					
1	3.450	9	.383	1.500	10	.150	4.950	19	2.556
2	2.200	9	.244	1.000	10	.100	3.200	19	2.444
3	1.250	9	.139	2.500	10	.250	3.750	19	.556
4	.800	9	.089	1.000	10	.100	1.800	19	.889
5	1.200	9	.133	3.000	10	.300	4.200	19	.444
6	1.050	9	.117	1.500	10	.150	2.550	19	.778
7	.450	9	.050	.500	10	.050	.950	19	1.000

CONTROL GROUP ANOVA FOR THE NUMBER OF IMPLANTATIONS PER PREGNANT FEMALE

	BETWEEN MALES			WITHIN MALES			TOTAL		
WEEK	SUMSQ	DF	MEANSQ	SUMSQ	DF	MEANSQ	SUMSQ	DF	F
				SINGLE TREATMENT					
1	189.250	5	37.850	55.000	3	18.333	244.250	8	2.065
2	138.200	9	15.356	179.000	10	17.900	317.200	19	.858
3	110.125	9	12.236	21.500	8	2.688	131.625	17	4.553
4	71.310	9	7.923	242.000	9	26.889	313.310	18	.295
5	152.560	9	16.951	22.000	6	3.667	174.560	15	4.623
6	124.561	6	20.760	5.500	5	1.100	130.061	11	18.873
7	149.280	9	16.587	76.000	7	10.857	225.280	16	1.528
8	30.000	9	3.333	52.000	10	5.200	82.000	19	.641
				MULTIPLE TREATMENT					
1	17.474	6	2.912	4.500	4	1.125	21.974	10	2.589
2	44.049	8	5.506	48.000	7	6.857	92.049	15	.803
3	27.750	9	3.083	22.000	5	4.400	49.750	14	.701
4	24.980	9	2.776	54.000	8	6.750	78.980	17	.411
5	65.540	9	7.282	69.000	4	17.250	134.540	13	.422
6	219.930	9	24.437	18.000	7	2.571	237.930	16	9.503
7	22.160	9	2.462	41.000	9	4.556	63.160	18	.540

CONTROL GROUP ANOVA FOR THE PRE-IMPLANTATION LOSS PER PREGNANT FEMALE

	BETWEEN MALES			WITHIN MALES			TOTAL		
WEEK	SUMSQ	DF	MEANSQ	SUMSQ	DF	MEANSQ	SUMSQ	DF	F
				SINGLE TREATMENT					
1	108.562	5	21.712	50.500	3	16.833	159.062	8	1.290
2	86.800	9	9.644	60.000	10	6.000	146.800	19	1.607
3	30.605	9	3.401	8.500	8	1.063	39.105	17	3.201
4	81.047	9	9.005	147.500	9	16.389	228.547	18	.549
5	67.160	9	7.462	28.000	6	4.667	95.160	15	1.599
6	73.500	6	12.250	1.500	5	.300	75.000	11	40.833
7	127.842	9	14.205	43.500	7	6.214	171.342	16	2.286
8	56.200	9	6.244	73.000	10	7.300	129.200	19	.855
				MULTIPLE TREATMENT					
1	6.046	6	1.008	2.500	4	.625	8.546	10	1.612
2	5.253	8	.657	4.500	7	.643	9.753	15	1.021
3	5.550	9	.617	3.000	5	.600	8.550	14	1.028
4	7.545	9	.838	18.500	8	2.313	26.045	17	.363
5	95.000	9	10.556	5.000	4	1.250	100.000	13	8.444
6	450.280	9	50.031	7.000	7	1.000	457.280	16	50.031
7	11.147	9	1.239	29.500	9	3.278	40.647	18	.378

CONTROL GROUP ANOVA FOR THE NUMBER OF DEAD IMPLANTS PER PREGNANT FEMALE

	BETWEEN MALES			WITHIN MALES			TOTAL		
WEEK	SUMSQ	DF	MEANSQ	SUMSQ	DF	MEANSQ	SUMSQ	DF	F
				SINGLE TREATMENT					
1	1.250	5	.250	1.000	3	.333	2.250	8	.750
2	4.450	9	.494	4.500	10	.450	8.950	19	1.099
3	7.480	9	.831	3.000	8	.375	10.480	17	2.216
4	10.160	9	1.129	7.000	9	.778	17.160	18	1.451
5	15.240	9	1.693	3.000	6	.500	18.240	15	3.387
6	3.418	6	.570	11.500	5	2.300	14.918	11	.248
7	8.543	9	.949	5.500	7	.786	14.043	16	1.208
8	10.200	9	1.133	8.000	10	.800	18.200	19	1.417
				MULTIPLE TREATMENT					
1	14.413	6	2.402	8.500	4	2.125	22.913	10	1.130
2	14.827	8	1.853	21.000	7	3.000	35.827	15	.618
3	8.337	9	.926	7.500	5	1.500	15.837	14	.618
4	24.000	9	2.667	6.000	8	.750	30.000	17	3.556
5	2.715	9	.302	2.500	4	.625	5.215	13	.483
6	42.520	9	4.724	12.000	7	1.714	54.520	16	2.756
7	5.147	9	.572	11.500	9	1.278	16.647	18	.448

96

CONTROL GROUP ANOVA FOR THE RATIO OF DEAD IMPLANTS TO TOTAL IMPLANTS PER PREGNANT FEMALE

	BETWEEN MALES			WITHIN MALES			TOTAL		
WEEK	SUMSQ	DF	MEANSQ	SUMSQ	DF	MEANSQ	SUMSQ	DF	F
				SINGLE TREATMENT					
1	.008	5	.002	.005	3	.002	.013	8	.940
2	.098	9	.011	.091	10	.009	.189	19	1.203
3	.088	9	.010	.062	8	.008	.150	17	1.253
4	.123	9	.014	.084	9	.009	.207	18	1.462
5	.675	9	.075	.506	6	.084	1.181	15	.890
6	.211	6	.035	.083	5	.017	.294	11	2.119
7	.288	9	.032	.082	7	.012	.370	16	2.733
8	.087	9	.010	.051	10	.005	.138	19	1.921
				MULTIPLE TREATMENT					
1	.094	6	.016	.047	4	.012	.141	10	1.329
2	.180	8	.022	.144	7	.021	.324	15	1.094
3	.235	9	.026	.105	5	.021	.339	14	1.248
4	.165	9	.018	.053	8	.007	.218	17	2.783
5	.088	9	.010	.017	4	.004	.105	13	2.233
6	.964	9	.107	.063	7	.009	1.027	16	11.884
7	.221	9	.025	.171	9	.019	.392	18	1.291

T-TEST OF THE NUMBER OF CORPORA LUTEA IN PREGNANT FEMALES.

WEEK	CONTROL			71-15 30 MG/KG				71-15 2.5 G/KG				71-15 5.0 G/KG				TEM .2 MG/KG			
	N PRG	MEAN	STD DEV	N PRG	MEAN	STD DEV	DF	T	N PRG	MEAN	STD DEV	DF	T	N PRG	MEAN	STD DEV	DF	T	N PRG	MEAN	STD DEV	DF	T
SINGLE TREATMENT																							
1	9	13.67	1.58	18	13.22	1.26	25	.793	11	13.27	1.68	18	.536	18	15.56	4.31	25	1.261	11	12.55	1.51	18	1.019
2	20	11.40	2.16	15	12.73	2.02	33	1.858	19	13.00	1.45	37	2.698	20	12.80	1.67	38	2.290	20	12.35	1.79	38	1.515
3	18	12.00	1.81	15	12.27	2.05	31	.396	18	13.06	1.59	34	1.856	19	12.84	2.01	35	1.336	17	11.53	1.59	33	.815
4	19	12.84	1.42	18	12.83	1.69	35	.017	17	13.82	1.91	34	1.759	18	12.72	2.59	35	.176	14	11.50	2.07	31	2.212
5	16	12.37	1.75	20	13.30	1.87	34	1.520	18	12.61	1.42	32	.435	19	12.63	1.71	33	.438	17	13.41	1.46	31	1.854
6	12	13.58	1.56	20	13.10	1.74	30	.788	17	12.12	2.71	27	1.679	20	11.45	2.68	30	2.500	20	12.45	1.70	30	1.819
7	17	12.53	1.81	19	12.79	1.47	34	.475	19	12.37	2.79	34	.203	15	13.47	1.46	30	1.601	18	13.00	1.57	33	.823
8	20	13.80	1.85	20	13.95	1.36	38	.292	20	13.75	1.37	38	.097	19	13.79	1.08	37	.022	20	13.20	1.77	38	1.049
MULTIPLE TREATMENT																							
1	11	12.82	1.17	20	13.20	2.04	29	.568	14	12.79	1.05	23	.073	16	13.56	1.55	25	1.350					
2	16	11.88	1.86	20	11.90	2.27	34	.036	20	12.20	2.65	34	.415	15	12.33	1.50	29	.753					
3	15	12.60	1.76	20	13.50	1.93	33	1.414	19	13.21	2.32	32	.843	19	12.84	1.26	32	.467					
4	18	12.06	1.59	18	13.06	1.39	34	2.008	19	12.68	1.60	35	1.198	16	12.12	2.00	32	.113					
5	14	13.07	2.30	18	12.78	1.86	30	.399	20	12.25	1.62	32	1.224	18	11.78	1.63	30	1.862					
6	17	14.41	2.94	19	13.21	2.51	34	1.324	18	12.33	2.38	33	2.307	15	13.07	1.49	30	1.600					
7	19	13.21	1.27	19	12.68	1.83	36	1.030	20	14.15	1.98	37	1.752	20	14.05	1.32	37	2.023					

August 1972

Compound Report No. 3 (Statistical Addendum--Dominant Lethal Gene Data)

STUDY OF MUTAGENIC EFFECTS OF GUM ARABIC (FDA No. 71-15)

Prepared for:

DHEW/PUBLIC HEALTH SERVICE
Food and Drug Administration
Rockville, Maryland

Contract No. FDA 71-267

SRI Project LSU-1348

Submitted by:

G. W. Newell and W. A. Maxwell

Approved:

W. A. Skinner

W. A. Skinner, Executive Director
Life Sciences Division

STATISTICAL SUMMARY

This addendum presents statistical treatment of the dominant lethal gene data for Gum Arabic, using the procedural outline of Miss Janet Springer, FDA. A description of the statistical procedures and an explanation of how the computations are accomplished were presented as Appendix A of Compound Report No. 8, Guar Gum (71-16). Summary tables of experimental data also are included for reference.

A review of these statistical evaluations continues to support the conclusions presented in the main report: i.e., Gum Arabic is not a mutagenic substance by the dominant lethal gene test.

September 1972

Compound Report No. 3 (Addendum--Acute Host-Mediated Assay)

STUDY OF MUTAGENIC EFFECTS OF GUM ARABIC (FDA No. 71-15)

Prepared for:

DHEW/PUBLIC HEALTH SERVICE
Food and Drug Administration
Rockville, Maryland

Contract No. FDA 71-267

SRI Project LSU-1348

Submitted by:

G. W. Newell and W. A. Maxwell

Approved:

W. A. Skinner, Executive Director
Life Sciences Division

p1

INTRODUCTION

Under contract to the Food and Drug Administration, Stanford Research Institute is examining the mutagenicity of 14 selected chemical compounds (Contract No. FDA 71-267). This report is an addendum to the third compound report on tests conducted on gum arabic (FDA 71-15).

In the acute host-mediated assay for Salmonella typhimurium G-46 the negative control value was approximately 100-fold higher than the expected value. The other frequencies in this test group also appeared to be proportionately higher. At the request of FDA the initial study was repeated to determine if, as shown by this result, gum arabic has no mutagenic effect on S. typhimurium G-46 in the host-mediated assay during an acute exposure.

SUMMARY

Gum arabic (71-15) caused no mutagenic response on S. typhimurium G-46 when administered on an acute basis. The results for this are shown in Tables 1 and 2.

102

Table 1

HOST MEDIATED ASSAY
SUMMARY OF DATA

Compound No.: 71-15 (Gum Arabic)

A. Acute

Treatment	Organism					
	Salmonella				Saccharomyces	
	G46		TA 1530		D-3	
	MF	MFt/MFc	MF	MFt/MFc	RF	RFt/RFc
Maximum	1.89×10^{-8}	1.62				
Intermediate	1.15×10^{-8}	0.98				
Low Level	1.97×10^{-8}	1.68				
Control (+)	6.01×10^{-7}	51.37				
Control (-)	1.17×10^{-8}	1.00				

B. Subacute

Treatment	Organism					
	Salmonella				Saccharomyces	
	G46		TA 1530		D-3	
	MF	MFt/MFc	MF	MFt/MFc	RF	RFt/RFc
Maximum						
Intermediate						
Low Level						
Control (-)						

Table 2

HOST MEDIATED ASSAY
INDIVIDUAL MOUSE DATA

Compound No.: 71-15 (GUM ARABIC)

Organism: G-46

Treatment: CONTROL (+)

A. Acute

Mouse No.	Ave. No. Mutant Colonies or Recombinants/ml	Ave. No. Colony Forming Units/ml	Mutation or Recombination Frequency
1	.285833333333ex 03	.775000000000ex 09	.368817204300ex-06
2	.618333333330ex 03	.680000000000ex 09	.909313725485ex-06
3	.762500000000ex 03	.766666666665ex 09	.994565217393ex-06
4	.409166666666ex 03	.688333333330ex 09	.594430992737ex-06
5	.430833333333ex 03	.578333333330ex 09	.744956772338ex-06
6	.381666666666ex 03	.766666666665ex 09	.497826086956ex-06
7	.340833333333ex 03	.650000000000ex 09	.524358974358ex-06
8	.327500000000ex 03	.885000000000ex 09	.370056497175ex-06
9	.326666666666ex 03	.901666666665ex 09	.362292051755ex-06
10	.518333333330ex 03	.808333333330ex 09	.641237113400ex-06
			.600785463585ex-06

B. Subacute

Mouse No.	Ave. No. Mutant Colonies or Recombinants/ml	Ave. No. Colony Forming Units/ml	Mutation or Recombination Frequency

104

Table 2 (continued)

HOST MEDIATED ASSAY
INDIVIDUAL MOUSE DATA

Compound No.: 71-15 (GUM ARABIC)

Organism: G-46

Treatment: CONTROL (-)

A. Acute

Mouse No.	Ave. No. Mutant Colonies or Recombinants/ml	Ave. No. Colony Forming Units/ml	Mutation or Recombination Frequency
1	.916666666665ex 01	.891666666665ex 09	.102803738317ex-07
2	.100000000000ex 02	.866666666665ex 09	.115384615384ex-07
3	.100000000000ex 02	.915000000000ex 09	.109289617486ex-07
4	.125000000000ex 02	.968333333330ex 09	.129087779690ex-07
5	.125000000000ex 02	.104500000000ex 10	.119617224880ex-07
6	.166666666666ex 02	.104333333333ex 10	.159744408945ex-07
7	.133333333333ex 02	.102833333333ex 10	.129659643436ex-07
8	.916666666665ex 01	.853333333330ex 09	.107421875000ex-07
9	.100000000000ex 02	.856666666665ex 09	.116731517509ex-07
10	.750000000000ex 01	.886666666665ex 09	.845864661655ex-08
			.117432688680ex-07

B. Subacute

Mouse No.	Ave. No. Mutant Colonies or Recombinants/ml	Ave. No. Colony Forming Units/ml	Mutation or Recombination Frequency

Table 2 (concluded)

HOST MEDIATED ASSAY
INDIVIDUAL MOUSE DATA

Compound No.: 71-15 (GUM ARABIC)

Organism: G-46

Treatment: LOW

A. Acute

Mouse No.	Ave. No. Mutant Colonies or Recombinants/ml	Ave. No. Colony Forming Units/ml	Mutation or Recombination Frequency
1	.150000000000ex 02	.541666666665ex 09	.276923076923ex-07
2	.116666666666ex 02	.686666666665ex 09	.169902912620ex-07
3	.208333333333ex 02	.800000000000ex 09	.260416666666ex-07
4	.183333333333ex 02	.104666666666ex 10	.175159235669ex-07
5	.183333333333ex 02	.695000000000ex 09	.263788968824ex-07
6	.250000000000ex 02	.115833333333ex 10	.215827338130ex-07
7	.133333333333ex 02	.678333333330ex 09	.196560196560ex-07
8	.916666665665ex 01	.800000000000ex 09	.114583333333ex-07
9	.833333333330ex 01	.528333333330ex 09	.157728706624ex-07
10	.125000000000ex 02	.903333333330ex 09	.138376383764ex-07
			.196926681910ex-07

B. Subacute

Mouse No.	Ave. No. Mutant Colonies or Recombinants/ml	Ave. No. Colony Forming Units/ml	Mutation or Recombination Frequency

Table 2 (continued)

HOST MEDIATED ASSAY
INDIVIDUAL MOUSE DATA

Compound No.: 71-15 (GUM ARABIC)

Organism: G-46

Treatment: INTERMEDIATE

A. Acute

Mouse No.	Ave. No. Mutant Colonies or Recombinants/ml	Ave. No. Colony Forming Units/ml	Mutation or Recombination Frequency
1	.666666666665ex 01	.663333333330ex 09	.100502512563ex-07
2	.916666666665ex 01	.873333333330ex 09	.104961832061ex-07
3	.141666666666ex 02	.100166666666ex 10	.141430948419ex-07
4	.116666666666ex 02	.758333333330ex 09	.153846153845ex-07
5	.158333333333ex 02	.144166666666ex 10	.109826589595ex-07
6	.100000000000ex 02	.127000000000ex 10	.787401574803ex-08
7	.500000000000ex 01	.623333333330ex 09	.802139037437ex-08
8	.116666666666ex 02	.801666666665ex 09	.145530145529ex-07
9	.116666666666ex 02	.138333333333ex 10	.843373493973ex-08
10	.241666666666ex 02	.158166666666ex 10	.152792413066ex-07
			.115218200569ex-07

B. Subacute

Mouse No.	Ave. No. Mutant Colonies or Recombinants/ml	Ave. No. Colony Forming Units/ml	Mutation or Recombination Frequency

Table 2 (continued)

HOST MEDIATED ASSAY
INDIVIDUAL MOUSE DATA

Compound No.: 71-15 (GUM ARABIC)

Organism: G-46

Treatment: MAXIMUM

A. Acute

Mouse No.	Ave. No. Mutant Colonies or Recombinants/ml	Ave. No. Colony Forming Units/ml	Mutation or Recombination Frequency
1	.125000000000ex 02	.773333333330ex 09	.161637931035ex-07
2	.550000000000ex 02	.686666666665ex 09	.800970873788ex-07
3	.916666666665ex 01	.856666666665ex 09	.107003891050ex-07
4	.100000000000ex 02	.536666666665ex 09	.186335403727ex-07
5	.158333333333ex 02	.104166666666ex 10	.152000000000ex-07
6	.100000000000ex 02	.114000000000ex 10	.877192982456ex-08
7	.750000000000ex 01	.685000000000ex 09	.109489051094ex-07
8	.750000000000ex 01	.821666666665ex 09	.912778904667ex-08
9	.416666666666ex 01	.568333333330ex 09	.733137829915ex-08
10	.116666666666ex 02	.941666666665ex 09	.123893805309ex-07
			.189364192767ex-07

B. Subacute

Mouse No.	Ave. No. Mutant Colonies or Recombinants/ml	Ave. No. Colony Forming Units/ml	Mutation or Recombination Frequency